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ABSTRACT
GENETIC AND MECHANISTIC ANALYSIS OF RAT MAMMARY CANCER
SUSCEPTIBILITY
Jennifer Sanders
June 9th, 2014
Breast cancer is a complex disease, which is influenced by genetic, epigenetic and
environmental components. Genetic susceptibility to breast cancer is made up o f high,
moderate and low penetrance alleles. High and moderate penetrance alleles are rare and
constitute only a small percentage of the genetic susceptibility. Most variation in genetic
susceptibility is controlled by low- penetrance, common polymorphisms. Comparative
genetics uses model organisms to study human disease. Rat strains exhibit different
susceptibility phenotypes to chemical induced carcinogenesis. The Wistar-Furth (WF) rat
strain is susceptible to chemically induced mammary carcinogenesis, while the WistarKyoto (WKy) and Copenhagen (COP) rat strains are resistant. Selective breeding and
linkage analyses of these rat strains after treatment with 7,12-dimethylbenz[a]anthracene
(DMBA) have been used to identify eight rat mammary cancer quantitative trait loci
(QTLs) in the rat. This dissertation focuses on two of these QTLs, mammary carcinoma
susceptibility loci 1b and 6 (Mcs1b and Mcs6). Mcs6 has been identified and physically
confirmed using WF.WKy congenic animals and maps to a 33Mb region. This locus will
have to be mapped to a narrower interval in order for functional studies to be practical. I
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was able to map the Mcs6 locus to a region of 8.5Mb on rat chromosome 7. The Mcs1b
locus maps to a region of 1.8Mb on r at chromosome 2. Mcs1b contains the rat
orthologous region to a breast cancer risk associated region marked by SNP rs889312.
This makes the Mcs1b congenic rat an ideal model for studying the mechanism of
rs889312. The goal of my project is to identify all Mcs1b sequence variants between the
two rat strains and test for gene regulatory functions. I was able to identify 70 SNPs and 2
INDELs using next- generation sequencing. Three rat SNPs have gene regulatory
function differences between the two rat alleles. Out of the seven human SNPs that tag
SNP rs889312, four exhibit gene regulatory differences between the major and minor
alleles, and therefore, may be functional orthologs to the rat Mcs1b candidate SNPs.
Overall, I was able to fine map the Mcs6 region and identify several candidate rat and
human Mcs1b/ MCS1B SNPs.
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CHAPTER I
INTRODUCTION
Breast Cancer Statistics
In 2013, approximately 232,340 ne w breast cancer cases was expected to be
diagnosed, making breast cancer the most commonly diagnosed cancer among women
(excluding skin cancer). A woman’s lifetime chance of developing breast cancer in 2013
was 1 in 8. T he lifetime chance of developing breast cancer has risen since the 1970’s
when a woman’s lifetime chance of being diagnosed with breast cancer was 1 in 11. This
rise in breast cancer diagnoses is attributed to an increase in life expectancy and breast
cancer incidence [1].
Breast cancer is the second leading causing of cancer related deaths in women
after lung cancer. However, for women between 20-59 years of age, breast cancer is the
leading cause of cancer related deaths [2]. Due to improvements in awareness, screening
and breast cancer treatments, the breast cancer death rate has dropped 34% between the
years 1990-2010 [1]. However, approximately 39,620 women will have died of breast
cancer in 2013, hi ghlighting the need for even better early detection and prevention
methods.

Breast Cancer Risk Factors
Breast cancer is a co mplex disease, made up of environmental, epigenetic and
genetic factors. A 12.5% lifetime chance of developing breast cancer is a population
1

based estimate and a woman’s individual risk may vary depending on breast cancer risk
factors [1]. These breast cancer risk factors include age, gender, reproductive history,
genetic and non- heritable factors [3]. Age and gender are the most important breast
cancer risk factors and breast cancer risk increases for females with increase in age [1].
However, there are several environmental breast cancer risk factors. These include but
are not limited to: radiation, estrogen exposure, smoking, high alcohol intake, unhealthy
diets and environmental pollutants such as polycyclic aromatic hydrocarbons [4-12].

A.

Radiation as a Risk Factor for Breast Cancer
Radiation is one of the most potent inducers of breast cancer, since the mammary

gland is sensitive to radiation induced carcinogenesis [13]. Timing of the radiation
exposure is essential, with exposed women under the age of 20 having a higher risk of
developing breast cancer than women exposed at an older age. This is likely due to the
breast tissue being relatively undifferentiated before the age of 20 [13, 14]. Women are
generally not exposed to high dosages of radiation; the few exceptions include survivors
of the atomic bomb detonations in Japan during World War II and the nuclear disaster at
Chernobyl. Breast cancer incidence data from these disasters suggests an increase in
breast cancer risk after high radiation exposure that is more pronounced in women who
were younger at the time of exposure and those who received higher the dose of radiation
was [14, 15]. Women can also be exposed to low dosages of radiation, usually due to
medical procedures. These include: 1) women being monitored for tuberculosis infection
by X-rays; 2) women being treated for benign breast disease or acute post-partum
mastitis; 3) childhood cancer survivors; 4) adult cancer survivors; 5) women treated for
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benign disorders as children using radiation and 6) breast cancer screening through
mammograms [7, 13]. Low dosage radiation exposure is considered carcinogenic but the
benefits from radiation treatments outweigh the risks [7]. The breast cancer risk after low
dose exposure increases if women are positive for a genetic mutation that increase breast
cancer susceptibility [6].

B.

Estrogens as a Risk Factor For Breast Cancer
The US National Toxicology Program of the Department of Health and Human

Services categorizes estrogens as carcinogens [9, 16]. The involvement of estrogens in
breast carcinogenesis was established through several key observations: 1) hormonal
replacement therapies, which increase circulating estrogens, also increase breast cancer
risk; 2) bilateral oophorectomy (reduction in circulating estrogens) in both animals and in
humans protects from breast cancer; 3) parity decreases breast cancer risk and 4)
treatment with anti-estrogen drugs such as tamoxifen decreases chances of developing
breast cancer [17-21].
The main estrogen studied in breast cancer carcinogenesis is 17β-estradiol (E2);
however, other estrogens include estrone (E1) and estriol (E3). E2 is secreted by the
ovaries in pre-menopausal women and is synthesized by the aromatase enzyme in premenopausal and post-menopausal women [9]. E2’s role in breast carcinogenesis is
complex and involves many different mechanisms and cellular pathways. E2 can bind
and activate estrogen receptors (ER) α and β, which in turn act as transcriptional
regulators of several genes involved in cell proliferation and cell cycle progression [9].
One example of this is the role of E2 in upregulating anti-apoptotic Bcl-2 and Bcl-Xl
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genes in breast cancer cell lines and therefore preventing apoptosis [22]. Another
example of a mechanism of E2’s involvement in breast cancer is the observation that E2
increases the secretion of interleukin 8 (IL-8) and vascular endothelial growth factor
(VEGF), both needed for the formation of blood vessels to growing tumors [23]. A more
controversial mechanism by which estrogens may be involved in breast cancer is through
initiating DNA damage. Some evidence suggests that estrogens and their metabolites can
cause direct and indirect DNA damage through the formation of free-radicals [18, 24].
The role of estrogens in breast cancer has been used to develop treatments
specific to estrogen-responsive breast cancers that express ERα, since this makes up the
majority of breast cancer cases (about 70%). Currently, there are three different types of
treatments for ER-positive cancers that use the role of estrogens as their basis. The first
type of treatment is selective estrogen receptor modulators (SERMs). These are synthetic
chemical compounds that compete with estrogens for ERα binding, but inhibit
transcriptional activity in a cell- type and promoter context. There are currently three
SERMs on the market: raloxifene, toremifene and tamoxifen [9, 25]. Another type of
treatment includes compounds that increase ER turnover in the cells. Fulvestrant is an
example of a drug approved for this type of treatment [26]. A third type of breast cancer
treatment that takes advantage of the role of estrogens in breast cancer is aromatase
inhibitors. Aromatase is an enzyme needed for the synthesis of estrogen and is extremely
important in post-menopausal women, since the synthesis of estrogen in the adipose
tissue becomes the primary source of estrogen for obese women [9].

C.

Alcohol as a Risk Factor for Breast Cancer

4

The link between alcohol intake and breast cancer risk has been established. A
meta-analysis of 100 e pidemiological studies identified a correlation between alcohol
intake and breast cancer risk at high alcohol consumption (<45g/day) with RR of 1.46
(95%CI= 1.33-1.61) compared to nondrinkers. This results in a 7.1% increase in breast
cancer risk with every 10g/ day of alcohol consumption [11, 27]. Interestingly, low
alcohol intake (1drink/day or 5-14g/day) is also associated with an increase in breast
cancer risk in several meta-analyses (relative risk (RR) = 1.05, 95% CI 1.02-1.08 in one
study) [11, 28]. Several mechanisms have been identified as to how alcohol is involved
in breast carcinogenesis. These mechanisms include changes in hormone and hormone
receptor levels, increased cell proliferation, DNA adduct formation, increased cyclic
adenosine monophosphate (cAMP), changes in potassium channels and modulation of
gene expression all due to alcohol or its metabolites [29]. Of important consideration is
the alcohol metabolite acetaldehyde, which is a known carcinogen. Acetaldehyde
promotes inflammation, can cause DNA damage and can inhibit DNA repair [30]. It is
recommended for females to limit alcohol intake to ≤1 drink/day [11].

D.

Smoking as a Risk Factor for Breast Cancer
Cigarette smoke contains thousands of chemicals, 69 of which are known

carcinogens, and 20 of them are mammary carcinogens [10, 31].

Many of these

carcinogens can be activated through enzymes and eventually lead to DNA adduct
formation. Some of these carcinogens found in cigarette smoke reach the breast tissue
[32].
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The relationship between smoking and breast cancer remains complex. Recent
studies have indicated that active smoking is associated with an increase in breast cancer
risk, particular when age of smoking initiation was very early (before the age of 20) [10,
31]. In one particular study, the risk of breast cancer associated with smoking was
determined to have an odds ratio of 1.28 (95% CI= 1.17-1.39) [33]. The relationship of
passive smoking and breast cancer remains even more elusive with several studies
showing no r elationship while some studies suggest that even passive smoking can
increase breast cancer risk [10]. A positive correlation between smoking and breast
cancer risk has been established in a subset of people, who carry the NAT2 slow
acetylation genotype, especially among post-menopausal women. In a meta-analysis of
breast cancer risk, the relative risk (RR) was 1.27 (95%CI= 1.16-1.39) in people with the
NAT2 slow acetylation genotype compared to a RR o f 1.05 (95%CI= 0.95-1.17) in
people with the rapid NAT2 acetylation genotype [31, 34]. NAT2 is involved in
detoxifying several carcinogens in tobacco smoke. A NAT2 slow acetylation genotype
person is homozygous for a NAT2 variant, while a rapid NAT2 genotype is composed of
a homozygous wildtype genotype [34]. This indicates that there is interplay between
genetics and the environment when it comes to smoking and increases in breast cancer
risk.

E.

Environmental Pollutants as a Risk Factor for Breast Cancer
The two environmental pollutants most often associated with breast cancer risk

are polycyclic aromatic hydrocarbons (PAHs) and polychlorinated biphenyls (PCBs).
PAHs are generated during combustion. Exposure to PAHs can occur through several
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ways. PAHs are present in smoked and grilled foods, air pollution, vehicular exhausts and
in cigarette smoke [10, 12]. Several PAHs are known mammary carcinogens, including
benzo(a)pyrene [12, 35]. PAHs form DNA adduct and subsequently cause DNA damage
[12]. Polychlorinated biphenyls (PCBs) were used in electrical equipment until banned in
the U.S. The main route of exposure to PCBs is through eating contaminated fish from
contaminated rivers near industrial areas. High PCB levels can be found in breast milk
post exposure since that PCBs accumulate in fat [12, 36]. PCBs can activate several
hormone receptors and PCB metabolites can form DNA adducts leading to
carcinogenesis [37].

F.

Diet and Breast Cancer
Diet plays an important factor in influencing breast cancer risk. Increased breast

cancer risk is associated with obesity, high fat intake in post-menopausal women and
high total energy intake in both pre- and post-menopausal women [4, 38, 39]. Breast
cancer risk is influenced by intake of different types of fats. High intake of saturated fats
is associated with increase in breast cancer risk in post-menopausal women, while
polyunsaturated fats increase breast cancer risk in both pre- and post-menopausal women.
Monounsaturated fats seem to have no influence on breast cancer risk [4, 40]. In addition,
a diet low in bread and fruits, as well as high in meat, fish, butter, other animal fats and
margarine is associated with in increase in breast cancer risk (hazard ratio= 2.00, 95% CI
1.30-3.09) [41]. It has been postulated that fats may increase E2 levels as a p ossible
mechanism for the increase in breast cancer risk [42]. There are also several foods which
have a p rotective effect against breast cancer. A diet rich in fiber reduces chances of
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developing ERα+ breast cancer [43]. Also, a diet rich in soy is associated with a
reduction in breast cancer risk, possibly due to some of the components of soy having
anti-oxidant and anti-inflammatory properties [44]. The American Cancer Society
suggests to reduce weight/ weight gain in overweight and obese people, to adopt a
physically active lifestyle, to eat foods high in vegetables and fiber, and to reduce intake
of fats to reduce the chances of developing breast cancer [45].

G.

Epigenetic Factors and Breast Cancer Risk
There are several pieces of evidence that suggest epigenetic factors are involved

in breast cancer risk. One example is that in a meta-analysis of the effects of genistein, a
compound in soy, on b reast cancer risk suggests that a d iet rich in genistein before
puberty protects from breast cancer later [46]. Genistein’s breast cancer protective effect
is thought to possibly act through the epigenetic effects of genistein [46]. Genistein is
known to affect DNA methylation by both increasing methylation and by inhibiting DNA
methyltransferase, resulting in a d ecrease in DNA methylation [47, 48]. Another study
that identified a link between epigenetics and breast cancer risk showed that lower levels
of DNA methylation of repetitive elements in white blood cells correlated with an
increase risk of developing breast cancer. A decrease in DNA methylation in repetitive
elements is associated with genomic instability. Some repetitive elements have the ability
to integrate themselves into different genomic regions. This can potentially disrupt gene
function, therefore repetitive elements are often highly methylated and therefore silenced
[49-51]. Another piece of evidence for the link between epigenetics and breast cancer
comes from the observation that the daughters of women given diethylstilbestrol (DES)
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(a synthetic estrogen) during their pregnancy are more likely to develop breast cancer
than women who haven’t been exposed. The generational jump in breast cancer risk
suggests that there may be epigenetic factors at play, possibly through the disregulation
of DNA methyltransferases expression levels [52, 53].

Genetic Factors of Breast Cancer Risk
A.

General Introduction to Genetic Factors of Breast Cancer Risk
The genetic contribution towards breast cancer has been approximated by

comparing the concordance of cancer between monozygotic and dizygotic pairs of twins.
The idea being that if there is a higher concordance of cancer between pairs of
monozygotic twins than there is between dizygotic twins, breast cancer susceptibility has
a genetic component. Overall, a monozygotic twin is more likely to be diagnosed with
breast cancer if there is an affected twin, suggesting that there is a genetic component to
breast cancer. About 25-32% of breast cancer susceptibility can be attributed to genetic
factors [54-56].
Breast cancer heritability is made up of three different classes of alleles. The first
class is made up of high penetrance risk alleles, such as BRCA1, BRCA2, STK11 and
TP53. These alleles have a s trong effect on breast cancer risk, with relative risk >8.
However, mutations in these genes are very rare and therefore, only a small percentage of
the population is affected [57-59]. It is estimated that only 20-25% of genetic heritability
of breast cancer can be explained by high penetrance risk alleles [60]. Family-based
linkage analysis were used to identify these high penetrance breast cancer risk genes [59].
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Genome-wide association studies have not mapped any additional high penetrance risk
alleles, suggesting that no further high-penetrance risk alleles exist [60].
A second class of breast cancer risk alleles is made up of moderate risk alleles.
These risk alleles have a relative risk of 2-8. Some of these breast cancer risk alleles were
identified through targeted sequencing, usually of genes known to interact with BRCA1
and BRCA2 or genes that are active in DNA repair pathways. Other breast cancer risk
alleles in this class were identified through linkage analysis of families suffering from
rare syndromes that include breast malignancies as a symptom [59]. Genes in this class of
breast cancer risk alleles include PTEN, PALB2, CDH1, ATM, BRIP1, and CHECK2 [5760]. These moderate risk alleles are rare in the population and therefore, the contribution
of this class of breast cancer risk alleles to the heritability of breast cancer is estimated to
be only 3% [60].
Since the majority of breast cancer heritability cannot be explained by high and
moderate penetrance alleles, the majority of breast cancer heritability is thought to be
made up of common, low penetrance risk alleles. These alleles make up the third class of
breast cancer risk alleles. The risk allele frequencies of common, low penetrance risk
alleles are >5% in a human population. This means this class of breast cancer risk alleles
affects a l arge part of the respective population. The relative risk of this class of risk
alleles is low and as of yet no risk allele in this group with a relative risk higher than 1.5
has been identified [59]. Initially, this class of breast cancer risk alleles was identified
through case- control, association studies using candidate genes. A more common and
more fruitful method of identifying these risk alleles was developed in 2007 when the
first genome-wide association study (GWAS) of breast cancer was published [59, 61].
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Since 2007, 72 c ommon, low penetrance risk alleles have been identified and the most
recent study suggested that up t o 1000 c ommon, low penetrance risk alleles may exist
[59, 62]. The 72 c ommon, low penetrance risk alleles identified so far only make up
about 14% of the heritability of breast cancer. The remaining heritability may be made up
of low penetrance risk alleles that have very low effect sizes that cannot be easily
identified through GWA studies due to limits of detection. Alternatively, risk alleles that
interact with each other and therefore cannot be identified through genome-wide
association studies may make up the remaining heritability [59, 62]. GWA studies are
designed to test a limited number of SNPs that tag enough SNPs to cover the whole
genome. Tagged SNPs are found in areas of low recombination and are therefore
inherited together with the GWA study SNP. Tagged SNPs are found at linkage
disequilibrium blocks or haplotypes. The boundaries of LD blocks or haplotype blocks
are delimited by recombination hot-spots. This means that a GWAS identified SNP may
tag the actual SNP, but the causative variant(s) may not be the SNP tested in the GWA
study [59]. Genes making up the three classes of genetic susceptibility and their minor
allele frequency can be found in Figure 1. Discussion of breast cancer susceptibility
genes will focus on germ line mutations in these genes.
Surprisingly, high and moderate penetrance risk mutations are found in coding
regions of their respective genes. This makes identifying the causative gene relatively
easy. However, low penetrance risk alleles are generally found in non-coding or
intergenic regions. This makes identifying the causative gene difficult, since the causative
gene can be long distances away and may affect gene regulation through complex
chromatin arrangements. Low penetrance risk alleles located in non-coding or intergenic

11

Figure 1: Architecture of genetic susceptibility to breast cancer. Adapted from
Ghoussaini et al. (2013) [59]. Figure shows the genetic architecture of breast cancer risk.
Relative risk and risk allele frequencies for breast cancer risk genes are shown. Breast
cancer risk genes are subdivided into classes of level of risk.
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regions are thought to be enhancers that affect the expression of genes long distances
away.

B.

BRCA1 and BRCA2
The first breast cancer gene was identified in 1990 and cloned in 1994. Breast

cancer susceptibility 1 or BRCA1 was identified through a linkage analysis of 23 families
with 146 cases of breast cancer. BRCA1 was mapped to chromosome 17q21 [63, 64].
The BRCA1 protein contains 24 e xons and is 1863 amino acids long. BRCA1 is an
extremely versatile protein, which interacts with several different proteins to form distinct
complexes. Its most known function is DNA repair, however, the protein is also involved
in cell cycle control and transcriptional regulation and generally acts as a t umor
suppressor [65, 66]. Upon DNA damage, the DNA damage sensors ataxia telangiectasia
mutated (ATM) and ataxia telangiectasia mutated rad3-related (ATR) will phosphorylate
BRCA1 leading to the recruitment of BRCA1 to DNA damage foci that locate to sites of
DNA damage. BRCA1 is involved in homologous recombination, an error-free pathway
to repair double stranded breaks [67].
BRCA1 is also known to be involved in cell cycle control. The protein interacts
with cell cycle proteins E2F, CDC2 and cyclins. BRCA1 levels increase in late G1 phase.
High levels of BRCA1 results in the upregulation of p21 and G1-S cell cycle arrest [65].
BRCA1 is a known transcriptional regulator. The C-terminus of the BRCA1
protein is known to interact with transcriptional activators and repressors. One protein
BRCA1 is known to interact with is the RNA polymerase II holoenzyme and functions as
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a transcriptional activator. BRCA1 is also known to interact with TP53 at the p21 gene,
resulting in the upregulation of p21 [65].
The second major breast cancer susceptibility gene (Breast cancer 2, early onset
or BRCA2) was identified in 1994 through a linkage analysis of 15 families with multiple
cases of early onset breast cancer. BRCA2 was localized to a region on chromosome 13
[68]. Like BRCA1, BRCA2 is involved in DNA damage repair, in particular, BRCA2 is
involved in homologous recombination. BRCA2 interacts with several DNA damage
repair proteins including RAD51, a protein known to cover single stranded DNA strands
formed during homologous recombination [69].
The risk of developing breast cancer by the age of 70 is as high as 85% in BRCA1
and BRCA2 mutation carriers [67]. BRCA1 and BRCA2 mutations also increase the risk of
being diagnosed with higher grade/ stage and ER negative tumors, and increase the risk
of metastasis [67, 70]. In fact, the majority of breast cancers in BRCA1 mutation carriers
are ER negative (70-90%), while the majority of breast cancers in BRCA2 mutation
carriers are ER positive (60-75%) [71]. More than 2000 mutations have been identified in
the BRCA1/2 genes [70]. The vast majority of BRCA1/2 mutations result in a truncated
protein with only a small minority resulting in amino acids substitutions [67]. Male breast
cancer is a rare disease with a ratio of 1:175 men to women developing breast cancer.
BRCA1 and BRCA2 are known risk factors for male breast cancer with BRCA2 being
more important in the genetic predisposition to male breast cancer [72]. The lifetime
chance of men developing breast cancer is 1.8% for BRCA1 carriers and 8.3% for BRCA2
carriers [71]. BRCA1/2 mutation carriers are often advised to take prophylactic measures
to prevent developing breast cancer or ensuring early detection. These measures include
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annual mammography or magnetic resonance imaging (MRI) starting at age 30. Other
prophylactic measures include bilateral mastectomy, salpingo-oophorectomy and
chemoprevention using the anti-estrogen tamoxifen [71, 73].

C.

TP53 and PTEN
Another breast cancer predisposition gene is TP53. TP53 is implicated in Li-

Fraumeni syndrome, which is a rare autosomal dominant syndrome that is associated
with an increase in childhood and adult cancers including breast cancer. TP53 is a tumor
suppressor protein involved in cell cycle control and apoptosis [74]. Breast cancer is the
most commonly found cancer in female TP53 mutation carriers. However, TP53
mutations are rare and make up only 0.1% of all breast cancer cases [73].
Mutations in PTEN are associated with another rare autosomal dominant cancer
syndrome called Cowden’s syndrome. Cowden’s syndrome is associated with an increase
risk in several cancers including skin, bowel, thyroid and breast and the presence of
pathognomonic physical features, including facial trichemmoma, acral keratoses and oral
papillomatous papules. PTEN is a tumor suppressor protein and female PTEN mutation
carriers have a lifetime chance of developing breast cancer that is 75% [74].

D.

FGFR2
The breast cancer susceptibility genes discussed so far are high penetrance risk

alleles and mutations in these genes increase a woman’s chance of developing breast
cancer significantly. However, another set of risk alleles are associated with a much
lower increase in breast cancer risk. Low penetrance risk alleles are found at a m uch
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higher frequency in the population than high penetrance risk alleles and therefore are
thought to make up the majority of genetic breast cancer risk. One of the earliest low
penetrance risk alleles identified through a genome- wide association study is located
within the fibroblast growth factor receptor 2 (FGFR2) gene and it has been confirmed
through several other studies in multiple populations [61, 75-78]. It is also the most
studied low penetrance breast cancer risk allele to date. SNPs associated with breast
cancer risk are located on a 7.5kb linkage disequilibrium block (LD block) within intron
2 of FGFR2 [61]. Several risk associated SNPs map to this locus and it is not known if
there is a single causative variant, multiple independent or multiple interacting variants in
this region. FGFR2 is expressed higher in homozygotes of the minor allele than the major
allele, suggesting that these SNPs are involved in gene regulation of FGFR2 possibly
through altering transcription factor binding sites [79]. Through electrophoretic mobility
shift assays (EMSAs), several transcritiption factors including OCT-1, RUNX2, FOXA1
and E2F1 were shown to bind to the minor and major alleles of the risk SNPs
differentially. Furthermore, chromosome confirmation capture (3C) of the FGFR2 locus
suggests that the FGFR2 risk SNPs are brought to close proximity of the FGFR2
promoter through chromosomal looping [79, 80]. The FGFR2 locus provides the first
mechanism into how low penetrance risk alleles that are located in intergenic or intronic
regions can affect gene regulation of candidate susceptibility genes.

E.

MAP3K1 and rs889312
The same study that identified a breast cancer risk SNP in the intron of FGFR2

also found several other SNPs that associate with breast cancer risk in an European
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population, one of them being rs889312 [61]. This SNP will be important for the majority
of the studies reported here. The minor allele frequency (MAF) of rs889312 is about 30%
in the European population. rs889312 increases breast cancer risk slightly with a per
allele odds ratio of 1.13 (95%CI= 1.10-1.16) [61]. GWA studies using a wide variety of
different populations confirmed previous findings for rs889312, indicating that this SNP
is associated with breast cancer risk in several different populations. This included
studies with populations of European, Korean, South American, Chinese and Tunesians
[78, 81-84]. The SNP is also found to be associated with several breast cancer subtypes
including ER+, ER- and triple negative [85, 86].
rs889312 is located in an intergenic region which is located within a linkage
disequilibrium block (LD block) of 280kb. This LD block contains three genes, namely
MAP3K1, SETD9 and MIER3. rs889312 is located closed to MAP3K1; therefore, it is
referred to by that name in the literature. Initially, MAP3K1 was considered the most
likely causative gene in this region due to its role in cell signaling. However, this does not
mean that MAP3K1 is the causative gene, since rs889312 is located on a haplotype block
with MAP3K1, SETD9 and MIER3, any of these genes could potentially be the causative
gene. SETD9 is not expressed in human breast tissue and there is little conservation
between human and rat SETD9. Therefore, SETD9 is an unlikely candidate for conferring
the mammary carcinogenesis phenotype of the rs889312 region. However, MIER3 is
expressed higher in breast tumors compared to normal breast tissue, suggesting that
MIER3 might have a role in mammary carcinogenesis [87]. rs889312 is in linkage
disequilibrium with at least six other SNPs at an r2 value of 0.8. All seven of these SNPs
are located on the 280kb LD block. This means that any of these seven SNPs could be the
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causative SNP. Therefore, rs889312 is not necessarily the causative SNP in this region
but tags the causative SNP. It is currently not known which of the rs889312 correlated
SNP is causative, or if multiple causative SNPs are present. Interestingly, with more and
more genomes being sequenced, more SNPs that tag rs889312 may be identified. This
also means that the causative SNPs for this region may not be in public databases yet.
Figure 2 shows the map of the LD block containing rs889312.

Animal Models of Breast Cancer
Studying human polymorphisms that associate with breast cancer risk comes with
a set of challenges. Studying these polymorphisms in humans directly is limiting. Crucial
experiments cannot be performed in humans directly due to ethical and feasibility
constrains.

A.

Human Breast Cancer Cell Lines

Human cell lines have been used to circumvent the challenge of studying diseases in a
human model. Human cells lines have several advantages. They can be immortalized and
easily grown. They can be transfected with foreign DNA and exposed to chemicals.
Genomic manipulation is also easily accomplished in human cell lines. However, there
are disadvantages to using human cell lines. There is a broad range of human breast
cancer cell lines that differ in their genomes and cell environments drastically. It is
important to select the cell line that is most appropriate for the experiment. Human breast
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Figure 2. LD block containing rs889312 and tagged SNPs. Blue lines indicate gene
transcripts in this region. The LD block is 280kb in size.
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cancer cell lines are prone to change genotypically and phenotypically with each passage,
giving rise to subpopulations. This is especially the case if these cells lines have been
used for long periods of time. Another problem with human cells lines is a high rate of
false misidentification and contamination with different cells lines [88, 89]. These
disadvantages have led to the identification of several non- human breast cancer animal
models that can be used instead of or to enhance cell line studies.

B.

Canine Models of Breast Cancer
The canine has been used as a b reast cancer animal model. Canines develop

mammary cancer spontaneously. Canine mammary tumors are similar to human breast
cancer biologically and clinically. In particular, several genes that are deregulated in
mammary cancer are deregulated in both humans and canines. Problems with canine
models include the relatively high costs of housing canines compared to rodents and
ethical considerations of using animals commonly viewed as pets [90].

C.

Mouse Models of Breast Cancer
Rodent breast cancer models have become increasing popular. The mouse model

of breast cancer has been popular because of the ability to perform genetic manipulations
in the mouse. There are several advantages of mouse models of breast cancer. The
biology and development of the mouse mammary gland is well known and characterized.
Mouse mammary glands develop mammary cancer spontaneously but mammary cancer
can also be induced with carcinogens such as 7,12-dimethylbenz[a]anthracene (DMBA).
With the identification of mammary gland specific promoters, many transgenic mouse
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models of breast cancer have become available. It is also possible to transplant a mouse
mammary gland [91]. Another advantage is that the mouse genome is very well
characterized and mapped, especially compared to other rodent models such as the rat
[92]. However, there are also disadvantages to mouse models of breast cancer. The
biology of mammary cancer in mouse differs in some aspects from the biology of human
breast cancer. While the majority of human breast tumors are responsive to estrogen
(ER+), mouse mammary tumors are generally independent of estrogen. Also, the majority
of human breast cancer metastases locate to the bone, while mouse mammary cancer
metastasis locate to the lung [91].
Several transgenic mouse models of breast cancer exist. These include mice that
overexpress breast cancer genes such as C-myc or Ras. These genes are often under the
control of the mouse mammary tumor virus long terminal repeat promoter (MMTV). This
results in a strong, gland-wide expression of the oncogene resulting in multifocal
tumorigenesis. This is in contrast to human, single focal point tumorigenesis [91, 93].
Also, mice carrying gene knock-outs have been used to study the function of several
mammary gland tumor suppressors. Brca1 and Brca2 knock- out mice all have been
established [94, 95]. In general, these mice develop mammary cancer with less
multifocality than transgenic animals. Conditional knock-out mice, that exhibit gene
knock-out only in targeted tissues, have been used to overcome negative effects from
whole- organism knock-outs of genes such as embryonic lethality [91].
Mice have also been used in experimental metastasis models of breast cancer.
Here, human breast cancer cells are injected into the heart of immune- compromised host
mice. This model has been used to study bone metastasis of human breast cancer cells in
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a mouse, however, this model skips important steps in the metastasis pathway, such as
cell-cell detachment, invasion of local tissue and intravasation. Several other
experimental metastasis models exist that differ in injection site and site of metastasis
[93].

D.

Rat Models of Breast Cancer
Another popular rodent model of breast cancer is the laboratory rat. While mouse

models of breast cancer have been very popular due to the fact that transgenic and knockout mice are readily available, the rat model has some advantages over the mouse models
of breast cancer. Rats develop spontaneous mammary tumors, but chemical or oncogene
induction is also possible [96]. Rat mammary tumors are more similar to human breast
tumors than mouse mammary tumors are in etiology and biology. Mice often develop
mammary tumors that are associated with a viral etiology unlike rat and human
mammary tumors. [92]. Rat mammary tumors are hormone sensitive, which is the same
with the majority of human breast tumors [97-99]. DMBA treatment of both rats and
mice can be used for carcinogenesis. However, rats require only a single dose, develop
more tumors and exhibit a shorter mean latency, which makes them easier to use in an
experiment. DMBA induced tumors in the rat do not often metastasize and are localized
to the mammary gland. However, in mice leukemias, skin, lung, ovarian and stomach
cancers are common, resulting in early termination of experiments [99]. Rats develop
spontaneous mammary tumors, but the tumor incidence rate, tumor grade and age of
tumor onset vary with different inbred rat strains [100]. Also, inbred rat strains exhibit
differential susceptibility to chemical, radiation and hormone induced carcinogenesis [96,

22

100]. A study using DMBA as a carcinogen showed that a single dose of DMBA is
sufficient to induce multiple mammary tumors in the outbred Sprague- Dawley strain
[101]. Subsequent studies with different inbred and outbred rat strains showed that rat
strains differ in their susceptibility to DMBA carcinogenesis. The Sprague-Dawley and
Wistar-Furth (WF) rat strains are highly susceptible to DMBA carcinogenesis, while the
Long-Evans and F344 are resistant [102]. Other studies revealed that the Copenhagen
(COP) and Wistar-Kyoto (WKy) are resistant to DMBA induced carcinogenesis [100,
103, 104].
Differences in susceptibility to tumorogenesis after DMBA treatment are not due
to a strain difference in the ability to metabolize DMBA [100]. This indicates that there is
a genetic component to mammary cancer susceptibility in different inbred rat strains.
These rat strains can be used to study genetic elements that determine genetic
susceptibility to mammary cancer. This can then be translated back to humans, making
the study of genetic elements of breast cancer possible.

Mammary Cancer Quantitative Trait Loci (QTLs) in the Rat
Several rat QTLs that associate with mammary cancer risk have been identified.
The first study to identify mammary cancer QTLs in the rat used the susceptible WF and
the resistant COP rat strains. Progeny from a (COP x WF)F1 x WF backcross were treated
with DMBA and tumors were counted. A genetic linkage analysis using informative
microsatellite markers between the two rat strains was performed. This resulted in the
identification of one mammary cancer QTL, named Mammary Cancer Susceptibility 1
(Mcs1) on rat chromosome 2, with a LOD score of 3.8 [105]. Several more Mcs loci were
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identified in an extension of the original study. Here, two independent (COP x WF)F1 x
WF backcrosses and a F2 generation were treated with DMBA and a linkage analysis was
performed. This resulted in the confirmation of Mcs1 and the identification of Mcs2-4
[106]. Mcs2-4 map to rat chromosomes 7, 1 and 8, respectively. While Mcs1-3 are
associated with a decrease in tumor number, the Mcs4 locus is associated with an
increase in tumor number in animals that carry the COP allele in the Mcs4 region [106].
In an additional study, a genetic linkage analysis using the susceptible WF and the
resistant WKy strain was performed to identify additional Mcs loci. In this study, a
(WFxWKy)F1 x WF backcross was used for the linkage analysis post DMBA treatment.
This resulted in the identification of four more loci, named Mcs5-8. These loci are located
on rat chromosomes 5, 7, 10 and 14 respectively. The WKy allele for Mcs5, Mcs6 and
Mcs8 all reduce the susceptibility to DMBA induced carcinogenesis, while the WKy
allele for Mcs7 increases susceptibility. In addition, a locus was identified that interacts
with Mcs8, named Modifier of Mcs or Mcsm1 [107]. Mcs2 and Mcs6 overlap extensively,
however it is currently not known if both QTLs map to the same locus [108].
The most studied Mcs locus is the Mcs5 locus. The Mcs5 locus was initially
confirmed and mapped to a region of 115Mb on rat chromosome 5 using congenic lines
[109]. Congenic lines are generated by mating two rat inbred strains to generate a F1
generation. One of the rat strains is considered the donor (in this case the COP or WKy
resistant rat strains) and the other rat strain is the recipient (in this case the WF or
susceptible rat strain). The F1 generation is then backcrossed to the recipient (in this case
the susceptible WF rat strain) for up to ten generations. At each generation the genotype
of the animals is determined and only animals that maintain the donor allele in the region
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of interest are selected. This results in the introgression of the donor allele in to a
recipient genetic background only in the region of interest. The phenotype of these
congenic animals can then be compared to the inbred parent strain to identify if the
genomic region of interest is involved in modulating the phenotype. A diagram of the
technique is shown in figure 3. DMBA treatment of several more congenic lines for the
Mcs5 locus resulted in the identification of three Mcs5 subloci, named Mcs5a, Mcs5b and
Mcs5c. WKy alleles in the Mcs5a and Mcs5c regions decrease susceptibility, while a
WKy allele in the Mcs5b region increases susceptibility [110]. Further fine mapping
using congenic resulted in the identification of a synthetic QTL within Mcs5a, where at
least one WKy allele has to be present on the same chromosome at two distinct loci
within the Mcs5a locus. These distinct loci are named Mcs5a1 and Mcs5a2. Mcs5a1 and
Mcs5a2 are located in close proximity to the genes Fbxo10 and Frmpd1. Mcs5a congenic
animals show differential expression levels of Fbxo10 and Frmpd1 in thymus tissue
compared to WF homozygous animals. Also, Mcs5a1 and Mcs5a2 contain the rat
orthologous region to human genomic loci that associate with breast cancer risk, making
this a great model to study the function of these human risk loci [111]. Mcs5a acts
through the immune system and the WKy allele at the Mcs5a is associated with an
increase of γδTCR+ T-cells in the mammary glands compared to WF homozygous rats
[112]. Furthermore, chromatin looping of the Mcs5a region appears to be a m echanism
by which the Mcs5a alleles affect Fbxo10 expression levels in T-cells and this
mechanism appears to be conserved between the rat and human [113]. Overall, the Mcs5a
locus exemplifies how the rat can be used as a model to study the mechanisms of breast
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Figure 3. Generation of congenic animals. Adapted from Kim et al. [114]. Two inbred
rat strains are mated to generate a h eterozygous F1 generation. The F1 generation is
backcrossed to the recipient strain for ten generations. At each generation, the genotype
of the animals is test to ensure donor DNA is present in region of interest. This method
will introgress donor DNA into recipient genome only in regions of interest. Black bars
indicate DNA from donor strain, while white bars indicate DNA from recipient strain.
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cancer susceptibility in the human. Another set of rat mammary cancer QTLs were
identified using DMBA treatment and a linkage analysis of crosses between the
susceptible (SPRD-Cu3) and the resistant WKy rat strain. This resulted in the
identification of Mcstm1 and Mcstm2 on rat chromosomes 5 and 18and two loci involved
in modifying tumor growth rate, named Mcsta1 and Mcsta2 on rat chromosomes 10 and
18 [115, 116].
The mammary cancer loci discussed so far have all been identified through
linkage analysis using DMBA as a method of carcinogenesis induction. However, several
rat mammary cancer QTLs have been identified through using E2 as a method of
inducing carcinogenesis. These studies used the August-Copenhagen-Irish (ACI) rat
strain, which is susceptible to E2- induced carcinogenesis and the COP or BrownNorway (BN) rat strains, which are resistant to E2- induced carcinogenesis. This resulted
in the identification of several rat mammary cancer QTLs, named Estrogen induced
mammary cancer loci or Emca1-2, Emca4-8 [117, 118].
Several rat mammary cancer QTLs overlap; however, at this point it is not known
if they map to the same loci. Further fine mapping studies using congenics are needed to
determine if overlapping mammary cancer QTLs map to the same region.

Mcs 6
The work presented in this dissertation will involve two different mammary
cancer susceptibility loci, Mcs6 and Mcs1b.
Mcs6 was identified in a linkage analysis using the susceptible WF and the resistant WKy
rat strain post DMBA treatment [107]. Mcs6 was confirmed using several WF.WKy
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congenic lines spanning potential regions of the locus as shown in Figure 4 and Table 1.
Congenic lines were generated in the same manner as depicted in Figure 3. WF.WKy
congenic lines A, B and F all had a phenotype of fewer tumors compared to WF
homozygous animals (3.5, 3.9, 3.4 a nd 7.3 tumors per rat respectively). This indicates
that there is a genetic element in these lines that is modifying mammary cancer
susceptibility and that these lines contain the Mcs6 locus. Lines C and E showed a similar
tumor multiplicity when compared to WF homozygous animals (8.0, 7.2 and 7.3 tumors
per rat respectively). This indicates that these lines do not contain the Mcs6 locus. This
maps the Mcs6 locus to a region of 33Mb on rat chromosome 7, between bp 22,382,725
and 55,364,398. Overall, the WKy allele at the Mcs6 locus results in a 55% reduction in
tumor multiplicity. Interestingly, the Mcs6 locus overlaps the Mcs2 locus, which was
confirmed and physically mapped using WF.COP congenic lines [108]. It is currently not
known if both loci map to the same location and the phenotype results from the same
genetic element(s) in both QTLs. There are 111 genes annotated in the Mcs6 region using
the UCSC Rat Nov. 2004 (Baylor3.4/rn4) Genome Browser [119]. None of these
annotated genes are known breast cancer susceptibility genes. Figure 5 contains all 111
genes annotated in the Mcs6 locus.
The human orthologous region of the Mcs6 locus maps to a contiguous region on
human chromosome 12 between base positions 71,299,117 to 105,502,699. The human
region is inverted with respect to the rat region. All genes annotated in the rat Mcs6
region are also annotated in the human orthologous MCS6 region [108]. Therefore, the
Mcs6 rat model can be used to study the human breast cancer susceptibility gene(s) in
this region. Several potential breast cancer susceptibility SNPs that map to the MCS6
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Figure 4. WF.WKy congenic lines that define the Mcs6 locus. Adapted from Sanders
et al. (2011) [108]. Figure shows segment of rat chromosome 7 where the Mcs6 locus is
thought to be located and congenic lines that led to the mapping of the locus. Informative
markers between the WF and WKy rat strains used for genotyping are shown on r ight.
Red bars indicate WF.WKy segments that resulted in a resistant phenotype of fewer
tumors compared to WF homozygous animals. These congenic lines are thought to
contain the Mcs6 locus. Yellow bars indicate WF.WKy segments that resulted in a
susceptible phenotype of the same number of tumors compared to WF homozygous
animals. These congenic lines are thought not to contain the Mcs6 locus. Grey bars
indicate regions of recombination for which informative markers are missing. Brown bars
indicate WF.WKy segments for the Mcs2 locus These congenic lines are thought to
contain the Mcs2 locus. The Mcs2 and Mcs6 locus overlap extensively, however it is not
known if the two loci map to the same region. Superscript letters next to congenic line
name indicate congenic line of origin. Overall, using these congenic lines, the Mcs6 locus
was mapped to a region of 33Mb on rat chromosome 7, as indicated by orange bar.
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Table 1. Summary of mammary carcinoma multiplicity phenotypes from WF.WKy and WF.COP rat chromosome 7 congenic lines used to map
Mcs6 and Mcs2. Adapted from Sanders et al. (2011) [108].

Figure 5. Annotated genes in the Mcs6 locus. Figure adapted from Sanders et al. (2011)
[108]. Known an predicted transcripts annotated in the UCSC Rat Nov. 2004
(Baylor3.4/rn4) Genome Browser. X- axis represents the region of rat chromosome 7 that
contains the Mcs6 locus. Dashed lines mark ends of the Mcs6 locus. Color filled bars
indicate congenic animals that have been tested for the Mcs6 locus. Grey bars indicate
regions of recombination with no known genetic markers. Genomic markers between the
WF and WKy rat strains are shown on the bottom.
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locus have been studied in GWA studies of breast cancer. Five of these SNPs reached the
final validation step of their respective GWA study, but did not reach genome-wide
significance after the validation step. These are rs4146372, rs1154865, rs17740709,
rs7310517 and rs10507088 [120-122]. A list of all GWAS identified SNPs for the
MCS6 locus can be found in Table 2. rs1154865 had a p-value that was closest to
reaching genome-wide significance at 6.6x10-7, with a p-value of 1x10-7 required for
significance [120]. In a recent GWA study rs17356907 was identified to associate with
breast cancer risk. This SNP is located with the human orthologous region to Mcs6. The
p-value for the SNP is 1.8x10-22 and reached genome-wide significance. It is located in
close proximity to the gene NTN4 [62].
The Mcs6 locus is currently too large for a practical functional study. Fine
mapping of this locus is needed to identify a smaller region and to identify candidate
genes. However, the Mcs6 model is ideal for studying breast cancer susceptibility in the
MCS6 region. The human orthologous region to the Mcs6 locus is located in a contiguous
region on hum an chromosome 12. This results in less complexity when studying the
locus. Also, the Mcs6 locus maps to a human orthologous region that contains several
GWA study identified polymorphisms. Fine mapping of this locus will be the main goal
discussed in this dissertation for the Mcs6 locus.
Mcs1b
The second part of this dissertation will discuss the Mcs1b locus. The Mcs1 locus
was identified through a linkage analysis using the DMBA carcinogenesis susceptible
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Table 2. Human SNPs in the Mcs6 Orthologous Region that Have Been Reported in
Genome-Wide Association Studies as Potentially Associating with Breast Cancer
Susceptibility. Adapted from Sanders et al. (2011) [108]
SNP ID

Human Chr Location

Rat Chr Location

OR

P-value

rs4146372

12q72131594

7q54588907

nr

7.0 x 10-5

rs1154865

12q 72276104

7q54476579

nr

6.6 x 10-7

rs17740709

12q83423340

7q43765270

0.91

0.002

rs7310517

12q89149235

7q37548015

nr

1.04x10-3

rs10507088

12q97879744

7q29148172

nr

5.12x10-4

rs17356907

12q 96027759

7q30853605

0.91

1.8 x 10-22

Chr, chromosome; OR, odds ratio; nr, not reported
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WF rat strain and the resistant COP rat strain [106]. WF.COP congenic lines spanning
different intervals of the Mcs1 locus revealed three subloci, named Mcs1a-c [123].
Subsequently, several WF.COP congenic lines for the Mcs1b locus were developed, that
spanned different regions of the potential Mcs1b locus as shown in Figure 6. Five
WF.COP congenic lines showed the same tumor multiplicity post DMBA treatment as
WF homozygous animals and these lines have a susceptible phenotype. These congenic
lines are K, F3, U2, W2 and I4. This indicates that these congenic lines do not contain the
Mcs1b locus. Two WF.COP congenic lines resulted in fewer tumors post DMBA
treatment as compared to WF homozygous animals and therefore have a r esistant
phenotype. These congenic lines are T and N3. Line T and N3 resulted in a similar tumor
multiplicity. This indicates that the Mcs1b is located within these congenic lines. This
delimits the Mcs1b locus to a region of 1.8Mb on rat chromosome 2. The exact location
for the Mcs1b locus is rat chr2:42,364,155-44,195,382. Animals homozygous for the
COP allele in the Mcs1b locus showed a 56% reduction in tumor multiplicity compared
to WF homozygous animal. An ectopic mammary gland transplant assay and subsequent
treatment with DMBA revealed that the Mcs1b locus is acting in a mammary gland
autonomous manner [87].
Interestingly, the Mcs1b locus has a human ortholog. The human orthologous
region to the Mcs1b locus is located on human chromosome 5. Its exact location is chr5:
54,816,178-57,003,049. The human orthologous region to the Mcs1b locus maps to the
GWAS identified risk locus defined by the SNP rs889312 at 5q11.2 that associates with
an increase in breast cancer risk [61]. This risk locus is often referred to by the name
MAP3K1 and has been previously discussed in this dissertation (see section E of Genetic
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Figure 6. Map of congenic lines that define the Mcs1b locus. Adapted from denDekker
et al. (2012) [87]. Map shows potential location for the Mcs1b locus on rat chromosome
2. Dark grey bars are WF.COP congenic lines that resulted in fewer tumors compared to
WF homozygous animals post DMBA treatment. These lines are thought to contain the
Mcs1b locus. White bars are WF.COP congenic lines that have a phenotype similar to
WF homozygous animals post DMBA treatment. These congenic lines are thought to not
contain the Mcs1b locus. Informative markers between the two rat strains are shown on
the right. Black bar is the location of the delineated Mcs1b locus. The Mcs1b is located
on rat chromosome 2 and is about 1.8Mb in size.
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factors of breast cancer risk and Figure 2). There are currently nine transcripts located
within the Mcs1b locus that are expressed within the rat mammary gland. These are
Gpbp1, Map3k1, MIER3, Ankrd55, Il6st, Il31ra, Ddx4, Slc38a9, and Ppap2a. None of
these transcripts have coding sequence variants between the COP and WF rat strains;
therefore the causative genetic variant(s) is likely to be regulatory in nature [87].
The Mcs1b locus is an ideal model for the 5q11.2 identified human breast cancer
risk locus. As previously discussed, there are seven potential risk SNPs in the human
MCS1B locus (see section E of Genetic factors of breast cancer risk and Figure 2). Since
there are seven potential risk SNPs in the human rs889312 marked breast cancer risk
locus, it is important to determine how many potential risk associated sequence variants
there are in the rat Mcs1b locus. Therefore, identifying all sequence variants between the
two rat strains in the Mcs1b locus and identifying potential mechanisms of their action
will be my goal for the Mcs1b locus.

Overall Goal
The overall goal is to identify genetic elements within the Mcs6 and Mcs1b loci
that modify mammary cancer susceptibility. The goal is then to determine the underlying
mechanism and identify orthologous genetic elements within human breast cancer risk
loci.

Hypothesis and Aims
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The hypothesis is that both the Mcs6 and Mcs1b contain genetic elements that
control mammary cancer susceptibility. These genetic elements can be identified and act
through regulation of gene expression within the Mcs6 and Mcs1b loci.
Aim 1: Fine map the Mcs6 locus to a smaller chr 7 defined chromosomal segment
using congenic WF.WKy lines and DMBA- induced mammary carcinoma multiplicity
phenotyping.
Aim 2: Map and annotate Mcs1b sequence differences between susceptible WF
and resistant COP alleles using sequence capture, next-generation sequencing and in
silico approaches.
Aim 3: Perform functional analysis on Mcs1b sequence variants and human
tagged rs889312 SNPs.
Aim 4: Perform analysis of the overlap between rat genetic loci that associate
with mammary cancer risk and human GWAS identified breast cancer risk SNPs.
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CHAPTER II
FINE MAPPING OF THE MCS6 LOCUS
Introduction
The Mcs6 locus was initially identified in a linkage analysis. The DMBA
carcinogenesis susceptible WF rat strain and the resistant WKy were bred to generate a
F1 generation. Subsequently, the F1 generation was backcrossed to the susceptible WF
rat strain, generating an (WFxWKy)F1 x WF backcross. This was repeated to generate the
F2 generation. Rats were then phenotyped for tumor multiplicity post DMBA treatment.
This resulted in the identification of four loci controlling mammary cancer susceptibility
in the WKy rat. These loci are Mcs5, Mcs6, Mcs7 and Mcs8 [107]. The Mcs6 locus was
physically confirmed and mapped using congenic lines as shown in Figure 4. The locus
currently maps to a region of 33Mb on rat chromosome 7. The exact location of the locus
is between genetic markers D7Rat171 and gUwm64-3 (chr7:22,382,725-55,364,398).
There are 111 transcripts annotated in this region using the UCSC genome browser and
none of them are known breast cancer susceptibility genes. Importantly, all of the rat
transcripts annotated in this region are also found in the human orthologous region to the
Mcs6 locus [108]. Some of the MCS6 genes are expressed differentially between normal
breast tissue and ductal breast cancer tissue using an Oncomine search. Out of the 111
annotated genes, 14 genes show increased expression levels in breast cancer tissue
compared to normal breast cancer tissue. Also, 9 genes are expressed lower in breast
cancer tissue compared to normal breast tissue.
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One gene was both expressed higher and lower in breast cancer tissue,
depending on which study was considered in the analysis. While there are 111 annotated
genes in the Mcs6 region according to the UCSC genome browser, there were far more
annotated genes in the Rat Genome Database (137 genes) and the Ensemble Genome
Browser (215 genes) [108].
The human orthologous region to the Mcs6 locus is found contiguously on human
chromosome 12. The human orthologous region is inverted with respect to the rat Mcs6
region and is found at human chromosome 12: 71,299,117 to 105,502,699 [108]. The rat
Mcs6 locus and human MCS6 orthologous region share 37.7% of the bases and the span
99.9% of the size according to the UCSC genome browser. The human MCS6 region
contains several SNPs that have been tested in GWA studies of breast cancer. Five of
these SNPs entered the final validation step of their respective study but were found not
to be genome-wide significant [120-122]. One SNP, rs17356907, was identified in a
large breast cancer GWA study in 2013. The minor allele odds ratio is 0.91 (0.89–0.93),
suggesting that the SNP has a protective effect on breast cancer [62]. The SNP was
identified in a GWA study using a population of European decent. The SNP was then
tested in a GWA study using a population of East Asian decent and similar results were
seen [124]. It is located in close proximity to the NTN4 gene. This makes the Mcs6 rat
model an ideal model for studying the mechanisms of breast cancer susceptibility that are
present in the human MCS6 region.
The Mcs6 locus as it is currently mapped is very large. There are over a hundred
genes present in this region, making identification of a candidate gene difficult. Also, it is
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difficult to target this region for DNA sequencing in both rat strains due to its size to
identify candidate genetic variants between the rat strains. The goal for this locus is to
fine map it to a region that is small enough in size to warrant functional analysis of this
locus.
To fine map the Mcs 6 locus, several WF.WKy congenic lines for the locus were
developed that span different intervals of current Mcs6 locus. Developing congenic lines
is a laborious process that involves the selective breeding of rats over a long period of
time. It is currently the preferred method of identifying smaller intervals for rat QTLs. It
would also be possible to perform RNA-seq for the genes in the targeted region.
However, analysis of the expression levels of so many genes can be complex. It is also
not known if the Mcs6 locus is autonomous to the rat mammary gland, and therefore
selecting the right cell type would be a challenge. It is also possible to identify all genetic
variation between the two rat strains in this region using whole genome sequencing. This
would result in the identification of a lot of sequence variants and parsing out a potential
candidate would be difficult. Another reason why fine mapping the Mcs6 locus is
essential is because there is a possibility of several distinct QTLs may be present in this
region, which will only be identified through fine mapping of this locus. Several Mcs loci
have been mapped to distinct subloci upon fine mapping using congenic lines, including
the Mcs1 and Mcs5 loci [110, 123]. This is particularly important since the Mcs6 locus
currently spans a large portion of the chromosome. The Mcs6 locus would therefore
benefit from fine mapping to a smaller region. None of the annotated transcripts in the
Mcs6 region are known breast cancer susceptibility genes. Therefore, studying this locus
can result in the identification of a novel breast cancer susceptibility gene.
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The goal for the Mcs6 locus is to fine map the locus to a smaller region on r at
chromosome 7. The hypothesis is that the Mcs6 locus is located within on of three
independent WF.WKy congenic lines that span the 33Mb of the locus.

Methods
A.

Generating WF.WKy congenic animals for the Mcs6 locus
All animals used for this study were housed by the University of Louisville

Research Resources Center Animal Facility. All protocols were approved by the
University of Louisville IACUC committee.
Three WF.WKy congenic lines were developed to fine map the Mcs6 locus. These
are lines D, H and I. WF.WKy congenic line D was developed through a backcross of the
resistant Mcs6 congenic line B (Shown in Figure 4) to the WF rat strain (obtained from
Harlan). The resulting pups were genotyped for informative markers in the Mcs6 region
and recombinants were determined. A recombinant would be any animal that showed a
shorter WKy allele than the original line B. Recombinants were crossed again to WF
animals to expand the line. Brothers and sisters containing the same recombinant WKy
allele in the regions were mated to fix the new line. WF.WKy congenic lines H and I
were generated through the same breeding scheme as shown in Figure 3. In short, WF
and WKy inbred rats were obtained from Harlan and bred with each other. The resulting
heterozygous F1 males were backcrossed to WF inbred females to generate a
(WFxWKy)F1 x WF backcross. The resulting pups were genotyped to ensure a WKy
present at the Mcs6 locus. The rats were then backcrossed seven more times until the N8
generation. At each backcrossing the animals were genotyped to ensure the desired WKy
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allele was still present. At the N8 generation, brothers and sisters that contained the same
WKy allele were mated. The brothers and sisters used for this mating were heterozygous
for the WKy allele of interest. Their pups will be 25% WF homozygous, 50%
heterozygous and 25% WKy homozygous for the area of interest. The WF homozygous
and WKy homozygous females were selected for phenotyping. Line I was also tested at
the N9 generation. To get the N9 generation, the N8 generation was backcrossed to WF
females. Brothers and sisters were mated and resulting homozygous offspring were
tested.

B.

Genotyping of Animals
Animals had to be 12 w eeks of age for breeding. Pups were tail clipped at 5-8

days of age and tattooed for identification. Tails were digested in genomic lysis solution
supplemented with proteinase K at 15mg/ml. Tails were digested at 55°C overnight and
extracted using protein precipitation solution (Qiagen) and an isopropanol- ethanol DNA
extraction. DNA was amplified using GeneAmp Fast PCR Master Mix (Life
Technologies) and primers for microsatellite markers between the two rat strains. PCR
reactions were run on a 3% high resolution agarose gel (GeneMate) alongside PCR
reactions of control DNA samples. SNPs between the two rat strains were also used for
genotyping. DNA was amplified using a TaqMan Genotyping Master Mix (Life
Technologies) and primers and probes specific for the SNP marker. Analysis was done on
a StepOne Plus QPCR machine (ABI) using the StepOne software for genotyping
analysis. Informative markers used to generate congenic lines for the Mcs6 locus are
shown in Table 3.
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Position#
Forward sequence

Reverse sequence

Probe sequence (rat strain this
probe matches)

Used for
congenic
lines
D, H

29,204,226- AGTCCGAAGCCATATGTTGG TAAACCTATGAATTGCCCGC
29,204,458

33,195,152- CAAATGTTCAGACCACTAGA TACCCACCTCCACCCAGATA
33,195,408 TGAGA

37,616,505- CAGGTGAGGAGTGAATGAGG CCCAGGCAGAGATCATCAAT
37,616,890 A

44,462,790- CTGGTGCTTTTGGGTCTGTT
44,463,229

D7Mit28

D7Rat182

D7Rat83

D7Rat103

TCTCTTTGCCAGTCTGTTTT

68,056,925- GAGGAGGAAACAGAGGTGGT CACTCCCTGAGGCTCCTATG
68,057,251 C
D7Rat51
50,883,678- TTTGATGGACTTGGGACTTTC GTGGGCAAGGAATGAGTAGG
50,883,793
g7UL3-17
53,034,818- CACTGTTTGGTCTCCCTGTGG ACCAGAAGGAACAGGCAGCA
53,034,865
D7Mgh6
96,648,984- ACCCCAAAGACTTAAAAAAT TGGCTTGTTAATCGTGACTACTG
96,649,133 TAGC
D7Rat171
22,382,725- CGATGTTGTTCGAGGTGCTA CCTTCATTCCACCTTTGGTC
22,382,935
#
Position on rat chromosome 7 using RGSC Genome Assembly 3.4, Wf is Wistar- Furth and WKy is Wistar- Kyoto rat strain

D7Rat45

gUwmn64-3 55,364,143- AACAGTTCTCCTTTCCCTTC
55,364,398

47,145,688- ACATACATACACACCAGAAC ATCACTGAACGTAACAGGTGAC
47,145,774 GC

D7ARB16

GTGTCAAACTGTGGGGATCC

25,498,127- CATTGCTGTCCGCTCAACAC TGGTGCTTGTCCAGCTCTCTC
25,498,190

g7UL1-39

H

I

I

I

I

I

D, I

D, I

D, H

D, H

D, I

D, H

rs13459010 25,172,732 AATTACCTTTCTACCATTAGC CCACCCCAGATAAAAAGGAATTA AGGACAGTTCAATTC (WKy)
TTTGACA
A
TAAAAGGACAGTCCAATTC (WF)
rs65052669 46,915,037 TGCACATCTCCATCTTAAGAG ATACAATGGACTTTTTCAGCCAT TTATGTTTCACAGGAGC (WKy) D, I
CTT
AAA
TTATGTTTCACAGGAACCC (WF)

ID

Table 3. Informative markers used to genotype congenic lines for Mcs6.

C.

Phenotyping of animals
For each congenic lines, 18-65 female rats were tested. Female rats used in

phenotyping experiments were housed in an all-female rat room to ensure no exposure to
male rat hormones. The animals were administered DMBA at 50-55 days of age with a
single dose of 65mg/Kg body weight through oral gavage. DMBA was prepared by
suspension with sesame oil at 20mg/ml and then heated in a boiling waterbath for 20
minutes. The experiment was stopped 15 w eeks post DMBA treatment and tumor
multiplicity was determined by counting all mammary tumors
≥3x3mm. The spleens
were removed for phenotyping using the method described above. The data was analyzed
using Systat 13™. A nonparametric Mann- Whitney U test was performed, comparing
each congenic lines to the WF homozygous animals tested, after a significant KruskalWallis test for congenic lines H and I. A nonparametric Mann-Whitney U test was
performed comparing line D animals to WF animals tested alongside line D animals.

D.

Functional analysis of Mcs6 congenic lines
Location and annotated genes of the possible Mcs6 locus were determined using

the UCSC genome browser with the rat genome assembly Nov. 2004 ( Baylor 3.4/ rn4)
[119]. The human orthologous region to the Mcs6 locus was determined using the “In
other genomes (convert)” function in the UCSC Genome Browser. To determine
informative markers between the two rat strains, sequences for regions of interest were
downloaded from the UCSC genome browser and manually scanned for regions of
dinucleotide repeats. Primers against the repeats were designed and tested using WF and
WKy control DNA as described in the genotyping methods section. SNPs between the
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two rat strains were identified using the “SNPlotyper” function from the Rat Genome
Database [125]. Primers were designed against potential SNP regions using Primer 3. A
PCR reaction for WF and WKy control DNA was performed using Accuprime Taq (Life
Technologies) and the resulting samples were run on a 1% agarose gel. PCR products
were purified using a PCR Purification Kit (Qiagen). PCR products were then sequenced
using the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies). Sequenced
products were cleaned by adding Agencourt AMPure XL beads and 80% ethanol. Beads
were washed with 80% ethanol and DNA was eluted using molecular grade water.
Sequences were submitted to the University of Louisville DNA Core for analysis. To
identify SNPs tagged by GWAS identified polymorphisms, the software Haploview
version 2 was used. All SNPs with an r2 of 0.8 were considered tagged [126].

Results
A.

Phenotyping of WF.WKy congenic line D

The first WF.WKy congenic line tested was line D. Line D was initially tested at the
University of Wisconsin- Madison in the Dr. Michael Gould lab. In total, 35 c ongenic
line D females were tested in Wisconsin. These animals developed on average 5.6 tumors
per rat with a standard deviation of 4.0. Nineteen WF homozygous animals tested
alongside the line D congenic animals showed a tumor multiplicity of 7.3 tumors per rat
with a standard deviation of 3.6. A statistical analysis resulted in a p -value of 0.049.
Since this p-value is only marginally significant and there may be complexity to the Mcs6
locus and more animals needed to be tested. Thirty more line D congenic animals and 22
WF homozygous animals were tested at the University of Louisville. The line D congenic
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females developed 5.1 t umors per rat with a standard deviation of 2.6, w hile the WF
homozygous females developed 5.0 tumors pre rat with a standard deviation of 2.8. The
data were then pooled: A total of 65 congenic females and 41 WF homozygous females
were tested. Line D congenic females showed a tumor multiplicity of 5.4 tumors per rat
with a standard deviation of 3.4. R esults are shown in Table 4. T he WF homozygous
females showed a tumor multiplicity of 6.0 rats per animals with a standard deviation of
3.3. The tumor multiplicity data for the WF females was lower than previously reported
[107]. This may be due to differences in the environments at different animal care
facilities. The tumor multiplicity between the line D congenic animals and the WF
homozygous animals is not statistically significant (p-value 0.18). This suggests that the
Mcs6 locus is not located within line D. The original mapping of the Mcs6 locus is shown
in Figure 4. The Mcs6 locus was mapped to a region of 33Mb on rat chromosome 7. An
updated congenic line map that includes line D is shown in Figure 7. Note, some of the
congenic lines that are not needed to further fine map the Mcs6 locus have been removed
from Figure 7. Line F as shown in Figure 7 spans the entirety of the originally mapped
Mcs6 locus. Congenic line D overlaps line F extensively. Since the WF.WKy congenic
line D has a susceptible phenotype and does not contain the Mcs6 locus, this splits the
locus into two possible locations. The first possible location is the region of
recombination for line D and F. There are no know n genetic markers between the WF
and WKy rat strains in this region. This region is 325Kb in size. The second possible
location is the region on non-overlap between the congenic lines F and D. This region is
8.5Mb in size. To test if the Mcs6 locus is located in one of these two possible locations,

48

49

Figure 7. Mcs6 congenic line map with the addition of WF.WKy congenic line D.
Yellow bars indicated WF. WKy congenic lines have a susceptible phenotype. This
means these animals developed the same amount of tumors as WF homozygous animals
and the Mcs6 locus is not located within these genomic regions. The red bar (line F)
indicates a WF.WKy congenic line that has a resistant phenotype. This means these
animals developed fewer tumors compared to WF homozygous animals and the Mcs6
locus is found in this genomic region. Tumor multiplicity and number of animals tested is
shown inside congenic line. Line F spans the entirety of the previously mapped Mcs6
locus. Grey bars indicate regions of recombination. Informative markers between the two
rat strains are missing in these regions. Congenic line C spans a larger genomic region as
shown in this figure. The entirety of line C can be seen in Figure 4. Congenic line D splits
to Mcs6 locus into two possible locations indicated by orange bars.
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two independent congenic lines spanning the regions of interest were developed and
phenotyped.

B.

Phenotyping of WF.WKy congenic lines H and I

Two separate WF.WKy congenic lines spanning the two possible location of Mcs6 were
developed as described in Figure 3. The two independent congenic lines were named H
and I and their genomic location are shown in Figure 8. Eighteen WF.WKy congenic line
H animals were treated with DMBA and tumors were counted. Line H animals developed
on average 6.6 t umors per animal with a standard deviation of 2.3 t umors. Eighteen
animals were also tested for line I. Line I animals developed on average 3.4 tumors per
rat with a standard deviation of 2.2 tumors. The tumor multiplicity of these two congenic
lines was compared to WF homozygous animals that were treated at the same time as
congenic lines H and I. Overall, 20 W F homozygous animals were tested. The WF
homozygous animals developed on average 7.7 tumors per rat with a standard deviation
of 3.9 tumors. Results are shown in Table 4. Line H is not statistically different from WF
homozygous animals with a p-value of 0.27. Line I is statistically significant with a pvalue of 0.0005. A WKy allele in the line I genomic region results in a 56% reduction in
tumor multiplicity compared to WF homozygous animals. These results map the Mcs6
locus to part of the line I genomic region. An updated congenic line map for the Mcs6
locus is shown in Figure 9. T he map shows the new location of the Mcs6 locus. It is
interesting that the tumor multiplicity phenotype for congenic lines I and F are identical,
suggesting that the same genetic element may be acting in both congenic lines. The Mcs6
locus was reduced in size from 33Mb to 8.5Mb on rat chromosome 7 using congenic
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Figure 8. Mcs6 congenic line map showing the location of independent congenic lines
H and I. Yellow bars indicated WF. WKy congenic lines have a susceptible phenotype.
This means these animals developed the same amount of tumors as WF homozygous
animals and the Mcs6 locus is not located within these genomic regions. The red bar (line
F) indicates a WF.WKy congenic line that has a resistant phenotype. This means these
animals developed fewer tumors compared to WF homozygous animals and the Mcs6
locus is found in this genomic region. Tumor multiplicity and number of animals tested is
shown inside congenic line. Line F spans the entirety of the previously mapped Mcs6
locus. Grey bars indicate regions of recombination. Informative markers between the two
rat strains are missing in these regions. Green bars indicate the location of the two
independent WF.WKy congenic lines H and I. These lines were generated to map the
Mcs6 locus to two possible locations indicated by orange bars.
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Table 4. Summary of mammary carcinoma multiplicity phenotypes from WF.WKy
congenic lines D, H and I used to map Mcs6
WF.WKy congenic line
WF.WKy
congenic line
WF
WF
H
I
D
~D7Rat171/
D7rat83/
rs13459010/
Congenic region
D7Rat182
D7Mgh6
D7ARB16
Marker/Marker1
3.4 (2.2)
7.7 (3.9)
5.4 (3.4)
6.0
Mean (SD4) mammary 6.6 (2.3)
(3.3)
carcinomas per rat
18
18
20
65
41
N
0.272
0.00052
0.183
p-value
1

Markers spanning the maximal WKy or COP Chr 7 segment that was introgressed onto a
susceptible WF genetic background are given. Note proximal end of line H is not known.
2
p-values are from Mann-Whitney nonparametric post hoc tests comparing each congenic
line to the WF phenotype after a statistically significant Kruskal-Wallis test with a p-value
0.0002
3
p-value is from Mann-Whitney nonparametric test comparing line D to the WF phenotype
4
Standard deviation
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Figure 9. Mcs6 congenic line map of fine mapped Mcs6 locus. Yellow bars indicated
WF.WKy congenic lines have a susceptible phenotype. This means these animals
developed the same amount of tumors as WF homozygous animals and the Mcs6 locus is
not located within these genomic regions. The red bars (line F and I) indicate WF.WKy
congenic lines that have a resistant phenotype. This means these animals developed fewer
tumors compared to WF homozygous animals and the Mcs6 locus is found in these
genomic regions. Tumor multiplicity and number of animals tested is shown inside
congenic line. Grey bars indicate regions of recombination. Informative markers between
the two rat strains are missing in these regions. Phenotyping results from WF.WKy
congenic lines map the Mcs6 locus to the region shown in orange. The locus was reduced
in size from 33Mb to 8.5Mb using congenic lines D, H and I.
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lines D, H and I. The location of the Mcs6 locus is now on r at chr7: 46,915,03755,364,398.
Discussion
The goal of aim 1 was to fine map the Mcs6 locus to a smaller genomic region.
The Mcs6 locus was initially mapped to a region of 33Mb on rat chromosome 7 using
WF.WKy congenic animals. The Mcs6 locus was fine mapped to a region of 8.5Mb using
three WF.WKy congenic lines and DMBA- induced mammary carcinoma multiplicity
phenotyping. The new location for the Mcs6 locus is chr7: 46,915,037-55,364,398. Fine
mapping of the Mcs6 locus resulted in a 75% reduction in size of the locus. Previously,
111 transcripts were annotated in the Mcs6 locus, making a functional analysis of this
locus difficult [108]. The fine mapped Mcs6 locus contains 22 t ranscripts. These are
shown in Figure 10. None of these genes are known breast cancer susceptibility genes,
but all transcripts found in the rat Mcs6 locus are also found in the human orthologous
region. Therefore, studying the Mcs6 locus can result in the identification of a novel
breast cancer susceptibility gene. It is possible to perform RNA seq or design primers for
RT-QPCR for the 22 genes annotated in this region. This could reveal any differences in
the expression levels between the two rat strains and could help identify a candidate gene
for the Mcs6 locus. However, it is necessary to determine if the Mcs6 locus acts in a
mammary gland autonomous manner in order to determine which tissue type to use for
RNA expression analysis.
An Oncomine search revealed that several of the genes found in the Mcs6 locus
are differentially expressed between normal human breast tissue and ductal breast cancer
tissue. These genes are PPP1R12A, ZDHHC17, NAV3 and TSPAN [108]. PPP1R12A or
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Figure 10. T ranscript map of the fine mapped Mcs6 locus. Yellow bars
indicated WF. WKy congenic lines that resulted in a susceptible phenotype. This means
these animals developed the same amount of tumors as WF homozygous animals and the
Mcs6 locus is not located within these genomic regions. The red bar (line I) indicates a
WF.WKy congenic line that has a r esistant phenotype. This means these animals
developed fewer tumors compared to WF homozygous animals and the Mcs6 locus is
found in this genomic region. Grey bars indicate regions of recombination. Informative
markers between the two rat strains are missing in these regions. Congenic lines D, C and
I map the Mcs6 locus to a 8.5Mb region shown in orange. Informative markers used to
delineate congenic lines are shown at the bottom. Rat orthologous region to human breast
cancer GWAS identified SNPs are shown on t op right. All annotated transcripts
according to the UCSC genome browser Nov. 2004 (Baylor 3.4/rn4) assembly are shown
in blue. The fine mapped Mcs6 locus contains 22 annotated transcripts.
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Myosin Phosphatase- Targeting Subunit 1 (MYPT1) is a subunit of Myosin Phosphatase
and is involved in smooth muscle contraction and possibly hypoxia [127]. MYPT1 is also
involved in phosphorylation of RB1 leading to cell cycle progression [128]. ZDHHC17
or Huntingtin- Interacting Protein 14 (HIP-14) is a protein involved in endocytosis and is
implicated in Huntington’s disease [129]. NAV3 or Neuron Navigator 3 is a protein
involved in axonal guidance. Chromosomal aberrations of chromosome 12 i n several
cancers have resulted in the loss of the NAV3 gene. This implicates this gene in several
types of cancers including colorectal cancer, T-cell lymphomas, neuroblastomas and
squamous cell carcinomas [130-133]. TSPAN or Tetraspanin is part of a family of
transmembrane proteins involved in cell signaling. Proteins in this family are involved in
regulation of cell growth and motility. Members of the Tetraspanin family are implicated
with a variety of cancers including ovarian carcinomas [134].
Six human GWAS identified polymorphisms map to the rat orthologous region of
the Mcs6 locus. A list of the SNPs can be found in Table 2. O ne of these GWAS
identified polymorphisms reached genome-wide significance in its respective study. This
SNP is rs17356907. The rat orthologous region of this SNP maps to the proximal end of
WF.WKy congenic line D. The SNP was found to reduce breast cancer risk with an OR
of 0.91 [62]. It is interesting that this polymorphism maps to a congenic line that has a
susceptible phenotype and therefore does not contain the Mcs6 locus, indicating that
rs17356907 may not be the human ortholog to the Mcs6 locus. It is possible that the
Mcs6 locus is complex and that there are multiple genetic elements controlling mammary
cancer susceptibility. It appears that there is at least one genetic element in congenic line
I that modifies mammary cancer susceptibility. However, congenic line D is very large
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and may contain phenotypically opposing genetic elements that mask the phenotype. To
identify if there are opposing genetic elements located in congenic line D, recombinant
congenic lines that span shorter intervals than line D need to be phenotyped.
Two GWAS identified polymorphisms map to the rat orthologous region
contained in congenic line I. These are rs1154865 and rs4146372. Both SNPs failed the
last validation step in their respective study. rs1154865 was the closest to reaching
genome-wide significance with a p -value of 6.6x10-7 when 1x10-7 is required for
genome-wide significance. rs1154865 tags at least six other SNPs. There is no tagging
information for SNP rs4146372 in the Haploview database. It is possible that one of these
two identified SNPs or the SNPs they tag are the human ortholog of Mcs6. However, it is
also possible that the MCS6 SNP has not been identified in a GWAS study or has not
been made available in public databases yet.
There are currently seventeen known SNPs between the WF and WKy rat strains
in the Mcs6 region. These were identified using the SNPlotyper software at the Rat
Genome Database [125]. The identified SNPs in the Mcs6 region are shown in Table 5.
There are likely to be many more sequence variants between the two rat strains in this
region. It is necessary to sequence both rat strains in the Mcs6 region to identify all
sequence variants. However, sequencing technique for targeted sequencing currently
available require smaller genomic regions for sequencing. Further fine mapping of the
Mcs6 locus using recombinant congenic lines that originate from line I may be necessary
to feasibly identify candidate Mcs6 sequence variants.
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Table 5. Mcs6 SNPs between the WF and WKy rat strain.
ID
Position#
Forward Primer
rs1349010
22613971 TGCTGAAACTGCATTCAAAGA
rs13457291

29833956

TCAACCTTTGCCCTTTCATT

SNP2793282
rs63992414

40318750
41254704

TCCTTTTGCCCATGTTTCTC
AGGACAAAAGACATCCCCAGT

SNP2793293
SNP2793296

41716640
42001299

rs64625218

44306171

TGTCATTGCTTCCCCTCAAT
AAGAAAAGAAAATGTGGGAC
CTT
TTAGAAAAGGAAGCGGGTCA

rs64542424

44669020

Reverse Primer
TTGCATCTCTAACTCCTGGGT
A
GGGTTGCAGAGGGATATACT
GA
TCTTGATGGCTTCATGGACA
CATGAATCTCAAAAGGAGCT
GTT
AAGAGGCAGCGTTTAAGGTG
CGGGCATGAAAATGTCAATC
CAGCATTGAAAAGGAGATGG
A
AGCGTCGCTGGTAGTGGTAG

GGATAGGTCTAATCGTGG
AGGA
rs1348617
46124020 CCCACCCACTCTACCTCATC
ACTGCCATGAATGGAAGGTC
rs66070275
46166066 ATTGCATCAGTTCGCACAAG
ATTCAGTGGCCTGGTTCATC
rs65272077
46420580 ATGCTTGCGGTCTTTGTACC
AATATGCCTGAGCCGTTTTG
rs65052669
46915037 TGTGACTTGCACATCTCCATC
TGGATACTGGCACCTCAATG
rs13453157
47762262 CTGAAGGAACTCGTGGAGGA
GGCCACAGGGGTACAGAGT
rs66140753
51524725 TCTCAGTCTGGGACACCTCA
CAACACCCCACAAGGAGACT
rs63864648
51704903 AGAGCCCAGACTTCGTCCTT
GCAATGACAGGGGTCTCAGT
rs64230269
52093888 GCTTGCGTGCTGGTTTTACT
TTTCTCGTGAATGGGGAAAG
SNP2793378
53123731 GCTTTGAGCACTGATGCTTTC
TGCGTGTACAATCCCAACAT
#
positions are on rat chromosome 7 using UCSC Genome Browser Nov.2004 (Baylor 3.4/rn4)
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In conclusion, the Mcs6 locus was fine mapped from a region of 33Mb to a region
of 8.5Mb. Previously, the locus contained 111 a nnotated genes, while the fine mapped
Mcs6 locus contains 22 g enes. The fine mapped Mcs6 locus can be used to identify
candidate genes by testing the differences in expression levels of the Mcs6 genes between
the two rat strains.
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CHAPTER III
IDENTIFICATION OF MCS1B SEQUENCE VARIANTS

Introduction
The second part of this dissertation is focused on t he rat mammary cancer
susceptibility locus Mcs1b. The Mcs1 locus was identified through a linkage analysis of
the DMBA mammary carcinogenesis resistant COP rat strain and the susceptible WF rat
strain [106]. The Mcs1 locus contains three subloci that were identified using several
WF.COP congenic lines. These subloci are Mcs1a, Mcs1b and Mcs1c [123]. The Mcs1b
locus was further fine mapped using congenic animals. It maps to a region of 1.8Mb on
rat chromosome 2 [87]. A map showing the congenic lines defining the Mcs1b locus is
shown in Figure 6.
The Mcs1b locus has a human ortholog. The SNP rs889312 was identified in a
breast cancer genome-wide association study in 2007. The SNP has an OR of 1.13 (1.101.16), meaning that the minor allele of this SNP increases the chances of developing
breast cancer [61]. rs889312 is in linkage disequilibrium with at least six other SNPs,
meaning that any of these SNPs could be the actual causative SNP. rs889312 and the six
SNPs it tags are located on a haplotype block that is 280kb in size. The haplotype block is
shown in Figure 2. There are three transcripts located within the rs889312 haplotype
block. These are MAP3K1, SETD9 and MIER3. However, Setd9/ SETD9 is not expressed
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in the rat mammary gland and human breast tissue [87]. There is the potential of more
SNPs tagged by rs889312 being identified through ongoing sequencing studies such as
the 1000 G enomes Project. This means that the causative SNP may not be located in
public databases yet. This makes studying the genetic elements controlling genetic
susceptibility to breast cancer in the human difficult. It is easier to study the genetic
elements in the rat, since only two inbred rat strains need to be sequenced to identify all
the genetic variation that is present between the two rat strains in this region. Since there
are multiple candidate SNPs in the human, it is likely that there will be multiple genetic
variants present in the rat. Note, only SNPs are used in human breast cancer genomewide association studies. It is possible that rs889312 tags an INDEL that is the actual
causative genetic element. Therefore, SNPs and INDELs will be identified between the
two rat strains in the Mcs1b region. It is not possible to identify copy number variation
(CNV) with the sequence capture technique that was used for this aim. Sequence capture
depends on a microarray chip and complementary primers, which introduces bias when it
comes to sequence frequency. Identification of copy-number variation depends on t he
analysis of sequence frequency across a region.
The goal for this aim is to identify all the genetic variants between the COP and
WF rat strains in the Mcs1b region to generate a list of candidates. The hypothesis is that
there are multiple genetic variants between the two rat strains in this region.

Methods
A.

Sanger sequencing of rat orthologous region to rs889312 risk SNP bin
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Figure 2 shows the human haplotype block that associates with breast cancer risk.
The rs889312 correlated SNP are found in a SNP bin cluster within this haplotype block.
The rat orthologous region to the rs889312 risk SNP bin was sequenced in the WF and
COP rat strain using standard Sanger sequencing. This region is on rat chr 2: 43,168,80643,185,894. For this, the splenic DNA from a homozygous WF and homozygous COP
animal was used. The region to be sequenced was divided into 14 f ragments and
overlapping primers for each fragment were designed using Primer 3. DNA was
amplified using Accuprime Taq (Life Technologies) and the resulting samples were run
on a 1 % agarose gel (GeneMate) and stained with SybrGold (Life technologies). PCR
products were purified using a QiaQuick PCR Purification Kit (Qiagen) or if multiple
bands were present, the right size band was extracted using a QiaQuick Gel Purification
Kit (Qiagen). PCR products were sequenced using the BigDye Terminator v3.1 C ycle
Sequencing Kit (Life Technologies). Sequenced products were cleaned by adding
Agencourt AMPure XL beads and 80% ethanol. Beads were washed with 80% ethanol
and DNA was eluted using molecular grade water. Sequences were submitted to the
University of Louisville DNA Core for analysis. Sequences were analyzed using the
DNASTAR Lasergene 8 SeqMan program.

B.

Library preparation for sequence capture of the Mcs1b locus
The targeted region for sequencing the Mcs1b locus is on rat chromosome 2:

42,200,000- 44,500,000. The DNA sequence for this targeted region was identified by
using the UCSC Genome Browser DNA function. The Nov. 2004 ( Baylor 3.4/rn4)
assembly was used and this sequence is based on the Brown Norway (BN) rat strain. The
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targeted DNA sequence was then submitted to NimbleGen. The sequence capture arrays
were custom NimbleGen Sequence Capture Developer 385K Arrays. The custom
NimbleGen sequence capture microarrays covered 88.9% of the targeted bases in the
Mcs1b region. As a control, a human sequence capture microarray was used. The human
practice array used was NimbleGen Sequence Capture Practice 385K Array. DNA
libraries for the sequence capture were prepared using the GS FLX Titanium General
Library Preparation Method Kit (Roche). DNA used was from a WF homozygous animal
and a WF.COP line T congenic animal. DNA was extracted using the Blood and Tissue
DNAeasy kit (Qiagen). Human genomic DNA (Bioline) was used for practice arrays. The
libraries were prepared according to the library preparation manual. In short, the libraries
were prepared by fragmenting 10μg of gDNA using a nebulizer and nitrogen gas for 1
minute. T he fragmented DNA was run on a 1% low melting agarose gel (Lonza) and
stained with SybrGold (Life technologies). Fragments between 800-500bps were gel
extracted using a Gel Purification Kit (Qiagen). DNA quality was assessed using a DNA
Bioanalyzer DNA 7500 LabChip (Agilent). DNA fragments were polished and adapters
were ligated. DNA fragments were then immobilized on magnetic streptavidin-coated
beads, via the biotin moiety of one of the adaptors. A fill- in reaction was performed to
remove any nicks in the DNA. As a final step the library was melted off the beads,
resulting in single stranded DNA. The quality and quantity of the ssDNA was determined
using a Bioanalyzer RNA Pico 6000 LabChip (Agilent).

C.

Sequence capture of Mcs1b libraries
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The prepared libraries were hybridized to the microarrays using the Titanium
Optimized Sequence Capture Array Delivery Kit according the manufacturer’s
instructions. In short, the pre-captured DNA was amplified using the GC-RICH PCR
system dNTP pack (Roche) according to manufacturer’s instructions. PCR primers used
are shown in Table 6. PCR products were purified using the QiaQuick PCR Purification
Kit (Qiagen). DNA quality and yield were measured using a Bioanalyzer DNA 7500
LabChip (Agilent). The amplified libraries were then annealed to the microarray
sequence capture chips using the NimbleGen Hybridization System 4. The hybridization
system was heated to 42°C for three hours prior to hybridization. 3µg human COT DNA
(C0t) was added to the amplified libraries to get rid of repetitive DNA. Hybridization
enhancing oligos were added to the amplified DNA and the DNA was denatured at 95°C
for 10 m inutes. The DNA was loaded onto the microarray sequence capture chip and
allowed to hybridize in the hybridization machine for 72 hours at 42°C. Microarrays were
washed and captured DNA was eluted using 125mM NaOH. Captured DNA was purified
using the Qiagen MinElute PCR Purification Kit. Samples were amplified using the same
conditions as for the pre-captured LM- PCR. Samples were purified using the Qiagen
QiaQuick PCR Purification Kit. Quantity and Quality of the captured DNA was
determined using a Bioanalyzer DNA 7500 LabChip (Agilent) and NanoDrop 2000
spectrophotometer.

D.

RT- QPCR on captured versus pre-captured samples to determine enrichment of
libraries in Mcs1b DNA
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Table 6. Primers used for Mcs1b sequence capture.
Name
Sequence
LM-PCR 454 Ti-A Oligo
CCA TCT CAT CCC TGC GTG TC
LM-PCR 454 Ti-B Oligo
CCT ATC CCC TGT GTG CCT TG
Hybridization Enhancing 454 Ti-A
CCA TCT CAT CCC TGC GTG TCC CGA CTC
Hybridization Enhancing 454 Ti-B
CCT ATC CCC TGT GTG CCT TGG CAG TCT
QPCR oligo NSC-0237, forward
CGC ATT CCT CAT CCC AGT ATG
QPCR oligo NSC-0237, reverse
AAA GGA CTT GGT GCA GAG TTC AG
QPCR oligo NSC-0247, forward
CCC ACC GCC TTC GAC AT
QPCR oligo NSC-0247, reverse
CCT GCT TAC TGT GGG CTC TTG
QPCR oligo NSC-0268, forward
CTC GCT TAA CCA GAC TCA TCT ACT GT
QPCR oligo NSC-0268, reverse
ACT TGG CTC AGC TGT ATG AAG GT
QPCR oligo NSC-0272, forward
CAG CCC CAG CTC AGG TAC AG
QPCR oligo NSC-0272, reverse
ATG ATG CGA GTG CTG ATG ATG
A50 control inside 1 forward
CAC TCT CGG GTG AGA CAA CA
A50 control inside 1 reverse
TGT CGA AGG CAC AAA GAC TG
A50 control inside 2 forward
GGA GTG CTT TTC GGA CAG AG
A50 control inside 2 reverse
CGG AAG GAA AGC AAG AGT TG
A50 control inside 3 forward
ACA GTA CCC ACT GGC TGG TC
A50 control inside 3 reverse
GCT GGT TGC TCA TTC TAG GG
A50 control inside 4 forward
CAC ATG GCA CCA TCT CAA GT
A50 control inside 4 reverse
CCT GGT TGC CAC TAC AGT CA
A50 control outside 1 forward
GAG GCT GTT GAT GAT GCA GA
A50 control outside 1 reverse
TGG GAA GTG CCA TGT TGT AA
A50 control outside 2 forward
CAT GCT TCT GGT TTT GGT GA
A50 control outside 2 reverse
TGG AGA AAG CAT GAC CAC AG

Step used for
Pre- and post- capture LM-PCR
Pre- and post- capture LM-PCR
Hybridization step
Hybridization step
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment
Confirmation of Mcs1b DNA enrichment

To determine if the sequence capture was successful in enriching the postcaptured libraries in Mcs1b DNA, a RT- QPCR reaction can be performed on t he precaptured versus the post- captured samples. For the QPCR reaction, SyrbGreen (Life
Technologies) and 1ng of ssDNA was used. As a control, gDNA was used. Primers for
the QPCR reaction are shown in Table 6. The RT- QPCR reactions were run on an ABI
PRISM 7900HT Sequence Detection System. The Ct values for the post-captured
samples were then subtracted from the Ct value of the pre-captured sample. A positive
delta Ct value indicates enrichment.

E.

454 next-generation sequencing, assembly of Mcs1b genomes for WF and COP
rat strains and identification of genetic variants
Mcs1b enriched WF and COP libraries were sent to the University of Kentucky

for 454 next-generation sequencing. Two lanes of an 8- well plate were used for the WF
library and 3 lanes were used for the COP library. The resulting sequences were aligned
separately against the Rattus norvegicus (Brown- Norway) genome build 4.1 us ing
SSAHA2 to generate BAM files. A pileup and BCF file were made for each position with
a coverage of ≥1 on rat chromosome 2: 42,200,000-44,500,000. If the allele count of the
non reference allele made up less than 25% of the total coverage, that record was flagged.
An SQL query was used to select those positions from the database where either sample 1
was different from the reference and had a total coverage of 20 or greater OR sample 2
was different from the reference and had a total coverage of 15 or greater AND that
consensus call that had a sufficient enough coverage to pass was not flagged. After a
position was selected, the calls for all samples at that position were retrieved. If the call
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was heterozygous and one of the alleles had a count of 2 or less, it was converted into a
homozygous call of the stronger allele. If both alleles had a count of 2 or less, it was
converted to a N/N.

F.

Confirmation of Mcs1b genetic variants
All 454 ne xt generation sequencing data was visualized using IGV 2.0

(http://www.broadinstitute.org/igv/v2.0). The data were filtered using an SQL query to
identify SNPs between the two rat strains. Also, the data was filtered to identify any
INDELs between the two rat strains with a coverage of ≥5 for each sample. Primers were
designed for each SNP and INDEL to be confirmed using Primer 3. In total, primers were
designed for 130 potential SNPs and 13 INDELs. The WF and line T (COP) DNA used
for confirmation of genetic variants was pooled from three homozygous animals each.
DNA was amplified using Accuprime Taq (Life Technologies) and the resulting samples
were run on a 1% agarose gel (GeneMate) and stained with SybrGold (Life technologies).
PCR products were purified using an ExcelaPure 96-well UF PCR Purification kit
(EdgeBio) or QiaQuick PCR Purification kit (Qiagen). PCR products were sequenced
using the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies). Sequenced
products were cleaned by adding Agencourt AMPure XL beads and 80% ethanol. Beads
were washed with 80% ethanol and DNA was eluted using molecular grade water.
Sequences were submitted to the University of Louisville DNA Core for analysis.
Sequences were analyzed using the DNASTAR Lasergene 8 SeqMan program.

G.

Sequencing of gaps using Sanger sequencing
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There are several gaps in the Mcs1b sequencing data for the WF and COP rat
strain. Sequencing gaps in the rat orthologous region to the rs889312 haplotype block
were sequenced using standard Sanger sequencing (RNO2: 42,974,029-43,219,434). To
identify gaps, the program IGV 2.0 was used to visualize the WF and COP assemblies.
The rat orthologous region to the rs889312 was scanned manually for gaps between the
two rat strains and location of gaps were noted. Primers surrounding the gaps were
designed using Primer3. The DNA from three homozygous WF and three homozygous
WF.COP line T animals were used for sequencing. DNA was sequenced as described
above.

H.

Bioinformatic analysis of A46-SNP-A, A074-SNP-17 and A074-SNP-18
The

program

Alternative

Splice

Site

Predictor

(http://wangcomputing.com/assp/index.html) was used to determine changes in splicing
sites for the Map3k1 gene. The entire Map3k1 sequence was added to the program
(RNO2: 43,062,252-43,102,501) and differences in the predicted splicing sites when
changing the SNP alleles were determined.
The

program

Variant

Visualizer

from

the

Rat

Genome

Database

(http://rgd.mcw.edu/rgdweb/front/select.html) was used to identify the Mcs1b candidate
SNP alleles in different rat strains. The program uses the RGSC Genome Assembly 3.4.
The region of interest was entered into the program and all available rat strains were
selected for analysis. Additionally, genotyping data for the WF/Nhsd and COP/NHsd rat
strains were added since the program does not include the WF rat strain.
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The UCSC Genome Browser “in other genomes (convert)” function was used to
identify the human orthologous region to the identified sequence variants between the
two rat strains. When there was no orthologous region identified, the LAGAN alignment
tool with the settings VISTA for CNS - window: 30 bp, m in width: 30bp, CNS identity:
60%, Min Y%: 50 was used. The UCSC Genome Browser uses a large window size to
determine orthology resulting in no orthologous regions identified.
The human orthologous region for A102-INDEL-2 was determined using the
UCSC Genome Browser “in other genomes (convert)” function. Since the INDEL does
not have a human orthologous region using the genome browser, additional surrounding
sequence was added until an orthologous region was found. DNA was then downloaded
from the genomes browser for the human orthologous region with an additional ±50kb of
surrounding sequence. This was pasted into Microsoft Word and manually analyzed for
repetitive elements.

Results
A.

Identification of A046-SNP-A through Sanger sequencing of the WF and COP rat
strain
We initially sequenced the rat orthologous region to the human rs889312 SNP bin

to identify any sequence variants between the WF and COP rat strain. The rat
orthologous region to the rs889312 SNP bin is located on rat chromosome 2: 43,168,80643,185,894. This 17kb region was divided into 14 fragments and overlapping primers for
the 14 fragments were designed. Out of the 14 f ragments, 11 w ere fully sequenced in
both the WF and COP rat strain using Sanger sequencing. No PCR could be generated for
fragments that did not yield sequence. Sequencing resulted in the identification of one
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SNP named A046-SNP-A. This is located on rat chromosome 2: 43,175,144. The WF and
Brown-Norway (BN) reference share the same allele, while the COP allele is different.

B.

Confirmation of Mcs1b enrichment after sequence capture
Sequencing of the rs889312 SNP bin resulted in the identification of A046-SNP-

A. It is possible that there are more genetic variants that are located outside the
orthologous region to the rs889312 SNP bin that are involved in the Mcs1b phenotype.
Therefore, it is necessary to sequence the entire Mcs1b region. NimbleGen sequence
capture arrays were used to sequence the 1.8Mb defining Mcs1b region, since it is not
feasible to sequence the entire Mcs1b region using Sanger sequencing. This will result in
the identification of every sequence variant between the two rat strains. The NimbleGen
Sequence Capture mircoarrays can be used to enrich a DNA library in a targeted region.
Compared to whole genome sequencing, sequence capture allows for less sequencing
reactions to get a good coverage across the targeted region. A RT-QPCR reaction can be
performed on t he pre-captured versus the post-captured sample to ensure that a D NA
library has been enriched in the targeted region after sequence capture. The idea is that
the post-captured sample should have a lower Ct value than the pre-captured sample. The
post-captured sample is then subtracted from the pre-captured sample to get a delta Ct
value. The delta Ct value should be positive if there is enrichment of the DNA library in
the targeted region. Primers used for the QPCR reactions are shown in Table 6.
The results of the RT- QPCR reactions are shown in Table 7. The NCS primers
are recommended by NimbleGen. These primers are complementary to sequences that are
found on e very NimbleGen Sequence Capture array and contain sequences that are
universal among different species. Several primer pairs used were specific to the Mcs1b
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Table 7. RT-QPCR results for enrichment in targeted regions of sequence capture libraries.
NCS primers are used for every NimbleGen Sequence Capture array and are universal for
different species. A50 primers are specific to the Mcs1b rat region and can therefore not be used
on human control DNA.
Delta Ct value for sample
Primer
Human
WF (susceptible)
COP (resistant)
NCS 0237
10.0
4.9
4.6
NCS 0247
9.3
4.3
5.2
NCS 0268
10.8
6.9
6.4
NCS 0272
10.1
6.3
5.2
A50 control inside 1
11.2
10.5
A50 control inside 2
10.2
10.0
A50 control inside 3
10.4
9.7
A50 control inside 4
7.0
8.4
A50 control outside 1
-1.7
-2.7
A50 control outside 2
-0.6
-0.9
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targeted region. Two primer pairs were located outside the Mcs1b locus and four pairs
were located inside the targeted region. The delta Ct values are positive for all samples
when using the NCS primers indicating that these targeted regions were enriched. NCS
regions are included on all sequence capture microarrays. However, the Ct values for the
WF and COP libraries are lower than for the human library. This could indicate that the
human library is of better quality. However, all three libraries were prepared at the same
time and should be of equal quality. NimbleGen recommends the NCS primers as being
universal for different species. It is possible that there is a difference in the affinity of the
primers to human versus rat DNA, resulting in lower delta Ct values.
Primers that are located within the targeted Mcs1b region (A50 control inside
primers) show a positive delta Ct value for both the WF and COP rat strains, indicating
that the libraries were successfully enriched in the Mcs1b DNA. As a control, primers
outside of the targeted region (A50 control outside primers) show no enrichment,
indicated by a negative delta Ct value.

C.

Identification of Mcs1b genetic variants between the WF and COP rat strain
The WF and COP libraries were sequenced using 454 next- generation

sequencing. The goal was to get a coverage of at least 15X for both assemblies. The
coverage for the WF rat strain was 20.0X and for the COP rat strain 15.7X. The average
read length for the WF sequences was 328bp and for the COP sequences 317. Overall,
the sequencing resulted in coverage for 91.7% of all the bases found in the targeted
region. The WF and COP assemblies were filtered for sequence variants between the two
rat strains and primers were designed to confirm potential sequence variants using Sanger
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sequencing. Out of 130 potential SNPs, 67 S NPs were confirmed between the two rat
strains. A list of the identified SNPs is shown in Table 8. N o PCR product could be
generated for nine potential Mcs1b SNPs and therefore these SNPs could not be
confirmed. A list of potential Mcs1b SNPs that could not be confirmed is found in Table
9. Out of 13 INDELs that were tested between the two rat strains, two were confirmed
using Sanger sequencing. A transcript map for the Mcs1b locus including the sequence
variation in the locus is shown in Figure 11. Most of the sequence variation between the
two rat strains is located at the extreme ends of the Mcs1b locus. WF.COP congenic
animals that have a susceptible phenotype and do not contain the Mcs1b locus were
genotyped using the new markers. These congenic lines extend to the ends of the markers
located at the extreme ends of the Mcs1b locus. This means that all these sequence
variants are ruled out as candidate causative sequence variants for the Mcs1b locus. The
positions for the WF.COP susceptible congenic lines are shown in Figure 11. This leaves
four potential sequence variants: A046-SNP-A, A074-SNP-17, A074-SNP-18 and A102INDEL-2. These potential genetic variants are marked in Figure 11 and bolded in Table 8.
A046-SNP-A, A074-SNP-17 and A074-SNP-18 are located within the rat orthologous
region to the human haplotype block containing the rs889312 SNP bin. A102-INDEL-2 is
upstream of the Gpbp1 gene.

D.

Filling in gaps in the Mcs1b sequence using Sanger sequencing
The Mcs1b sequence capture assemblies for the WF and COP rat strain contain

gaps. These gaps are due to three different issues: 1) there are gaps in the Brown Norway
rat reference sequence used to design the sequence capture microarrays. 2) There are gaps
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Table 8. SNPs and INDELs between the WF and COP rat strains in the Mcs1b region. The
SNPs are organized according to genomic location. The table also includes A046-SNP-A. INDELs
are organized according to genomic location. Bolded variants are Mcs1b candidate sequence
variants.
Name
Location#
Reference (BN)
WF allele
COP allele
allele
A074-SNP-1
42364375
A
G
A
A074-SNP-65
42364706
C
C
T
A074-SNP-2
42365768
G
A
G
A074-SNP-3
42366362
T
G
T
A074-SNP-4
42367078
A
T
A
A074-SNP-5
42367311
C
G
C
A074-SNP-6
42367553
G
A
G
A074-SNP-66
42374226
A
G
A
A074-SNP-7
42374481
T
C
T
A074-SNP-64
42375050
C
T
C
A074-SNP-8
42375207
A
T
A
A074-SNP-9
42375271
A
T
A
A074-SNP-10
42375321
C
T
C
A074-SNP-67
42375547
G
A
G
A074-SNP-11
42376800
A
G
A
A074-SNP-12
42377178
C
T
C
A074-SNP-13
42378143
C
T
C
A074-SNP-14
42378758
C
T
C
A074-SNP-15
42378793
C
T
C
A074-SNP-16
42378804
C
T
C
43071787
C
C
A
A074-SNP-17
43090006
C
T
C
A074-SNP-18
43175144
C
C
T
A046-SNP-A
A074-SNP-19
44147176
C
A
C
A074-SNP-20
44148139
G
A
G
A074-SNP-21
44149528
G
T
G
A074-SNP-22
44150206
T
T
G
A074-SNP-23
44152022
A
G
A
A074-SNP-24
44152126
G
A
G
A074-SNP-25
44152673
A
A
G
A074-SNP-26
44152745
A
G
A
A074-SNP-27
44152882
T
G
T
A074-SNP-28
44152995
T
C
T
A074-SNP-29
44153181
A
T
A
A074-SNP-30
44153277
G
A
G
A074-SNP-31
44153858
G
A
G
A074-SNP-32
44156135
G
G
A
A074-SNP-33
44157354
T
T
G
A074-SNP-34
44157459
C
T
C
A074-SNP-35
44157568
C
C
T
A074-SNP-36
44158255
G
C
G
A074-SNP-37
44158391
G
A
G
A074-SNP-38
44158578
G
G
A
A074-SNP-39
44158871
G
G
T
A074-SNP-40
44158875
C
C
T
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Table 8 continued.
A074-SNP-41
44161442
G
G
A074-SNP-42
44165615
A
T
A074-SNP-43
44167496
A
T
A074-SNP-44
44167791
G
C
A074-SNP-45
44170531
A
A
A074-SNP-46
44170619
T
T
A074-SNP-47
44170980
C
T
A074-SNP-48
44171160
T
C
A074-SNP-49
44172139
A
G
A074-SNP-50
44192478
T
T
A074-SNP-51
44193102
A
G
A074-SNP-52
44196643
T
C
A074-SNP-53
44199441
G
A
A074-SNP-54
44201507
C
G
A074-SNP-55
44201538
A
T
A074-SNP-56
44205934
G
A
A074-SNP-57
44206713
G
A
A074-SNP-58
44206843
G
A
A074-SNP-59
44207194
G
A
A074-SNP-60
44207705
G
A
A074-SNP-61
44208687
G
A
A074-SNP-62
44209120
A
G
A074-SNP-63
44209260
C
C
A102-INDEL 1
42378873
TTG
42709213
TAGA
TAGA
A102-INDEL 2
#
rat chromosome 2. UCSC Genome Browser Nov. 2004 (Baylor 3.4/rn4)
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A
A
A
G
G
C
C
T
A
G
A
T
G
C
A
G
G
G
G
G
G
A
A
TTG

Table 9. Potential Mcs1b SNPs that cannot be confirmed using Sanger sequencing.
Position
Reference
WF allele
COP allele
WF
COP
(BN) allele
coverage
coverage
43,775,309 G
A/G
A/G
16
10
44,108,905 T
C/T
C/T
17
10
44,108,908 T
G/T
G/T
17
10
44,108,958 G
A/C/G
A/G
19
8
44,108,967 A
A/T
A/T
28
13
44,138,671 T
A/T
A/T
7
11
44,138,675 T
C/T
C/T
8
11
42,826,948 T
C/T
T
5
1
42,672,597 T
T
C
24
1
#
rat chromosome 2. UCSC Genome Browser Nov. 2004 (Baylor 3.4/rn4)
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Figure 11. Transcript map for the Mcs1b locus showing all genetic variation
between the two rat strains. Pink bar indicated the length of the Mcs1b locus. Blue bar
indicates the rat orthologous region to the human haplotype block containing rs889312
tagged SNPs. Yellow bars indicate WF.COP congenic lines that have a susceptible
phenotype and do not contain the Mcs1b locus. SNPs are shown in black, while INDELs
are shown in red. Mcs1b transcripts are shown in black. Also shown are transcripts
located within this region.
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due to repetitive elements in the sequence. When designing the sequence capture arrays,
NimbleGen will remove all repetitive elements and these regions will not be included on
the arrays. 3) There are gaps due to some regions having a low coverage either in one of
the rat assemblies alone or in both. We focused on f illing sequencing gaps in the rat
orthologous region to the rs889312 haplotype block. There are 75 gaps in this region. The
size of the gaps varies from 1-1200bps. Standard Sanger sequencing was used to fill in
these gaps. Out of the 75 gaps, 45 (60%) were fully sequenced between the WF and COP
rat strain. There were no additional sequence variants found between the two rat strains.
Three gaps were only partially sequenced, meaning that the entire gap could not be
sequenced. Out of the 75 gaps, 27 (36%) were not sequenced at all. The 75 gaps make up
a total of 17,008bps. The gaps that were not sequenced make up 10,883bps or 64% of the
gap bases that we attempted to sequence.

E.

Bioinformatic analysis of Mcs1b sequence variants
A074-SNP-17 and A074-SNP-18 are located within introns of the Map3k1 gene.

A074-SNP-17 is located in intron 11 and A074-SNP18 is located in intron 2 of Map3k1. It
is possible that one or both of these SNPs result in a change in the splicing of the Map3k1
gene.

To

test

this,

the

program

Alternative

Splice

Site

Predictor

(http://wangcomputing.com/assp/index.html) was used. This program scans sequences for
consensus splicing sites. There are no changes in the splicing pattern between the WF and
COP A074-SNP-17 and A074-SNP-18 alleles. This indicates that A074-SNP-17 and
A074-SNP-18 do not change splicing of the Map3k1 gene. Previous QPCR experiments
in the lab also revealed no additional Map3k1 splicing variants.
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To determine if the rat alleles for the Mcs1b candidate SNPs are common among
different rat strains, the program Variant Visualizer from the rat genome database was
used. This program allows for the identification of the sequence for all known SNPs
among different rat strains. In total, there is information for 19 rat strains in this program.
We added the genotyping information for the COP/NHsd and WF/NHsd rat strains, since
these are not found using the program. Results from the analysis can be found in Table
10. The variant allele for A046-SNP-A is found both in the COP and ACI rat strains.
Since the COP and ACI rat strain differ in their susceptibility, it may be unlikely that
A046-SNP-A is an independently acting variant for the Mcs1b phenotype. However,
genetic susceptibility to mammary cancer is a complex trait and not all information about
the genetic make-up of these two rat strains is known. The variant allele for A074-SNP18 is found in the DMBA carcinogenesis susceptible WF and SS (Salt-Sensitive) rat
strains. Since the Mcs1b phenotype is due to the presence of the COP allele in the Mcs1b
region, it is likely that the variant allele is found in the COP rat strain. Therefore, A074SNP-18 is not likely to be an independently acting variant for the Mcs1b phenotype.
However, A074-SNP-17 is a rare polymorphism. The variant allele of A074-SNP-17 is
found only in the COP or resistant rat strain. Since the causative Mcs1b variant is likely
to be found in the COP rat strain and not common to rat strains with susceptible DMBA
phenotypes, A074-SNP-17 is a strong candidate for the Mcs1b phenotype conferred. It is
possible, however, that all three or a combination of the Mcs1b candidate SNPs are
responsible for the Mcs1b phenotype.
The sequencing of the Mcs1b region between the two rat strains resulted in the
identification of one INDEL called A102-INDEL-2. This INDEL is located outside of the
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Table 10. Sequence results for candidate rat SNPs in different rat strains using Variant
Visualizer. The Rat Genome Database program Variant Visualizer was used. Highlighted sequences
show variant allele.
Sensitivity to
Rat strain
A074-SNP-17
A074-SNP-18
A046-SNP-A
DMBA
carcinogenesis
BN/NHsdMcwi
C
C
C
BN/SsN
C
C
C
Resistant
COP/Crl
A
C
T
COP/NHsd
A
C
T
SHR/Olalpcv
C
C
C
Wky/N
C
C
C
ACI/Eur
C
C
T
Intermediate
ACI/N
C
C
T
F344/N
C
C
C
Le/Stm
C
C
C
Buf/N
C
C
C
Susceptible
SS/JrHsdMcwi
C
T
C
WF/NHsd
C
T
C
BN-Lx
C
C
C
FHH/EurMcwi
C
C
C
FHL/EurMcwi
C
C
C
Unknown
GH/OmrMcswi
C
C
C
M520/N
C
C
C
MR/N
C
C
C
SHRSP/Gcrc
C
C
C
SR/JrHsd
C
C
C
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rat orthologous region to the rs889312 haplotype block. A102-INDEL-2 is located within
a stretch of repetitive sequence. The INDEL repeat and surrounding sequences for A102INDEL-2 are found in Table 11. The WF allele has one additional TAGA repeat that is
shown in Table 11. T he three candidate Mcs1b SNPs have a human ortholog with the
rs889312 SNP bin. To identify any human orthologous INDELs, we manually scanned
the human orthologous region to A102-INDEL-2 and an additional ±50kb surrounding
sequence for repetitive regions. To identify the immediate orthologous region for the
INDEL, we had to go 500bp out on e ither side of the INDEL until a region that is
conserved between humans and rats was found. No repetitive sequence was found in this
region, suggesting that there is no human ortholog to A102-INDEL-2 or it is located
outside of the queried region.

Discussion
Sequence capture and 454 next-generation sequencing has proven to be a fruitful
technique for the Mcs1b locus. The Mcs1b locus was initially mapped using WF.COP
congenic lines to be 1.8Mb in size [87]. Using sequence capture, 69 variants between the
two rat trains were discovered. A046-SNP-A was identified using standard Sanger
sequencing. Another two SNPs in the Mcs1b region were previously known. These are
A12-oo and A12-v. There are a total of 72 va riants between the two rat strains in the
Mcs1b region. There are only two confirmed INDELs and the rest of the variants are
SNPs. Most of these variants are located at the extreme ends of the Mcs1b locus. The list
of potential candidate rat variants was further narrowed using WF.COP congenic lines for
the Mcs1b locus. Genotyping of susceptible congenic Mcs1b lines indicated that
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Table 11. Sequences for WF and COP alleles of A102-INDEL-2 and surrounding sequence. Red
script indicates sequence variation between the two rat strains.
Strain
Sequence
WF
ATCCAGGGCAGATAGATGATAGATAGATAGATAGATAGATAGATAGATAG
ATAGATAGATAGATAGACAGACAGACAGACAGACAGACAGACAGACATAG
GAAAGAAGAGTGAGG
COP
ATCCAGGGCAGATAGATGATAGATAGATAGATAGATAGATAGATAGATAG
ATAGATAGATAGA--CAGACAGACAGACAGACAGACAGACAGACATAGGAAAGAAGAGTGAGG
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all of the sequence variants at the extreme ends of the Mcs1b locus are ruled out as the
causative variants. That leaves four candidate Mcs1b sequence variants.
The first candidate Mcs1b variant is an INDEL called A102-INDEL-2. However,
analysis of the human orthologous region surrounding A102-INDEL-2 has not resulted in
the identification of a human ortholog. This could be due to several reasons: 1) A102INDEL-2 might not have a human ortholog, since it has no functional activity and there is
no evolutionary pressure to retain this region, 2) the human ortholog to A102-INDEL-2
may be located outside of the region tested. When looking for the human orthologs, we
restricted the region of interest to 100kb s urrounding the human orthologous region to
A102-INDEL-2. Extending the search to a larger region may result in the identification of
an ortholog. Because there is no know n human ortholog for A102-INDEL-2, the
functional analysis of the Mcs1b variants will be focused on the candidate SNPs that were
identified. However, WF.COP congenic lines that will test the involvement of A102INDEL-2 in the Mcs1b phenotype are currently being generated.
Three candidate rat SNPs were identified in the Mcs1b region. These are A074SNP-17, A074-SNP-18 and A046-SNP-A. All three of these SNPs are located within the
rat orthologous region to a human haplotype block that associates with breast cancer risk.
The human haplotype block is marked by the SNP rs889312, which is in linkage
disequilibrium with at least six other SNPs. We hypothesized that since there are multiple
breast cancer associated SNPs in the human MCS1B region, there are multiple candidate
SNPs in the rat Mcs1b region. This hypothesis is confirmed with the identification of the
three Mcs1b candidate SNPs. Functional analysis of Mcs1b variants will focus on these
three SNPs, since they have a human ortholog in the rs889312 correlated SNPs. An
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analysis of the frequency of the SNP alleles in different rat strains revealed that the
variant allele of A046-SNP-A is found in both DMBA carcinogenesis resistant and
susceptible animals. This suggests that this SNP may not be independently acting on the
Mcs1b phenotype. The variant allele for A074-SNP-18 is found in two different
susceptible rat strains. The Mcs1b causative variant is likely found to be present in the
COP rat strain and possibly other DMBA carcinogenesis resistant rat strains. This is due
to the fact that the COP allele in the Mcs1b region modifies the Mcs1b DMBA
carcinogenesis phenotype. This would suggest that the variant allele for A074-SNP-18 is
not an independently acting functional genetic element. However, the variant allele for
A074-SNP-17 is only found in the COP rat strain, making this an ideal candidate for the
Mcs1b mammary cancer resistance. It is possible that all three or a combination of the
Mcs1b candidate SNPs are involved in modulating mammary cancer susceptibility.
Therefore, all three candidate SNPs will be included in a functional analysis of the Mcs1b
candidate SNPs.
A074-SNP-17 and A074-SNP-18 are located within two different introns of the
gene Map3k1. However, analysis of the predicted splice sites for the Map3k1 gene
revealed that the SNPs are not predicted to alter splicing sites. A046-SNP-A is located
within an intergenic region downstream of the Map3k1 gene. It is possible that any one of
these SNPs or a combination of them are involved in gene regulation of Mcs1b genes by
being located in a regulatory element.
There are gaps in the Mcs1b sequencing data. These gaps result from gaps in the
rat reference genome used to make the sequence capture microarrays, from highly
repetitive regions, which were not included on the microarray and from low coverage of
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the sequencing data. To fill in some of these gaps, we focused on t he rat orthologous
region to the rs889312 haplotype block. Out of 75 gaps in this region, we were unable to
sequence 27 gaps. This means that we failed to sequence over 10,000 bases that we
attempted to sequence in this region. Reasons why sequencing failed were problems with
primer design in the regions and problems with getting PCR product in highly repetitive
regions. Since there are over 10,000 bases unsequenced in this region, it is possible that
there are more genetic variants. It is not possible to sequence these bases with the current
techniques available; however, future sequencing techniques may be able to sequence
across repetitive regions and can be used to sequence the last remaining bases in this
region.
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CHAPTER IV
FUNCTIONAL ANALYSIS OF MCS1B GENETIC VARIANTS

Introduction
Sequencing of the Mcs1b region resulted in the identification of four candidate
Mcs1b sequence variants. These are A102-INDEL-2, A046-SNP-46, A074-SNP-17 and
A074-SNP-18. The Mcs1b SNPs A046-SNP-A, A074-SNP-17 and A074-SNP-18 are
located within the rat orthologous region to a human haplotype block that is associated
with breast cancer risk. These three rat SNPs are our candidate Mcs1b rat SNPs. The
human haplotype block that is associated with breast cancer risk is shown in Figure 2 and
is marked by the SNP rs889312 [61]. rs889312 is in linkage disequilibrium with at least
six other SNPs as shown in Figure 2. This means that any one or a combination of these
SNPs could be the causative one. However, since there are ongoing sequencing
experiments such as the 1000 G enomes Project that are identifying new SNPs in the
human, it is possible that the causative SNP is not in public databases yet. For this reason,
the functional analysis of candidate sequence variants for this aim will mainly focus on
the three identified rat SNPs, since all sequence variation between the two rat strains in
the Mcs1b region is known. Note, the three Mcs1b rat SNPs have a human ortholog in the
rs889312 correlated SNPs. There is no know n human ortholog for A102-INDEL-2. A
manual search for regions of high repetitive sequences in the human orthologous region
to the A012-INDEL-2 region did not yield any orthologs.
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Therefore, the functional analysis of Mcs1b sequence variants will focus on the three
candidate rat SNPs identified.
Genetic variants can be located in exons or introns of genes or they can be located
in intergenic regions. SNPs can influence a given phenotype through several
mechanisms. A SNP that is located within the coding region of a gene could have no
effect on t he transcribed protein, result in amino acid substitutions or in truncated
proteins. However, none of the Mcs1b candidate SNPs are located within the proteincoding region of a Mcs1b gene and are therefore not involved in changing the amino acid
sequence of a protein.
Some SNPs are located within gene introns. These SNPs can change the splicing
pattern of a gene, potentially resulting in a new splice product of a gene. Both A074-SNP17 and A074-SNP-18 are located within introns of Map3k1. However, an extensive
analysis of potential splicing site changes revealed that neither the COP nor WF allele for
both SNPs result in splicing site changes for Map3k1. Also there is no additional splice
variants annotated in the USCS Genome Browser for Map3k1. Furthermore, no splice
variants were identified using a QPCR based approcach. Therefore, it is unlikely that
these two SNPs are involved in changing the Map3k1 splicing pattern.
SNPs found in intergenic and intronic regions can be located in enhancer/
repressor and promoter regions. These genetic elements are all involved in regulating
gene expression. Proximal promoters are typically located within 1kb of the transcription
start site (TSS) and are involved in the basic transcriptional regulation of a particular
gene [135]. None of the Mcs1b SNPs are located in close proximity to the TSS of any of
the Mcs1b genes and are therefore not likely to be located in gene promoters. Enhancers
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and repressors are genomic regions that are not in close proximity to transcription start
sites but can either activate or repress gene transcription through long- range interactions.
Enhancers/ repressors bind transcription factors that act to regulate gene expression.
Enhancers/ repressors act independently of their location and orientation to a gene
promoter. These gene regulatory elements can be over 1Mb away from the targeted gene.
The formation of chromatin loops is thought to bring enhancers/ repressors in proximity
of gene promoters. Enhancers/ repressors are often found within introns of genes they
regulate or within introns of neighboring genes. However, they can also be found within
intergenic regions [136, 137]. All three Mcs1b SNPs are located either in introns or
intergenic regions and could be located within enhancers/ repressors.
Several genes within the Mcs1b region are expressed differentially between the
WF and COP rat strain. Mammary gland transcript levels of Mcs1b genes were compared
between 12- week old WF and WF.COP line N3 congenic females. There was a
significant expression difference for genes Gpbp1, Map3k1, Mier3 and Il6st between the
two rat strains. When animals were treated with DMBA, a significant expression
difference for Mier3 between the two rat strains was observed [87]. Since there is a
difference in the regulation of Mcs1b genes between the two rat strains, it is possible that
the Mcs1b SNPs are involved in regulating the Mcs1b genes. Because of their location in
respect to the Mcs1b genes, it is likely that the Mcs1b SNPs are located within enhancer/
repressor regions. Because of this, any functional analysis of the three Mcs1b candidate
SNPs will focus on potential roles in gene regulation.
The goal of this aim is to perform functional analysis of the Mcs1b candidate
SNPs in regards to their function in regulation of Mcs1b genes. The hypothesis is that the
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Mcs1b candidate SNPs are located in enhancer/ repressor regions and regulate Mcs1b
gene expression levels. The main functional analysis will focus on the rat Mcs1b
candidate SNPs, since all candidate rat variants in this region are known. However, any
positive results for the rat Mcs1b SNPs will be tested using the human rs889312
correlated SNPs as well.

Methods
A.

Cloning of candidate Mcs1b SNPs and human rs889312 correlated SNPs into
pGL3- Promoter vector
Luciferase assay constructs were designed for the WF and COP A074-SNP-17,

A074-SNP-18 and A046-SNP-A alleles and the human major and minor rs889312,
rs1862625, rs1862626, rs12697152, rs1910020, rs4700485 and rs961847 alleles. The rat
SNP alleles were inverted, since the rat Mcs1b region is inverted with respect to the
human MCS1B region. The constructs included the SNP nucleotide and 12bps flanking
on either side for a total of 25bps. These 25bps were repeated in tandem five times to
increase the signal strength of the luciferase assay. The constructs also included sticky
Kpn1 and Xho1 restriction sites for cloning purposes. The constructs were generated by
Integrated DNA Technologies (IDT) and included Kpn1 and XhoI compatible overhangs.
The pGL3- Promoter firefly luciferase reporter vector was digested with Kpn1 and Xho1
to generate sticky ends. The constructs were cloned into the multiple- cloning site
upstream of the SV40 promoter. The pGL3- Promoter vector was selected because it is
designed to test potential enhancer elements. Constructs were annealed at a concentration
of 1pmol/μl using a 10mM Tris, 1mM EDTA and 50mM NaCl (pH 8.0) buffer. A Veriti
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96-well thermocycler (Life Technologies) was used to anneal the constructs by heating
them to 95°C and allowing them to cool down at a rate of 1°C/min for 70 minutes. The
annealed constructs were then ligated to the linearized pGL3-Promoter vector using a 3:1
insert: vector ratio and T4 DNA ligase (Promega). Top10 Chemically Competent Cells
(Life Technologies) were used in the transduction reaction according to manufacture’s
protocol. A screen for positive clones was performed using RV3 primers surrounding the
multiple cloning site and a FastPCR reaction was performed as previously described. The
PCR products were run on a 1% agarose gel and stained using SybrGold (Life
Technologies). As a control the pGL3-Promoter vector was used. Clones were extracted
using a Spin Miniprep kit (Qiagen) and sequenced to ensure the correct insert has been
ligated. Finally, the plasmids were extracted using a PureYield Plasmid Midiprep Kit
(Promega) and the entire plasmid was sequenced to ensure no s equence errors. The
sequences for the constructs and RV3 primers can be found in Table 12.

B.

Cloning of multiple Mcs1b rat SNP alleles into the same pGL3-Promoter vector
The rat alleles for A074-SNP-17 and A074-SNP-18 were cloned into the multiple

cloning site upstream of the SV40 promoter in the pGL3-Promoter vector. The rat alleles
for A046-SNP-A were cloned into the multiple cloning site downstream of the luciferase
gene. Note, A074-SNP-18 was placed upstream of A074-SNP17. Constructing the A074SNP-18/A074-SNP-17 constructs was complex. IDT cannot manufacture constructs that
are longer than 200bps. The A074-SNP-18/A074-SNP-17 constructs were each at least
250bps in length. Therefore, the A074-SNP-18 and A074-SNP-17 constructs were
designed separately with an internal BglII site. The A074-SNP-18 construct contained a
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5’TCGAGGAATGCACAGGTCCTGTAGAAGTTCGAATGCACAGGTCCTGTAGAAGTTCGAATGCACAGGTCCT
GTAGAAGTTCGAATGCACAGGTCCTGTAGAAGTTCGAATGCACAGGTCCTGTAGAAGTTCGGTAC’3
5’CGAACTTCTACAGAACCTGTGCATTCGAACTTCTACAGAACCTGTGCATTCGAACTTCTACAGA
ACCTGTGCATTCGAACTTCTACAGAACCTGTGCATTCGAACTTCTACAGAACCTGTGCATTCC’3
5’TCGAGGAATGCACAGGTTCTGTAGAAGTTCGAATGCACAGGTTCTGTAGAAGTTCGAATGCACAGGTT
CTGTAGAAGTTCGAATGCACAGGTTCTGTAGAAGTTCGAATGCACAGGTTCTGTAGAAGTTCGGTAC’3
5’CATTCCATGACATGTGCAGCTCATCAATTCCATGACATGTGCAGCTCATCAATTCCATGACATG
TGCAGCTCATCAATTCCATGACATGTGCAGCTCATCAATTCCATGACATGTGCAGCTCATCAC’3
5’TCGAGTGATGAGCTGCACATGTCATGGAATTGATGAGCTGCACATGTCATGGAATTGATGAGCTGCAC
ATGTCATGGAATTGATGAGCTGCACATGTCATGGAATTGATGAGCTGCACATGTCATGGAATGGTAC’3
5’CATTCCATGACATTTGCAGCTCATCAATTCCATGACATTTGCAGCTCATCAATTCCATGACATT
TGCAGCTCATCA ATTCCATGACATTTGCAGCTCATCAATTCCATGACATTTGCAGCTCATCAC’3
5’TCGAGGTTTTGGAGATACGTGCACATGGGCGTTTTGGAGATACGTGCACATGGGCGTTTTGGAGATAC
GTGCACATGGGCGTTTTGGAGATACGTGCACATGGGCGTTTTGGAGATACGTGCACATGGGCGGTAC’3
5’ CGCCCATGTGCACGTATCTCCAAAACGCCCATGTGCACGTATCTCCAAAACGCCCATGTGCACG
TATCTCCAAAACGCCCATGTGCACGTATCTCCAAAACGCCCATGTGCACGTATCTCCAAAACC’3
5’TCGAGGTTTTGGAGATACGTGCACATGGGCGTTTTGGAGATACGTGCACATGGGCGTTTTGGAGATAC
GTGCACATGGGCGTTTTGGAGATACGTGCACATGGGCGTTTTGGAGATACGTGCACATGGGCGGTAC’3
5’CGCCCATGTGCACATATCTCCAAAACGCCCATGTGCACATATCTCCAAAACGCCCATGTGCACA
TATCTCCAAAACGCCCATGTGCACATATCTCCAAAACGCCCATGTGCACATATCTCCAAAACC’3
5’TCGAGGTTTTGGAGATATGTGCACATGGGCGTTTTGGAGATATGTGCACATGGGCGTTTTGGAGATAT
GTGCACATGGGCGTTTTGGAGATATGTGCACATGGGCGTTTTGGAGATATGTGCACATGGGCGGTAC’3
5'-CGCTGGAGAAAGGAATGTGCAAATTAGCTGGAGAAAGGAATGTGCAAATTAGCTGGAGAAAGGA
ATGTGCAAATTAGCTGGAGAAAGGAATGTGCAAATTAGCTGGAGAAAGGAATGTGCAAATTAC-'3
5'- TCGAGTAATTTGCACATTCCTTTCTCCAGCTAATTTGCACATTCCTTTCTCCAGCTAATTTGCACATT
CCTTTCTCCAGCTAATTTGCACATTCCTTTCTCCAGCTAATTTGCACATTCCTTTCTCCAGCGGTAC-‘3

A63-A046-SNP-A WF ()
A63-A046-SNP-A COP
(+)
A63-A046-SNP-A COP
(-)

A91-A074-SNP-17 WF
(+)

A91-A074-SNP-17 WF
(-)

A91-A074-SNP-17 COP
(+)

A91-A074-SNP-17 COP
(-)

A91-A074-SNP-18 COP
(+)

A91-A074-SNP-18 COP
(-)

A91-A074-SNP-18 WF
(+)

A91-A074-SNP-18 WF
(-)

A63-rs889312 major (+)

A63-rs889312 major (-)

Table 12. Sequences for constructs and RV3 primers for cloning WF and COP A074-SNP-17, A074-SNP-18 and A046-SNP-A alleles and
human major and minor rs889312, rs1862625, rs1862626, rs12697152, rs1910020, rs4700485 and rs961847 alleles. Nucleotides in red are SNP
Construct/ Primer ID
Sequence
A63-A046-SNP-A WF
5’CGAACTTCTACAGGACCTGTGCATTCGAACTTCTACAGGACCTGTGCATTCGAACTTCTACAGG
(+)
ACCTGTGCATTCGAACTTCTACAGGACCTGTGCATTCGAACTTCTACAGGACCTGTGCATTCC’3
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5'-TCGAGTAATTTGCACATGCCTTTCTCCAGCTAATTTGCACATGCCTTTCTCCAGCTAATTTGCACATG
CCTTTCTCCAGCTAATTTGCACATGCCTTTCTCCAGCTAATTTGCACATGCCTTTCTCCAGCGGTAC-‘3
5’-CCTATGCAAATGCAGAGGTACAAGATCTATGCAAATGCAGAGGTACAAGATCTATGCAAATGCA
GAGGTACAAGATCTATGCAAATGCAGAGGTACAAGATCTATGCAAATGCAGAGGTACAAGATC-‘3
5’-TCGAGATCTTGTACCTCTGCATTTGCATAGATCTTGTACCTCTGCATTTGCATAGATCTTGTACCTCT
GCATTTGCATAGATCTTGTACCTCTGCATTTGCATAGATCTTGTACCTCTGCATTTGCATAGGGTAC-‘3
5’-CCTATGCAAATGCGGAGGTACAAGATCTATGCAAATGCGGAGGTACAAGATCTATGCAAATGCG
GAGGTACAAGATCTATGCAAATGCGGAGGTACAAGATCTATGCAAATGCGGAGGTACAAGATC -‘3
5-TCGAGATCTTGTACCTCCGCATTTGCATAGATCTTGTACCTCCGCATTTGCATAGATCTTGTACCTCC
GCATTTGCATAGATCTTGTACCTCCGCATTTGCATAGATCTTGTACCTCCGCATTTGCATAGGGTAC-‘3
5’-CGCATGGCTAGATTTCAGCCTGTGCTGCATGGCTAGATTTCAGCCTGTGCTGCATGGCTAGATT
TCAGCCTGTGCTGCATGGCTAGATTTCAGCCTGTGCTGCATGGCTAGATTTCAGCCTGTGCTC-‘3
5’TCGAGAGCACAGGCTGAAATCTAGCCATGCAGCACAGGCTGAAATCTAGCCATGCAGCACAGGCTGA
AATCTAGCCATGCAGCACAGGCTGAAATCTAGCCATGCAGCACAGGCTGAAATCTAGCCATGCGGTAC‘3
5’-CGCATGGCTAGATGTCAGCCTGTGCTGCATGGCTAGATGTCAGCCTGTGCTGCATGGCTAGATG
TCAGCCTGTGCTGCATGGCTAGATGTCAGCCTGTGCTGCATGGCTAGATGTCAGCCTGTGCTC-‘3

A63-rs889312 minor (-)

A75-rs961847 major (+)

A75-rs961847 major (-)

A75-rs961847 minor (+)

A75-rs961847 minor (-)

A75-rs1862626 major (+)

A75-rs1862626 major (-)

A75-rs1862626 minor (-)

5’TCGAGAGCACAGGCTGACATCTAGCCATGCAGCACAGGCTGACATCTAGCCATGCAGCACAGGCTGAC
ATCTAGCCATGCAGCACAGGCTGACATCTAGCCATGCAGCACAGGCTGACATCTAGCCATGCGGTAC-‘3

5'-CGCTGGAGAAAGGCATGTGCAAATTAGCTGGAGAAAGGCATGTGCAAATTAGCTGGAGAAAGGC
ATGTGCAAATTAGCTGGAGAAAGGCATGTGCAAATTAGCTGGAGAAAGGCATGTGCAAATTAC-‘3

A63-rs889312 minor (+)

A75-rs1862626 minor (+)

Sequence

Construct/ Primer ID

Table 12 continued.
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5’-TCGAGTAACCCTTCTTGCCCTCTGCCCCTCTAACCCTTCTTGCCCTCTGCCCCTCTAACCCTTCTTGC
CCTCTGCCCCTCTAACCCTTCTTGCCCTCTGCCCCTCTAACCCTTCTTGCCCTCTGCCCCTCGGTAC-‘3
5’-CGATATTGTGTCTCTAGATATAAAGGGATATTGTGTCTCTAGATATAAAGGGATATTGTGTCTC
TAGATATAAAGGGATATTGTGTCTCTAGATATAAAGGGATATTGTGTCTCTAGATATAAAGGC-‘3
5’-TCGAGCCTTTATATCTAGAGACACAATATCCCTTTATATCTAGAGACACAATATCCCTTTATATCTAG
AGACACAATATCCCTTTATATCTAGAGACACAATATCCCTTTATATCTAGAGACACAATATCGGTAC-‘3
5’-CGATATTGTGTCTTTAGATATAAAGGGATATTGTGTCTTTAGATATAAAGGGATATTGTGTCTT
TAGATATAAAGGGATATTGTGTCTTTAGATATAAAGGGATATTGTGTCTTTAGATATAAAGGC-‘3
5’-TCGAGCCTTTATATCTAAAGACACAATATCCCTTTATATCTAAAGACACAATATCCCTTTATATCTAA
AGACACAATATCCCTTTATATCTAAAGACACAATATCCCTTTATATCTAAAGACACAATATCGGTAC-‘3
5’-CAGCCAAGGTGGGTGCATAAGAAGGCAGCCAAGGTGGGTGCATAAGAAGGCAGCCAAGGTGGGT
GCATAAGAAGGCAGCCAAGGTGGGTGCATAAGAAGGCAGCCAAGGTGGGTGCATAAGAAGGCC-‘3
5’-TCGAGGCCTTCTTATGCACCCACCTTGGCTGCCTTCTTATGCACCCACCTTGGCTGCCTTCTTATGCA
CCCACCTTGGCTGCCTTCTTATGCACCCACCTTGGCTGCCTTCTTATGCACCCACCTTGGCTGGTAC-‘3
5’-CAGCCAAGGTGGGCGCATAAGAAGGCAGCCAAGGTGGGCGCATAAGAAGGCAGCCAAGGTGGGC
GCATAAGAAGGCAGCCAAGGTGGGCGCATAAGAAGGCAGCCAAGGTGGGCGCATAAGAAGGCC-‘3
5’-TCGAGGCCTTCTTATGCGCCCACCTTGGCTGCCTTCTTATGCGCCCACCTTGGCTGCCTTCTTATGCG
CCCACCTTGGCTGCCTTCTTATGCGCCCACCTTGGCTGCCTTCTTATGCGCCCACCTTGGCTGGTAC-‘3

A75-rs1862625 minor (-)

A75-rs1910020 major (+)

A75-rs1910020 major (-)

A75-rs1910020 minor (+)

A75-rs1910020 minor (-)

A75-rs12697152 major (+)

A75-rs12697152 major (-)

A75-rs12697152 minor (+)

A75-rs12697152 minor (-)

5’-TCGAGGAGTAGACGTCTCAGTTTAAACCAGGAGTAGACGTCTCAGTTTAAACCAGGAGTAGACGTCTC
AGTTTAAACCAGGAGTAGACGTCTCAGTTTAAACCAGGAGTAGACGTCTCAGTTTAAACCAGGGTAC-

5’-CGAGGGGCAGAGGGCAAGAAGGGTTAGAGGGGCAGAGGGCAAGAAGGGTTAGAGGGGCAGAGGG
CAAGAAGGGTTAGAGGGGCAGAGGGCAAGAAGGGTTAGAGGGGCAGAGGGCAAGAAGGGTTAC-‘3

A75-rs1862625 minor (+)

A75-rs4700485 major (+)

5’-TCGAGTAACCCTTCTTGTCCTCTGCCCCTCTAACCCTTCTTGTCCTCTGCCCCTCTAACCCTTCTTGT
CCTCTGCCCCTCTAACCCTTCTTGTCCTCTGCCCCTCTAACCCTTCTTGTCCTCTGCCCCTCGGTAC-‘3

A75-rs1862625 major (-)

5’-CCTGGTTTAAACTGAGACGTCTACTCCTGGTTTAAACTGAGACGTCTACTCCTGGTTTAAACTG
AGACGTCTACTCCTGGTTTAAACTGAGACGTCTACTCCTGGTTTAAACTGAGACGTCTACTCC-‘3

5’CGAGGGGCAGAGGACAAGAAGGGTTAGAGGGGCAGAGGACAAGAAGGGTTAGAGGGGCAGAGGA
CAAGAAGGGTTAGAGGGGCAGAGGACAAGAAGGGTTAGAGGGGCAGAGGACAAGAAGGGTTAC-‘3

A75-rs1862625 major (+)

A75-rs4700485 major (+)

Sequence

Construct/ Primer ID

Table 12 continued.
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Sequence
5’-CCTGGTTTAAACTAAGACGTCTACTCCTGGTTTAAACTAAGACGTCTACTCCTGGTTTAAACTA
AGACGTCTACTCCTGGTTTAAACTAAGACGTCTACTCCTGGTTTAAACTAAGACGTCTACTCC-‘3
5’TCGAGGAGTAGACGTCTTAGTTTAAACCAGGAGTAGACGTCTTAGTTTAAACCAGGAGTAGACGTCTT
AGTTTAAACCAGGAGTAGACGTCTTAGTTTAAACCAGGAGTAGACGTCTTAGTTTAAACCAGGGTAC-‘3
5'-CTA GCA AAA TAG GCT GTC CC-'3
5'-AAC AGT ACC GGA ATG CCA AG-'3

Constructs/ Primer ID

A75-rs4700485 minor (+)

A75-rs4700485 minor (-)

RV3 +

RV3 -

Table 12 continued.

sticky Kpn1 site at the 5’ end and a sticky BglII site at the 3’ end. The A074-SNP-17
construct contained a complementary sticky BglII site at the 5’ end and a sticky Xho1 site
at the 3’ end. Both constructs had to ligate to each other and ligate into the plasmid to get
a successful ligation reaction. All components were added to the same ligation reaction.
The constructs for A046-SNP-A were designed as described previously, with the
exception of the restriction enzymes used. The Sal1 and BamH1 enzymes were used. The
sequences for the constructs can be found in Table 13. The pGL3- Promoter vector was
digested with the Kpn1 and Xho1 enzymes first and the A074-SNP-18/A074-SNP-17
constructs were cloned first. Cloning reactions and plasmid extractions were performed
as previously described. Plasmids were extracted using the Spin Miniprep kit (Qiagen)
and sequenced. The plasmids containing the A074-SNP-18/A074-SNP-17 constructs were
digested with the Sal1 and BamH1 enzymes and the A046-SNP-A constructs were cloned
into the vector. Cloning reactions and plasmid extractions were performed as previously
described, with the exception of using the RV4 primers for analysis of positive clones. A
list of constructs and primers used for cloning is shown in Table 13.

C.

Transfection of T47D and MDA-MB-231 cells and luciferase assays
T47D and MDA-MB-231 were ordered from ATCC. T47D cells were grown in

RPMI-1640 with the addition of 10% fetal bovine serum (FBS), antibioticsantimycrobials (Anti-anti, Life Technologies) and 0.2 U nits/ml bovine insulin. MDAMB-231 cells were grown in DMEM medium with 10% FBS and anti-anti (Life
Technologies). Plasmids were transfected into T47D and MDA-MB-231 cells using
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Sequence
5’CGCCCATGTGCACATATCTCCAAAACGCCCATGTGCACATATCTCCAAAACGCCCATGTGCACA
TATCTCCAAAACGCCCATGTGCACATATCTCCAAAACGCCCATGTGCACATATCTCCAAAACA’3
5’GATCTGTTTTGGAGATATGTGCACATGGGCGTTTTGGAGATATGTGCACATGGGCGTTTTGGAGAT
ATGTGCACATGGGCGTTTTGGAGATATGTGCACATGGGCGTTTTGGAGATATGTGCACATGGGCGGTAC’3
5’CGCCCATGTGCACGTATCTCCAAAACGCCCATGTGCACGTATCTCCAAAACGCCCATGTGCACG
TATCTCCAAAACGCCCATGTGCACGTATCTCCAAAACGCCCATGTGCACGTATCTCCAAAACA’3
5’GATCTGTTTTGGAGATACGTGCACATGGGCGTTTTGGAGATACGTGCACATGGGCGTTTTGGAGATAC
GTGCACATGGGCGTTTTGGAGATACGTGCACATGGGCGTTTTGGAGATACGTGCACATGGGCGGTAC’3
5’GATCTATTCCATGACATGTGCAGCTCATCAATTCCATGACATGTGCAGCTCATCAATTCCATGACATG
TGCAGCTCATCAATTCCATGACATGTGCAGCTCATCAATTCCATGACATGTGCAGCTCATCAC’3
5’TCGAGTGATGAGCTGCACATGTCATGGAATTGATGAGCTGCACATGTCATGGAATTGATGAGCTGCAC
ATGTCATGGAATTGATGAGCTGCACATGTCATGGAATTGATGAGCTGCACATGTCATGGAATA’3
5’GATCTATTCCATGACATTTGCAGCTCATCAATTCCATGACATTTGCAGCTCATCAATTCCATGACATT
TGCAGCTCATCAATTCCATGACATTTGCAGCTCATCAATTCCATGACATTTGCAGCTCATCAC’3
5’TCGAGTGATGAGCTGCAAATGTCATGGAATTGATGAGCTGCAAATGTCATGGAATTGATGAGCTGCAA
ATGTCATGGAATTGATGAGCTGCAAATGTCATGGAATTGATGAGCTGCAAATGTCATGGAATA3’
5’ GATCCGAACTTCTACAGGACCTGTGCATTCGAACTTCTACAGGACCTGTGCATTCGAACTTCTACAGG
ACCTGTGCATTCGAACTTCTACAGGACCTGTGCATTCGAACTTCTACAGGACCTGTGCATTCG’3
5’TCGACGAATGCACAGGTCCTGTAGAAGTTCGAATGCACAGGTCCTGTAGAAGTTCGAATGCACAGGTC
CTGTAGAAGTTCGAATGCACAGGTCCTGTAGAAGTTCGAATGCACAGGTCCTGTAGAAGTTCG’3
5’ GATCCGAACTTCTACAGAACCTGTGCATTCGAACTTCTACAGAACCTGTGCATTCGAACTTCTACAGA
ACCTGTGCATTCGAACTTCTACAGAACCTGTGCATTCGAACTTCTACAGAACCTGTGCATTCG’3
5’TCGACGAATGCACAGGTTCTGTAGAAGTTCGAATGCACAGGTTCTGTAGAAGTTCGAATGCACAGGTT
CTGTAGAAGTTCGAATGCACAGGTTCTGTAGAAGTTCGAATGCACAGGTTCTGTAGAAGTTCG’3
5’GAC GAT AGT CAT GCC CCG CG’3
5’CGC TTC GAG CAG ACA TGA TA’3

Construct/ Primer ID
A117-A074-SNP-18 WF (+)

A117-A074-SNP-18 WF (-)

A117-A074-SNP-18 COP (+)

A117-A074-SNP-18 COP (-)

A117-A074-SNP-17 WF (+)

A117-A074-SNP-17 WF (-)

A117-A074-SNP-17 COP (+)

A117-A074-SNP-17 COP (-)

A117-A046-SNP-A WF (+)

A117-A046-SNP-A WF (-)

A117-A046-SNP-A COP (+)

A117-A046-SNP-A COP (-)

RV4 +

RV4 -

Table 13. Sequences of constructs and primers for cloning all three Mcs1b candidate SNPs into same pGL3- Promoter. Nucleotides in red are SNP
nucleotides.

Lipofectamine 2000 (Life Technologies) according to manufacture’s instructions. 24hrs
prior to transfection, 20,000 cells were plated in a 96-well dish using media without
Antibiotics- antimycotics and allowed to grow to 95% confluency. A total of 200ng/ well
were transfected of the constructs containing plasmids and 10ng/ well of pRL-TK
(Renilla expressing vector) were used for T47D cells. A total of 100ng/ well were
transfected of the constructs containing plasmids and 5ng/ well of pRL-TK (renilla
expressing vector) were used for MDA-MB-231 cells. Transfections were done in
triplicate. The luciferase activity was determined 18-24hrs post transfection using the
Dual- Luciferase Reporter Assay System (Promega) according to manufacturer’s
instructions. The reaction products of the luciferase and renilla genes were read on a
Biotek Synergy 2 Plate Reader. As a control, the luciferase and renilla activity of the
pGL3-Promoter and pGL3-Basic vector were determined.

D.

Statistical analysis of luciferase activity
Luciferase and Renilla values were downloaded into Excel. The luciferase activity

was divided by the Renilla activity to account for differences in transfection efficiency.
An average of the triplicate value was then determined. And the values were divided by
the average of the pGL3-Promoter vector to adjust for differences between experiments.
Adjusted values were then pooled. Each plasmid transfection had at least nine values
from three independent experiments. A Kruskal-Wallis analysis was performed, followed
by a Conover- Inman post hoc test to determine the p-values using SYSTAT 13.

E.

EMSAs and EMSA supershifts
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Oligos used for electrophoretic mobility shift assays (EMSAs) were biotin labeled
using the Biotin 3’ End DNA Labeling Kit (Thermo Scientific) according to the
manufacturer’s protocol. In short, oligos were ordered from IDT and resuspended to a
concentration of 100μM in water. The oligoes were diluted to a working concentration of
1μM and incubated with TdT reaction buffer, Biotin-N4-CTP and TDT enzyme for
30min at 37°C. The biotin labeled oligos were then extracted using a chloroform: isoamyl
alcohol extraction. A list of the oligos used in the EMSA reactions are shown in Table 14.
Oligos were annealed by adding equal amounts of forward and reverse oligo and
incubating them in a thermocycler. The oligos were allowed to heat to 95°C and were
cooled down at a rate of 1°C/ min for 70min.
Nuclear extracts of T47D and MDA-MB-231 cells were performed using NEPER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific) according to
manufacturer’s protocol. Nuclear extracts were quantified using a Biorad protein assay
kit. Nuclear extract aliquots were stored at -80°C.
EMSAs were performed using the LightShift Chemiluminescent EMSA kit
(Thermo Scientific) according to manufacturer’s protocols. In short, 1μL of biotin labled
oligos were incubated with binding buffer, 2.5% glycerol, 100nM MgCl2, 50ng/μL
Poly(dI•dC), 0.05% NP-40 and 10μg nuclear extract at room temperature for 20min.
200x unlabeled cold probe was added as competitor. Note, for Figure 14B, 13x cold
competitor probe was used. For Figure 18 an increase in cold competitor probe from 10x
to 200x was used. A 4 or 5% polyacrylamide gel was pre- run in 0.5% TBE at 100V for
30min. 5μl loading dye was added to the binding reactions and the entire sample was
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Table 14. List of oligos used in EMSA and EMSA supershift experiments.
ID
Sequence
A90-A046-SNP-A WF (+)
GAATGCACAGGTCCTGTAGAAGTTC
A90-A046-SNP-A WF (+)
GAACTTCTACAGGACCTGTGCATTC
A90-A046-SNP-A COP (+)
GAATGCACAGGTTCTGTAGAAGTTC
A90-A046-SNP-A COP (+)
GAACTTCTACAGAACCTGTGCATTC
A118-A074-SNP17 WF (+)
TGATGAGCTGCACATGTCATGGAAT
A118-A074-SNP17 WF (-)
ATTCCATGACATGTGCAGCTCATCA
A118-A074-SNP17 COP (+)
TGATGAGCTGCAAATGTCATGGAAT
A118-A074-SNP17 COP (-)
ATTCCATGACATTTGCAGCTCATCA
A118-A074-SNP18 WF (+)
GTTTTGGAGATATGTGCACATGGGC
A118-A074-SNP18 WF (-)
GCCCATGTGCACATATCTCCAAAAC
A118-A074-SNP18 COP (+)
GTTTTGGAGATACGTGCACATGGGC
A118-A074-SNP18 COP (-)
GCCCATGTGCACGTATCTCCAAAAC
A90-rs1862626 major (+)
GCATGGCTAGATTTCAGCCTGTGCT
A90-rs1862626 major (-)
AGCACAGGCTGAAATCTAGCCATGC
A90-rs1862626 minor (+)
GCATGGCTAGATGTCAGCCTGTGCT
A90-rs1862626 minor (-)
AGCACAGGCTGACATCTAGCCATGC
A90-rs889312 major (+)
GCTGGAGAAAGGAATGTGCAAATTA
A90-rs889312 major (-)
TAATTTGCACATTCCTTTCTCCAGC
A90-rs889312 minor (+)
GCTGGAGAAAGGCATGTGCAAATTA
A90-rs889312 minor (-)
TAATTTGCACATGCCTTTCTCCAGC
A107-A046-SNP-A 1bp Deletion (+)
GAATGCACAGGTCTGTAGAAGTTC
A107- A046-SNP-A 1bp Deletion (-)
GAACTTCTACAGACCTGTGCATTC
A107-A046-SNP-A 3bp deletion (+)
GAATGCACAGGTGTAGAAGTTC
A107-A046-SNP-A 3bp deletion (-)
GAACTTCTACACCTGTGCATTC
A107-A046-SNP-A 5bp deletion (+)
GAATGCACAGGTAGAAGTTC
A107-A046-SNP-A 5bp deletion (-)
GAACTTCTACCTGTGCATTC
A107- A046-SNP-A random insert 9bps (+)
GAATGCACCGTCTCTGGAGAAGTTC
A107- A046-SNP-A random insert 9bps (-)
CAACTTCTCCAGAGACGGTGCATTC
A107- A046-SNP-A random insert 13bps (+) GAATGCTTGTCGTCCATTTAAGTTC
A107- A046-SNP-A random insert 13bps (-) GAACTTAAATGGACGACAAGCATTC
A107- A046-SNP-A random insert 17bps (+) GAATGCTTTTACTGCCCGTACGTTC
A107- A046-SNP-A random insert 17bps (-) GAACGTACGGGCAGTAAAAGCATTC
A118-A074-SNP-17 3bp deletion (+)
TGATGAGCTGCTGTCATGGAAT
A118-A074-SNP-17 3bp deletion (-)
ATTCCATGACAGCAGCTCATCA
A118-A074-SNP-18 3bp deletion (+)
GTTTTGGAGATTGCACATGGGC
A118-A074-SNP-18 3bp deletion (-)
GCCCATGTGCAATCTCCAAAAC
A124- E-box (+)
GCGCTCCCCACGTGGCGGAGGG
A124- E-box (-)
CCCTCCGCCACGTGGGGAGCGC
A124-ARE (+)
CAGTCACAGTGACTCAGCAGAATCT
A124-ARE (-)
AGATTCTGCTGAGTCACTGTGACTG
A124- random oligo (+)
CGCCGGGCGATAGTGGAGTTAGTAG
A124- random (-)
CTACTAACTCCACTATCGCCCGGCG
A128-PRE (+)
GATCCTGTACAGGATGTTCTAGCTACA
A128-PRE (-)
TGTAGCTAGAACATCCTGTACAGGATC
A128- NF1C (+)
AGGTTGGCAAAAAGCCAAGG
A128- NF1C (-)
CCTTGGCTTTTTGCCAACCT
A128- ARRE2 (+)
gatcGGAGGAAAAACTGTTTCATACAGAAG
GCGT
A128- ARRE2 (-)
ACGCCTTCTGTATGAAACAGTTTTTCCTCC
gatc
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loaded onto the gel. The gel was run at 100V for until the blue dye had migrated ¾ down
the length of the gel (approximately 45min). The protein-DNA complexes were
transferred to a Biodyne B Pre-cut Modified Nylon Membrane (Thermo Scientific) using
a TransBlot SD Semi-dry Transfer Cell (Bio-Rad) at 25V for 10min. DNA and proteins
were crosslinked using UV crosslinking instruments for 15min. Membranes were washed
and chemiluminescence detected using Luminol/ Enhancer Solution, Stable Peroxide
Solution and x-ray film.
EMSA supershifts were performed as previously described. However, during the
binding reaction 2μg of antibody was added to the reaction, allowed to incubate for
30min before adding biotin labeled probes and incubating for 20 more minutes at room
temperature. As a control 2μg of Negative Control for Rabbit IgG Ab-1 (Thermo
Scientific) was used. The antibodies used are c-MYC, NRF2, PR, NFIC and ILF2 (Santa
Cruz Biotechnology: sc-764x, sc-722x, sc-538x and Abcam: ab86570, ab28772).

F.

Luciferase assays of A074-SNP-17 SNP alleles co-expressed with protein
expression vectors
Luciferase assays in T47D cells were performed as described above. An

additional 200ng/ well of the protein expression vector was added and luciferase activity
was measured 18-24hrs post transfection. The c-MYC protein expressed is the human
isoform and the plasmid backbone is the pWZL plasmid. The NRF2 expressed is human
isoform and the plasmid backbone is the pCI- neo vector. As a control, the pc3.1 vector
was used. The ARE control plasmids used for the NRF2 co-expression luciferase
experiments contains the minimum promoter (164 bp) of the rat Glutatione S-transferase

103

A2 gene in the pGL3- Basic vector. Each experiment was performed in triplicate and the
results from three independent experiments were pooled. Results were analyzed as
previously described.

G.

Western Blot for c-Myc
20μg of each protein extract were used in the Western Blot. Equal volume of

Leammli buffer (Biorad) were added to the protein extracts and heated at 95°C for 5min.
A prestained protein marker was used (New England Biolabs). Samples were run on a
stacking polyacrylamide gel at 60V until samples reached stacking gels’ interface.
Samples were then run at 100V until pink dye ran off the gel in running buffer (Trisglycine/ SDS). A PVDF membrane (GE Healthcare) was prepared by soaking in
methanol for 20s, then water for 20s and then 10min in Towbin buffer (25 mM Tris, 192
mM glycine, 20% (v/v) methanol (pH 8.3)). Samples were transferred in semi-dry
apparatus for 40min at 15V. Membrane was blocked in PBS-tween + milk (0.1% Tween20, 5% milk) for 1hr. Membranes were incubated with 1/2000 c-Myc antibody (sc-764,
Santa Cruz) and 1/4000 GAPDH antibody (A300-641-A, Bethyl) in PBS- tween + milk
overnight at 4°C. Membranes were washed twice with PBS-tween and then four times for
5 min. Goat anti-rabbit secondary antibody was added at 1/4000) in PBS-tween for 1hr
while shaking. Membranes were washed twice with PBS- tween then three times for
5min and once for 5min in PBS. Equal amounts of Pico reagents (Thermo Scientific)
were added for 5min and membrane was exposed to X-ray film.
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H.

Identification of candidate proteins binding to A074-SNP-17 using TF search and
Mass spectrometry
To identify candidate proteins binding to the WF and COP alleles for A074-SNP-

17,

we

used

the

online

program

TF

Search

(http://www.cbrc.jp/research/db/TFSEARCH.html). The 25bp ol igos used for the A074SNP-17 EMSAs were used for the analysis. The parameters were set to “use all matrices”
and the threshold score was set to 75. We noted all proteins that were predicted to bind
the two alleles differentially.
For DNA pulldowns, 30μl of Streptavidin Magnetic Particles (Roche) were
washed three times with 100μl of TEN100 (10mM Tris-HCl), 1mM EDTA, 100mM
NaCl, pH 7.5) on a rotator for 1min at room temperature. Particles were placed into a
magnet and the liquid was removed. Particles were resuspended with 100μl TEN100 and
3μg of the A074-SNP-17 COP, WF or 3bp deletion oligo was added. Oligos used have
the same sequence as shown in Table 14, however, they were ordered from IDT with a 3’
biotin molecule. The samples were rotated for 10min at room temperature. Samples were
washed twice with TEN1000 (10mM Tris-HCl, 1mM EDTA, 1M NaCl, pH 7.5).
Samples were blocked with 0.5% milk in TEN100 for 15min on ice and washed once
with TEN100. 750μg of T47D nuclear extracts and 700μl of TEN100 were added to the
samples and incubated for 30min at room temperature with rotation. The liquid was
removed and DNA was eluted using 40μl of buffer C (20mM HEPES, 1.5mM MgCl2,
0.2mM EDTA, 25% v/v glycerol, pH 7.9). A control EMSA using the A074-SNP-17
COP, WF and MUT was performed using the DNA pulldown and T47D nuclear extract
as described previously. 5μl of the DNA pulldown and 3μl of the T47D nuclear extracts
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were used. The samples were submitted to the University of Louisville Mass
Spectrometry Core and trypsin digestion followed by LC-MS/MS was performed.
Proteins were identified through Proteome Discoverer and visualized using Scaffold 3.

I.

5’ RACE of Mier3 and cloning of Mier3 promoter into pGL3 promoter vector
We used the FirstChoice RLM-RACE Kit (Ambion) to perform 5’ Rapid

Amplification of cDNA Ends (RACE) on the Mier3 gene according to the manufacturer’s
instructions. The mammary gland total RNA from six 12-week old WF females was
pooled for the analysis. 10μg total RNA was treated with Tobacco Acid Pyrophosphatase
(TAP) for 1hr at 37°C. 5’RACE adapters were ligated and the RNA was reversetranscribed using M-MVL Reverse Transcriptase. An outer 5’RML-RACE PCR was
performed using Mier3 specific primers, followed by an inner PCR. Mier3 specific
primers for 5’RACE are shown in Table 15. 5μl of the PCR reaction were run on a 2%
high resolution agarose gel (GeneMate) and stained with SybrGold (Life Technologies).
PCR products were cloned into a pCR2.1 TA cloning vector using the Original TA
Cloning Kit (Life Technologies) and 17 clones were sequenced using the University of
Louisville Sequencing Core.
The splenic DNA of one WF animal was used for cloning of the Mier3 promoter.
The PCR reaction was performed using the A buffer of the FailSafe PCR Premix
Selection Kit (Epicentre), Accuprime PCR enzyme (Life Technologies) and the primers
shown in Table 15. The PCR reaction was then cloned into the pCR2.1- TA vector using
the Original TA Cloning Kit (Life Technologies). A clone was amplified and extracted
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Table 15. Primers for 5’RACE and cloning of Mier3 promoter.
ID
Sequence
A132- 5’RACE outer primer
CATGTTGTGTTTGATCGTAAAGG
A132- 5’RACE inner primer
CATCTGAGAAGACTGGGTTTC
A132- Mier3 specific 5’ primer
GAAGGAAATATGCCTCTAGAAGAT
A132- Cloning 3F
GGAAGATCTGAACCTGTGGCAACTTGGAT
A132- Cloning 3R
CCCAAGCTTATGACTGGAGGGTGAAGACG
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using the Qiagen Spin Miniprep Kit and sequenced. The PCR primers used contain BglII
and HindIII restriction sites and the correct insert were excised using these two enzymes.
The pGL3 promoter vector was digested with the BglII and HindIII enzymes to remove
the SV40 promoter. The linearized vector was gel extracted using the QiaQuick Gel
Extraction Kit (Qiagen). Excised insert and linearized pGL3 Promoter vector were ligated
using T4 DNA Ligase (Promega) and cloned. Vectors were sequenced for correct insert
and extracted using the Qiagen Midiprep Kit. T47D cells were transfected and luciferase
activity was determined as described above.
To identify transcription factors binding to the cloned Mier3 promoter, we used
the online program TF SEARCH (http://www.cbrc.jp/research/db/TFSEARCH.html). We
set the parameters to a threshold score of 85 a nd used the vertebrate matrix only. The
function of individual transcription factors was looked up us ing the online database
UniProt (http://www.uniprot.org/uniprot/).

J.

Preparation of mammary epithelial cell enriched cell preps for 3C and bisulfite
sequencing
We extracted mammary epithelial cell enriched preps (MEC preps) from 18 rats

in total. Six WF.COP Line N3 congenic and six WF/NHsd WF females received DMBA
as previously described. Three WF.COP Line N3 and three WF/NHsd females did not
receive DMBA. At twelve-weeks of age, the animals were euthanized. The D and E
glands without lymph nodes were collected and pooled for each animal and placed into
DMEM/F12 media (Life Technologies). Pooled glands were minced and placed into cell
culture flask containing 10ml DMEM/F12 with 0.01g/ml collagenase type III
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(Worthington) and incubated for 2.5hr at 37°C with gentle horizontal shaking. 0.2μg/ml
deoxyribonuclease I (Wothington) was added and the flasks were incubated for 10min at
37°C with vigorous shaking. Cells were transferred to 15ml tubes and centrifuged for
10min at 1000rpm. The layer of fat was removed and cells were washed once with
DMEM/F12. The cells were suspended in 2ml HBSS (Life Technologies) with 0.025%
trypsin (Worthington) and 6.8mM EDTA and incubated horizontally for 5min at 37°C.
4ml of DMEM/F12 with 10% FBS was added to stop the reaction. Cells were centrifuged
and resuspended in DMEM/F12 with 10% FBS. Cells were allowed to pass through a
BD-40 filter and filters were rinsed with 2ml DMEM/F12 with 10% FBS. Cells were
centrifuged and resuspended in 200μl PBS. Cells were counted using a h emocytometer
using tryptan blue.

K.

Chromosome conformation capture
MEC prep cells were diluted in 40ml of PBS and 1.7ml of 37% formaldehyde was

added. Cells were left at room temperature for 10min. 2.7ml of 2M glycine was added
and the cells were incubated for 5min at room temperature and then on ice for 15min.
Cells were centrifuged for 10min at 800 x g and resuspended in 0.5ml of ice-cold lysis
buffer (10mM Tris-HCl, 10mM NaCl, 0.2% NP-40 and Halt Protease Inhibitor Cocktail
(Thermo Scientific)) for 15min. Cells were Dounce homogenized on ice for 15 strokes,
incubated on i ce for 1min and then homogenized with an additional 15 strokes. Cell
nuclei were centrifuged for 5min at 2,500 x g. Nuclei were washed with 0.5ml of BglII
buffer (New England Biolabs) and resuspended in 362μl of BglII buffer. 38μl of 1% SDS
was added and the solution was incubated at 65°C for 10min. 44μl of 10% Triton-X and
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400U of BglII were added and the solution was incubated overnight at 37°C. 86μl of 10%
SDS was added and incubated for 30min at 65°C. Solution was transferred to 15ml
conical tubes and 745μl of 10% Triton-X, 745μl of 10x ligation buffer (500mM Tris-HCl,
100mM MgCl2 and 100mM DTT), 80μl of 10mg/ml BSA, 80μl of 100mM ATP, 5960μl
of molecular grade water and 4000U T4 Ligase (New England Biolabs) was added and
incubated for 2hrs at 16°C. 33μl of 20mg/ml proteinase K (New England Biolabs) was
added and solution was incubated overnight at 16°C. 33μl of proteinase K was added and
incubated for 2hrs at 42°C. Solutions were transferred to 50ml conical tubes and an equal
amount of phenol: chloroform: isoamylalcohol (P:C:I, 25:24:1) was added and vortexed
for 30sec. The solution was centrifuged for 5min at 2,460 x g and extracted again using
P:C:I, then with chloroform and precipitated with Ethanol/ Sodium acetate. Samples were
placed at -20°C for 30min and centrifuged at 10,000 rpm for 30min. The pellet was
washed with 70% ethanol and dissolved in 1ml of water. RNAse A (Promega) was added
and incubated for 30min at room temperature. Samples were split into two tubes and an
additional P:C:I and chloroform extraction was performed. Ethanol/ sodium acetate was
added and pellets were washed five times with 70% ethanol. Pellets were dissolved in
300μl TE buffer, incubated for 15min at 37°C and stored at -20°C. A BAC clone
containing the entire Mcs1b region of interest was used as a positive control. The BAC
used was Rattus norvegicus CH230-117D7 (Children's Hospital Oakland Research
Institute (CHORI)). 20μg of the BAC was digested overnight at 37°C using BglII in 1x
restriction enzyme buffer, 0.5μl BSA in a total volume of 50μl. The BAC was purified
using P:C:I and chloroform extractions, followed by ethanol precipitation. The BAC was
ligated using 5μl of 10x T4 DNA ligase buffer and 2U of T4 DNA ligase (Promega) and
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was incubated at 16°C overnight. The BAC was then extracted using P:C:I and
chloroform extraction followed by an ethanol precipitation. The BAC and DNA
concentration was determined using band intensity quantification.
The amount to use in a PCR reaction was determined empirically to be 50ng. The
BAC concentration to use in the PCR reaction was determined empirically to be 0.4ng.
The PCR reactions were prepared on ice by adding 50ng of DNA, 0.2mM of each dNTP,
0.4μM of each primer, 1x Herculase reaction buffer and 0.3μl Herculase Enhanced
polymerase (Agilent) in a total volume of 25μl. The reactions were run on a Veriti 96
well fact thermal cycler (Applied Biosystems) with the following conditions: 95°C for
1min, 34 cycles of 95°C 1min, 60°C for 45sec, 72°C for 2min and one cycle of 95°C for
1min, 60°C for 45sec, 72°C for 8min. 10μl of Ficoll dye (15% Ficoll 400 in water) was
added to the PCR reactions and 20μl was added to the wells. For the BAC 10μ of Ficoll
dye was added and 10μl was loaded onto the gel. PCR reactions and 500ng of a 100bp
DNA ladder were run on a 1% agarose gel. The gel was stained using 0.1ug/ml ethidium
bromide for 25min and destained in water for 15min. A picture was taken using a GE
Typhoon 9400. PCR products were analyzed using band intensity quantification with
ImageJ and divided by the intensity of the PCR band using the BAC. A list of 3C primers
used can be found in Table 16.

L.

Bisulfate sequencing
We performed bisulfite sequencing on three different groups of rats. Each group

contained three females. One group was treated with DMBA, the other two were not. All
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Table 16. Primers used for 3C analysis.
ID
A136- Fixed 7
A136-Moving B
A136-Moving E
A136-Moving F
A136-Moving G
A136-Moving H
A136-Moving I
A136-Moving J
A136-Moving K
A136-Moving L
A136-Moving M

Sequence
ATATAGCTTTCTGCCTGCGTGTAT
AGAGCTGACCGTTTGGTATTGTATAAC
ACTCCTGACTGTCTGTCTCCCTTTTA
GACACATCTATTTTATAGCCACAAACAC
AGTATCAGTGAGTGAGGTAGTTCAGAAA
AGATTATGGCATTACTGAGTCTGTCTAC
CTTGCTACTGGAGAATGTGATGATAAG
TAGAATTAAAGGCATATACCACCACAC
AGCATGGTCCTACAACTTTTAATACAG
ATTGAGAGTTCTTTCTTAGACCTGTAGC
CTAAAGTAGAAAATGCACATGGAGGAT
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animals were 12- weeks old. MEC preps were prepared as described previously. DNA
was extracted using the DNeasy Blood and Tissue Kit (Qiagen). DNA was bisulfate
converted using the Cell-to-CpG Bisulfite Conversion Kit (Life Technologies) using
manufacturer’s instructions. 2μg was used in the bisulfite conversion and samples were
pooled using equal amounts. The bisulfite conversion was performed under the following
conditions: 95°C for 3min, 65°C for 60min, 95°C for 3min, 65°C for 30min. PCR
reactions contained 150ng bisulfite converted DNA, 0.2mM of each dNTP, 1x buffer,
0.4μM of forward and reverse primers (list of primers can be found in Table 17), 0.5μl
Easy A High- Fidelity PCR Cloning Enzyme (Agilent) in a total volume of 50μl. The
PCR reaction were run using the following conditions: one cycle of 95°C for 15min, 18
cycles of 94°C for 45sec, 65°C for 45s (-0.5°C/ cycle)and 72°C for 1.5min, 22 cycles of
94°C for 45sec, 56°C for 45sec and 72°C for 1.5min, one cycle of 72°C for 8min. PCR
reactions were run and visualized on a 1% agarose gel. PCR reactions were gel extracted
using the Promega Wizard SV Gel and PCR Cleanup kit and cloned into a pCR-2.1
vector using the the Original TA Cloning kit (Life Technologies). Ten clones for each
PCR reaction were extracted using the Qiagen Miniprep or the DirectPrep 96 M iniprep
kit and sequenced.

M.

CRISPR knockout of A074-SNP-17

Guide sequences for the CRISPR knockout were designed to be in close proximity to the
A074-SNP-17 targeted site and contained BbsI restriction sites. The guide sequences for
target constructs are shown in Table 18. T he pX335-U6-Chimeric_BB-CBh-HSpCas9n
(D10A) vector (Addgene) was digested with the restriction enzyme BbsI. C onstructs
were annealed and cloned as previously described. RBA cells were grown in RPMI 1640
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Table 17. Primers for bisulfate sequencing of Mcs1b candidate SNPs
ID
Sequence
A139- A074-SNP-17- a1
TTTTTTGAGAATTATTAGGTTAGGAAA
A139- A074-SNP-17- a2
TTCTACAACTACCCTATCAAAACCTTC
A139- A074-SNP-17- b1.1
TGGGTTAGATGGTATGTATTATGTAGTTT
A139- A074-SNP-17- b1.2
ATTACTTCAACAACAATCTTCTAAAAA
A139- A074-SNP-17- b2.1
TTTTTGTAGTTGTTTTGTTAGAGTTTTTT
A139- A074-SNP-17- b2.2
AAACTACATAATACATACCATCTAACCCAT
A139- A074-SNP-18- a1
AGGTTTTTTGGATTAAATTTGGGTA
A139- A074-SNP-18- a2
TCCTTACAAAAAAACTAAATAATTCCT
A139- A074-SNP-18- b1
ATTGTTTTTGTAAAGGGATTGAGTG
A139- A074-SNP-18- b2
AACCTCTTAAACCAAATCTAAACACC
A139- A046-SNP-A- a1
GGGTAGAGTTATAATTTTTGGTGTG
A139- A046-SNP-A- a2
CATCCATTCTAATAAAAATACAAAATACCA
A139- A046-SNP-A- b1
AAAAAGGTGTTTAGGATTATTGGTT
A139- A046-SNP-A- b2
CACAACTCACTCATATAACATACCACA
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Table 18. Constructs for CRISPR knockout of A074-SNP-17.
ID
Sequence
A141-gSEQ Target 1 ON1
CACCGTTGTTGACCCAGTCGGAATTAAGG
A141-gSEQ Target 1 ON2
AAACCCTTAATTCCGACTGGGTCAACAAC
A141-gSEQ Target 2 ON1
CACCGCTGATGAGCTGCACATGTCATGG
A141-gSEQ Target 2 ON2
AAACCCATGACATGTGCAGCTCATCAGC
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(Life Technologies) with the addition of 10% FBS and anti-anti (Life Technologies).
LA7 cells were grown in DMEM with the addition of 10% FBS, anti-anti, 4.5g/L
glucose, 0.005 m g/ml insulin, 50 nM hydrocortisone and 20 m M HEPES. 5x105 cells
were plated into 6- well dishes 24hrs prior of transfection using media without anti-anti.
Cells were transfected using Lipofectamine 2000 (Life Technologies) according to the
manufacturer’s instructions. Cells were not transfected, transfected with 4μg of pEGFPC1, 2μg of target 1 and 2μg of target 2, or mock transfected with Lipofectamine 2000
only. Media was changed every 24hrs. 72hrs post transfection, the cells were harvested
with Tripsin- EDTA (Life Technologies), centrifuged for 5min at 500 x g and DNA was
extracted using the DNeasy Blood and Tissue Kit (Qiagen). The PCR reactions were
assembled on i ce and contained: 100ng of DNA, 1x Optimase buffer, 0.2mM of each
dNTP, 0.4μM of each primer and 1μ Optimase Polymerase (Transgenomics) in a total
volume of 50μl. A positive control included with the SURVEYOR Mutation Detection
Kit (Transgenomics) was used in the PCR reactions. The PCR reaction was run on a
Veriti 96 well fact thermal cycler (Applied Biosystems) under the following conditions:
94°C for 2min, 35 cycles of 94°C for 30sec, 60°C for 30sec, 72°C for 1.5min and 1 cycle
of 72°C for 5 m in. The PCR reactions were run on a 2% high resolution agarose gel
including 500ng of a 100bp ladder and 5μl 1kb ladder (Promega) and the band intensities
were quantified. 300ng of each PCR product was used for the heteroduplex formation
under the following conditions: 95°C for 10min, 95°C- 85°C (-2.0°C/s), 85°C for 1min,
85°C- 75°C (-0.3°C/s), 75°C for 1min, 75°C- 65°C (-0.3°C/s), 65°C for 1min, 65°C55°C (-0.3°C/s), 55°C for 1min, 55°C-45°C (-0.3°C/s), 45°C for 1min, 45°C-35°C (0.3°C/s), 35°C for 1min, 35°C- 25°C (-0.3°C/s), 25°C for 1min. Heteroduplexed DNA
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was then digested with SURVEYOR nuclease and run on a 2% high resolution agarose
gel. Cells were visualized using fluorescent microscopy using a Olympus IX51 inverted
research microscope at 10x.

Results
The goal of this aim is to perform functional analyses on the rat Mcs1b candidate
SNPs and the human rs889312 correlated polymorphisms. The hypothesis is that these
SNPs are located in regulatory regions that affect expression levels of Mcs1b/MCS1B
genes. It is known that several Mcs1b genes are expressed differently in mammary glands
of WF and COP females [87]. The SNPs are most likely located in enhancer/ repressor
regions, due to their genomic location and proximity to the nearest gene. A reporter gene
assay can be used to test if genomic regions are involved in gene regulation.

A.

Luciferase assays for rat Mcs1b candidate SNPs and rs889312 correlated SNPs
To determine if the rat Mcs1b candidate SNPs and the rs889312 correlated SNPs

are involved in gene regulation, a luciferase assay was used. Constructs containing the
SNP nucleotide and 12bps flanking on e ither side were cloned into a pGL3-Promoter
vector and the luciferase and Renilla activity was determined. Note, the 25bps of the SNP
regions were repeated five times in tandem to increase signal strength. The pGL3Promoter vector was used, since genomic regions suspected of being enhancers/
repressors can be tested using this vector. The luciferase activity was tested in two
different breast cancer cells lines: T47D and MDA-MB-231 cells. T47D cells are luminal
A, estrogen receptor (ER) and progesterone receptor (PR) positive, while MDA-MB-231
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cells are triple negative, ER, PR and human epidermal growth factor receptor 2 (HER2)
negative [138]. rs889312 appears not to be subtype specific. It is associated with breast
cancer risk in both ER positive and triple negative breast cancer subtypes [85, 86]. These
two breast cancer cell lines were chosen, because they are examples of two opposing
subtypes of breast cancer. A genotyping screen of 40 human breast cancer cell lines
revealed that both T47D and MDA-MB-231 cells are heterozygous at SNP rs889312,
which indicates they are also heterozygous at the six SNPs that rs889312 tags. The same
study also revealed that the expression level of MAP3K1 is among the highest in T47D
cells, while it is among the lowest in MDA-MB-231 cells [139]. Therefore, we chose
these two cell lines, since they represent two opposing states of gene expression of a
MCS1B candidate gene, yet they have the same genotype, indicating that differences in
the expression levels are likely due to differences in the cell environment. The luciferase
activity for the WF and COP alleles for all three Mcs1b candidate SNPs and the major
and minor alleles for all seven rs889312 correlated SNPs were determined in these two
cell lines to test for any affects on gene regulation.
The results for the rat Mcs1b candidate SNPs in T47D cells are shown in Figure
12A. The luciferase activity is significant lower than the pGL3- Promoter luciferase
activity for all SNP alleles except the COP allele of A074-SNP-18. This indicates that the
three Mcs1b candidate SNPs may act as repressors, rather than enhancers, to reduce
promoter activity. The luciferase activity is different between the COP and WF alleles for
all three Mcs1b candidate SNPs. The luciferase activity for A074-SNP-18 and A046-SNPA is lower for the WF allele than for the COP allele. The luciferase activity for A074-
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Figure 12. L uciferase assays for rat Mcs1b candidate SNPs. (

) D ark grey bars

indicate adjusted relative luciferase activity for the COP (resistant) allele. (

) Light grey

bars indicate adjusted relative luciferase activity for the WF (resistant) allele. Asterisks
indicate luciferase activity that is significantly different between the WF and the COP
alleles. All adjusted relative luciferase activities are at least nine values from three
independent experiments. Errors bars indicate standard error from pooled experiments.
As controls, the luciferase activity for the pGL3-Basic and pGL3-Promoter were
determined. The pGL3-Promoter activity was used to adjust the relative luciferase
activities to pool values from independent experiments. A) Luciferase activities in T47D
cells. Luciferase activity is different between the two rat alleles for all three Mcs1b
candidate SNPs. B) Luciferase activities in MDA-MB-231 cells. Luciferase activity was
different between the two rat alleles for A074-SNP-17 and A074-SNP-18, but not for
A046-SNP-A.
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SNP-17 shows the opposite pattern, with the COP allele activity being lower than the WF
allele activity. This pattern of gene regulation is the same as we see when looking at the
expression levels of Mcs1b candidate SNPs between the two rat strains. Map3k1, Gpbp1
and Mier3 are all expressed higher in the WF mammary gland compared to the COP
mammary gland in 12-week old females [87]. This makes A074-SNP-17 a strong
candidate for conferring the difference in expression levels of Mcs1b candidate genes
between the two rat strains.
The luciferase activities for the Mcs1b candidate SNPs in MDA-MB-231 cells are
shown in Figure 12B. The luciferase activity for A074-SNP-17 shows a similar pattern as
in T47D cells. The luciferase activity is lower in the COP allele than in the WF allele. For
A074-SNP-18 the pattern is the same as in T47D cells. The luciferase activity for the
COP allele is higher than for the WF allele. However, there is no statistical difference
between the two rat alleles for A046-SNP-A. This SNP showed a luciferase activity that
was different between the two alleles in T47D cells. This is likely due to a difference in
the cellular environments of the two breast cancer cell lines.
Next, we cloned the major and minor alleles for all seven rs889312 correlated
SNPs into the pGL3-Promoter vector and measured the luciferase activity in both T47D
and MDA-MB-231 cells. The luciferase activities for the rs889312 correlated SNPs in
T47D cells are shown in Figure 13A. The luciferase activities between the major and
minor alleles of four of the rs889312 correlated SNPs are statistically different in T47D
cells. rs889312 and rs12697152 have luciferase activities that show higher major allele
activities than the minor allele activities. The major and minor allele luciferase activities
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Figure 13. L uciferase assays for human rs889312 correlated SNPs. (

) D ark grey

bars indicate adjusted relative luciferase activity for the major (resistant) allele. (

)

Light grey bars indicate adjusted relative luciferase activity for the minor (susceptible)
allele. Asterisks indicate luciferase activity that is significantly different between the
major and the minor alleles. All adjusted relative luciferase activities are at least nine
values from three independent experiments. Errors bars indicate standard error from
pooled experiments. As controls, the luciferase activity for the pGL3-Basic and pGL3Promoter were determined. The pGL3-Promoter activity was used to adjust the relative
luciferase activities to pool values from independent experiments. A) Luciferase activity
in T47D cells. Luciferase activity is different between the two major and minor alleles for
four rs889312 correlated SNPs. B) Luciferase activity in MDA-MB-231 cells. Luciferase
activity is different between the major and minor alleles for the same four rs889312
correlated SNPs as seen in T47D cells.
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for rs12697152 both are lower than the pGL3-Promoter luciferase activity, suggesting
that this SNP may be located in a repressor element. rs889312 is the SNP used in several
GWA studies that identified the human MCS1B region. Its luciferase activity is different
between the major and minor allele with the major allele having a much higher luciferase
activity than the minor allele. The luciferase activity for rs1862626 and rs1862625 are
also different between the major and minor alleles. Both SNPs have a higher minor allele
activity compared to the major allele activity. The major allele activity for rs1862626 is
extremely low compared to the minor allele activity. However, the major allele activity is
statistically different than the luciferase activity for pGL3-Basic, indicating that not all
promoter activity is being repressed by the rs1862626 major allele. The pattern of gene
regulation, with the major or resistant allele having a lower luciferase activity than the
minor or susceptible allele is the same as with the expression level of candidate Mcs1b
genes and with the rat Mcs1b candidate SNPs, A074-SNP-17. This makes rs1862626 a
candidate functional ortholog for A074-SNP-17. Also, rs1862625 has the same pattern of
gene regulation in the luciferase assay, but its activity is not as exaggerated as with
rs1862626, therefore rs1862626 is considered the best candidate for a functional ortholog
to A074-SNP-17.
The luciferase activities for rs889312 correlated SNPs in MDA-MB-231 cells are
shown in Figure 13B. Only SNPs that showed a statistically significant difference
between the major and minor alleles are shown. All four human SNPs that showed a
luciferase activity that is different between the major and minor alleles in T47D cells also
do so in MDA-MB-231 cells. There are no changes in pattern or intensity of luciferase
activities for SNPs rs1862625 and rs12697152 compared to T47D cells. However, while
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the pattern of luciferase activity is the same for rs1862626 and rs889312 compared to
T47D cells, the intensity of the major allele for rs889312 is much higher and the intensity
for the minor allele for rs1862626 is much lower compared to T47D cells. This is likely
due to differences in the cell environments between the two different cell lines. It is
possible that different transcription factors bind to the SNPs in the two different cells or
that transcription factors are expressed at different levels between the two cell lines.
The differences in luciferase activities between the resistant and susceptible
alleles for the rat Mcs1b candidate SNPs and rs889312 correlated SNPs are likely due to
differences in transcription factors binding to the alleles. Therefore, we looked at the
patterns of DNA binding proteins binding to the rat and human SNP alleles.

B.

EMSAs of rat Mcs1b candidate SNPs and rs889312 correlated SNPs
We used electrophoretic mobility shift assays (EMSAs) to determine if there are

any DNA binding proteins binding to the SNP regions and if any bind differentially
between the WF and COP alleles. We initially focused on using T47D nuclear extracts
since, the luciferase assays for all three Mcs1b candidate SNPs are different between the
two alleles. The EMSAs for the three Mcs1b candidate SNPs using T47D nuclear extracts
are shown in Figure 14 A and B. We used oligos that contained the SNP nucleotide and
12bps flanking on e ither side, for a total of 25 bps. There are several DNA-protein
complexes present for A046-SNP-A. One predominant DNA-protein complex (marked
with arrow in Figure 14B) can be competed out with cold probe, indicating that this is a
specific DNA –protein interaction. The EMSA results indicate that there might be a
difference in the intensity of this band between the WF and COP allele, suggesting that
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Figure 14. E MSAs for A074-SNP-17, A074-SNP-18 and A046-SNP-A using T47D
nuclear extracts. DNA- protein complexes were run on a 5% polyacrylamide gel.
Protein extracts were T47D nuclear extracts. A) EMSAs and competition EMSAs for all
three Mcs1b SNPs. No competition EMSA for A046-SNP-A. Arrow indicates difference
between WF and COP alleles for A074-SNP-17 B) Competition EMSA for A046-SNP-A.
Arrow indicates band of interest for A046-SNP-A.
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the protein might not bind as tightly to the WF allele. The same is true for A074-SNP-18.
There are several specific DNA- protein interactions. There may be a d ifference in the
intensity of the band between the WF and COP alleles. There are several specific DNAprotein interactions for A074-SNP-17, however, one band is only found in the WF allele
and not the COP allele (marked with arrow in Figure 14A). This suggests that this DNAprotein interaction is unique to the WF allele and may represent a transcription factor that
binds only to the WF and not the COP allele. This makes A074-SNP-17 a great candidate
for the Mcs1b region, since it not only appears to be involved in gene regulation but it
also shows a differential pattern of DNA binding proteins for the two rat alleles.
We next performed the EMSA experiments using mutant oligos to determine if
any of the DNA-protein binding complexes seen in Figure 14 are due to proteins binding
directly to the SNP site and not to the rest of the oligo. We initially tested several
different mutant oligos for A046-SNP-A to determine which would be the best in
reducing specific DNA-protein interactions. We designed the oligos so that the SNP
nucleotide was either deleted or replaced by random sequence. The results are shown in
Figure 15. Overall, the 3bp deletion oligo worked the best at reducing the intensity of the
band of interest for A046-SNP-A. A 3bp de letion oligo will be used in subsequent
experiments which utilize mutant oligos for the Mcs1b candidate SNPs. Several oligos,
including the 5bp de letion and 17bp r andom insertion oligos actually increased the
intensity of the band of interest. It is not known, however, if the bands are due to the
same DNA- protein complexes.
To determine which DNA- protein complexes are due to proteins binding to the
SNP nucleotide, we performed an EMSA experiment using the 3bp deletion oligos
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Figure 15. E MSAs with mutant oligos for A046-SNP-A. EMSA were run on a 5%
polyacrylamide gels. T47D nuclear extracts were used for the EMSA. Mutant oligos are
shown above EMSA gel. COP wild type (WT) and WF wild type were added as controls.
Arrow indicates band of interest. The 3bp deletion oligo worked best at reducing the
intensity of DNA-protein interaction of interest (marked by arrow) and will be used in
subsequence experiments.
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described above. The results for the EMSA experiments using mutant oligos for all three
Mcs1b candidate SNPs and T47D nuclear extracts are shown in Figure 16. Figure 16A
shows the results for A074-SNP-17. The 3bp deletion oligo results in the loss of all DNAprotein complexes, including the complex of interested (indicated by arrow in Figure
16A). The results for A074-SNP-18 and A046-SNP-A indicate loss of the bands of interest
(marked by arrow in Figure 16B) when using the 3bp deletion oligo. This indicates that
all DNA-protein complexes for A074-SNP-17 are due to proteins binding to the SNP
nucleotide, while only complexes of interest for A074-SNP-18 and A046-SNP-A are due
to proteins binding to the SNP nucleotide. It is possible that DNA-protein complexes that
are lost with usage of the 3bp deletion oligos are made up of transcription factors.
We next performed the EMSA experiment using MDA-MB-231 nuclear extract as
a comparison to the results using T47D nuclear extracts. The results are shown in Figure
17. Note, instead of performing a competition EMSA to identify specific DNA-protein
complexes, we used 3bp deletion oligos to determine complexes that bind directly to the
SNP nucleotide. Overall, there are fewer DNA-protein complexes when compared to the
amount of DNA-protein complexes when using T47D nuclear extracts. A074-SNP-17 and
A074-SNP-18 show one predominant band that is lost when using the 3bp deletion oligo
(arrow #2 in Figure 17). A046-SNP-A shows several DNA-protein complexes. The DNAprotein complex marked with arrow #2 i n Figure 17 ha s the same intensity in both the
WF and COP allele, but is lost when the 3bp de letion oligo is used. This predominant
band migrates at the same size as the predominant band for A046-SNP-A using T47D
nuclear extracts (data not shown). There is a difference in the intensity of this band
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Figure 16. EMSA of Mcs1b candidate SNPs using 3bp deletion oligos and T47D
nuclear extracts. EMSA was run on a 5% polyacrylamide gel using T47D nuclear
extract. Wild type COP and WF and 3bp d eletion probes were used to identify DNA
protein complexes that are due to proteins binding to the SNP nucleotide. Arrows indicate
bands of interest. A) EMSA for A074-SNP-17 using 3bp deletion oligo. Band of interest
is marked with an arrow. All DNA- protein complexes are lost when the SNP nucleotide
and 2bp surrounding nucleotides are deleted. B) EMSA for A074-SNP-18 and A046-SNPA using 3bp d eletion oligo. Bands of interest are indicated by arrow. Deleting SNP
nucleotide results in the loss of the band of interest.
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Figure 17. EMSA of Mcs1b candidate SNPs using 3bp deletion oligos and MDA-MB231 nuclear extracts. EMSA was run on a 5% polyacrylamide gel using MDA-MB-231
nuclear extract. Wild- type COP and WF and 3bp deletion probes were used to identify
DNA protein complexes that are due to proteins binding to the SNP nucleotide. Bands of
interest are marked by arrows. One predominant band (marked by arrow 1) is found in all
samples and cannot be competed out, indicating a non-specific interaction. A
predominant band (marked by arrow 2) is found in all samples and can be competed out,
indicating a specific interaction.
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between the WF and COP allele when using T47D nuclear extracts, but the difference in
intensity is lost when using MDA-MB-231 nuclear extracts. The luciferase activities for
the COP and WF alleles of A046-SNP-A were different in T47D cells but the same in
MDA-MB-231 cells. It is possible that a transcription factor is not present in MDA-MB231 cells that is involved in binding to the A046-SNP-A SNP and functions as to regulate
gene expression. Interestingly, an additional band is found in EMSAs using MDA-MB231 extracts (marked by arrow #1 in Figure 17). This protein complex binds to all three
Mcs1b candidate SNPs and is not removed when using the 3bp d eletion oligos,
suggesting that this is a non-specific interaction.
We also determine the protein binding pattern for two of the four candidate
rs889312 correlated human SNPs using EMSAs. We focused on rs1862626 because it
has a similar pattern of luciferase activity as our candidate Mcs1b SNP A074-SNP-17. We
also performed an EMSA experiment for rs889312 since it is the SNP used in the initial
breast cancer GWA study and the major allele luciferase activity is affected greatly by the
cellular environment. The results are shown in Figure 18. There is one predominant band
in the rs1862626 EMSA for the major allele (Figure 18A, marked with arrow). This band
can be competed out with increasing amounts of cold probe, indicating that this is a
specific DNA- protein interaction. There is one predominant band when using the minor
allele probe. This band can also be competed out with increasing amounts of cold
competitor probe. There are four bands visible in the rs889312 EMSA. All of which can
be competed out with increasing cold competitor probes (Figure 18B, marked with
arrows #1- #4). There appear to be no DNA-protein complexes that are unique to one of
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Figure 18. EMSAs for rs889312 correlated SNPs rs1862626 and rs889312. EMSAs
were run on 5% polyscrylamide gel. T47D nuclear extracts were used. Cold competitor
concentration was increased from 10x to 200x. A) EMSA for rs1862626 showing one
predominant band marked with arrow. B) EMSA for rs889312 with several predominant
bands that can be competed out. Bands of interest are marked with arrows.

135

the alleles in the rs889312 EMSA. It is possible that there is a difference in the intensity
between the two alleles which indicates a difference in the affinity of a DNA binding
protein for one of the alleles. There is one DNA-protein binding complex that is found in
the rs1862626 EMSA for both the major and minor allele. It is possible that there is a
difference in the intensity of this band between the two alleles, which would indicate a
difference in the affinity of the DNA binding protein for the two alleles. It is possible that
this DNA-protein complex is responsible for the differential luciferase activity between
the major and minor alleles of rs1862626.

C.

Identification of candidate proteins binding to A074-SNP-17
A074-SNP-17 shows a DNA binding protein pattern that is different between the

WF and COP alleles. In particular, the WF allele for A074-SNP-17 shows an extra band
in an EMSA using T47D nuclear extract, indicating there is a unique DNA- protein
complex binding the WF allele (Figure 14A). Also, the luciferase activity between the
WF and COP allele for A074-SNP-17 is different, suggesting that there might be different
transcription factors binding to the two alleles. We wanted to identify which transcription
factors bind to the WF and COP alleles for A074-SNP-17. We initially used the online
program TF SEARCH to identify any DNA binding proteins that are predicted to bind the
WF and COP alleles differentially. The results are listed in Table 19. We focused on two
transcription factors, c-myc/max and Skn-1, an ortholog of the NRF1, 2 and 3 proteins,
because of their role in breast cancer. C- MYC is an important transcription factors that is
involved in regulating 15% of all human genes. It is a known proto-oncogene and is
involved in cell growth, transformation, angiogenesis and cell- cycle control [140, 141].
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Table 19. TF SEARCH results for A074-SNP-17. Scores indicate percentage of how close the
sequence is to the consensus sequence. Multiple scores indicate multiple predicted binding sites.
Protein
Name
COP score WF score
Function
SN
Snail
86.4
MyoD
Myblast determining factor
79.8
86.2/79.1
Skn-1
NRF1,2,3 ortholog
89/77
85.2
Transcription
factor
c-myc/max
85
Transcriptional
activator
USF
Upstream transcription factor 1 83.8/82.6/78.3/75.9 Transcriptional
activator
Mat alpha
Mating factor alpha 2
83.5/77.2
Cap
Cap signal transcription
83.1/80
80.0/78.7
initiation
N-Myc
78.4/76.3
COUP-TF
COUP-TF/HNF4 heterodimer
81.8
CdxA
78.2
E2F
77
Transcription
factor
ROR alpha RAR related orphan receptor
76.9
Transcriptional
alpha
activator
Cre-BP
Cre binding protein 1/ c-jun
75.6
Transcriptional
heterodimer
activator
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We performed an EMSA supershift assay to determine if c-MYC binds to the WF
and COP alleles of A074-SNP-17. The results are shown in Figure 19. There is no
supershift of any bands of the COP and WF A074-SNP-17 alleles, indicating that c-MYC
does not bind to A074-SNP-17 (Figure 19A). However, there is also no supershift for the
E-box positive control. E-box is the name of the c-MYC binding site consensus sequence.
The consensus sequence is CAC(G/A)TG and is found in the positive control, which has
previously been used successfully in a c-MYC supershift assay [142]. We t ested our cMYC antibody (Santa Cruz, sc-764) in a Western blot to determine if it is functional and
if c-MYC is expressed in T47D and MDA-MB-231 cells (Figure 19B). The antibody can
be used in a western blot and the two breast cancer cell lines express nuclear c-MYC. It is
possible that the antibody is not efficient for performing supershift assay and therefore
we did not see any supershifts in the positive control. We co-transfected an expression
vector containing the human c-MYC gene with the luciferase constructs for A074-SNP17. As shown in Figure 19C, there is no effect of c-MYC on the luciferase activity of the
A074-SNP-17 alleles, further indicating that c-MYC probably does not bind to A074SNP-17. H owever, it may also be possible that c-MYC is expressed at high levels in
T47D cells and further overexpression does not have an effect on A074-SNP-17
luciferase activity.
We also tested another protein predicted to bind the WF and COP alleles of A074SNP-17. Both the COP and WF allele are predicted to bind the protein Skn-1, which is
the C.elegans ortholog of the NRF1, 2, 3 p roteins. However, the A074-SNP-17 COP
allele is predicted to bind this protein more often and with a higher affinity (Table 19).
Nuclear factor (erythroid derived)- like 2 (NRF2) is a known transcription factor
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Figure 19. A nalysis of c-MYC binding to A074-SNP-17. A) Supershift EMSA for cMYC binding to A074-SNP-17. Supershift EMSA was run on a 5% polyscrylamide gel.
E-box oligo contains consensus site for c-MYC. No supershift for A074-SNP-17 rat
alleles or for the E-box consensus sequence was observed. B) Western blot for c-MYC
using T47D and MDA-MB-231 nuclear and cytoplasmic extracts. T47D and MDA-MB231 cells express c-MYC and the antibody is specific in a Western blot for c-MYC. C)
Luciferase assays for co-expression of A074-SNP-17 luciferase constructs and c-MYC
expression vector in T47D cells. (

) Light grey bars indicate luciferase activity of

A074-SNP-17 allele when co-expressed with empty expression vector. (

) Dark grey

bars indicate luciferase activity of A074-SNP-17 allele when co-expressed with c-MYC
expression vector. Error bars indicate standard error. Ns indicates non- significance.
Luciferase activity of the A074-SNP-17 allele co-expressed with the empty vector was
compared to the luciferase activity of A074-SNP-17 co-expressed with the c-MYC
expression vector. C-MYC does not have an effect on t he luciferase activity of A074SNP-17.
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involved in cancer. Under normal conditions, NRF2 is kept in the cytoplasm by the
protein KEAP1 and targeted for degradation. Under cellular stress, such as oxidative
stress, KEAP1 releases NRF2 and NRF2 locates to the nucleus, where it acts as a
transcription factor. There are basal levels of NRF2 found in the nucleus, even under
normal conditions [143, 144]. NRF2 can act as a tumor suppressor and oncogene
depending on t he context. NRF2 protects cells from cytotoxic stress but NRF2 also
regulates genes that are involved in cell survival under stress conditions [144]. We
performed a supershift EMSA to determine if NRF2 binds to the A074-SNP-17 alleles
using T47D nuclear extract. The results are shown in Figure 20A. NRF2 binds to DNA
sequences called Antioxidant Response Elements (AREs). We used a positive control for
the NRF2 supershift that contains an ARE [145]. There is a supershift in the presence of
NRF2 antibody (Santa Cruz, sc-722x) for all three oligos, marked by an arrow in Figure
20A. This suggests that NRF2 binds both the COP and WF allele of A074-SNP-17. The
band that is shifted upon addition of NRF2 antibody is of a high molecular weight. We
ran the EMSA supershift on a 4% polyacrylamide gel to better visualize the band.
However, in competition EMSAs for A074-SNP-17, this band could not be competed out,
suggesting that this interaction is not specific (data not shown). We therefore designed a
random 25bp oligo and performed a supershift EMSA for NRF2. As seen in Figure 20B,
using the random oligo also results in a supershift for NRF2. This indicates that NRF2
binds these oligos non-specifically or the antibody cross-reacts with another protein that
binds the oligos in a non-specific manner. To ensure that NRF2 does not affect the gene
regulation activity of A074-SNP-17, we performed a co -expression experiment using a
NRF2 expression vector and pGL3 vectors containing an ARE and the COP and WF
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Figure 20. A nalysis of NRF2 binding to A074-SNP-17. EMSAs were run on a 4%
polyacrylamide gel. A) Supershift EMSA for NRF2 binding to A074-SNP-17. ARE oligo
contains consensus site for NRF2. There is a supershift present for both rat alleles for
A074-SNP-17 and the ARE consensus site (indicated by arrow) B) Supershift EMSA for
a random oligo and NRF2. The NRF2 antibody supershifts a random oligo, indicating
that the interaction between the oligos and NRF2 is not specific. C) Luciferase assays for
co-expression of A074-SNP-17 luciferase constructs and NRF2 expression vector in
T47D cells. Co-expression of pGL3 vectors and an empty expression vector is shown
using light grey bars (

). Co-expression of pGL3 vectors with a NRF2 expression

vector is shown with dark grey bars (

). Luciferase activities of co-expression with

empty vector was compared to luciferase activity of NRF2 co-expressed with pGL3
vectors. Error bars indicate standard error. Asterisk indicates significance, while ns
indicates non-significance. There is no effect of the NRF2 over-expression on the A074SNP-17 pGL3 luciferase activity.
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A074-SNP-17 alleles. There results are shown in Figure 20C. The luciferase activity of
the ARE containing luciferase vector is increased when NRF2 is overexpressed in T47D
cells. However, the luciferase activities for A074-SNP-17 are not changed in the presence
of NRF2, suggesting that this protein has no e ffect on t he gene regulation activity of
A074-SNP-17. Note, NRF2 reduces the luciferase activity of the pGL3-promoter vector,
possibly through regulation of another protein that binds the SV40 promoter.
Since we were not able to identify any proteins binding to the A074-SNP-17
alleles using TF SEARCH, we performed a DNA pulldown and mass spectronomy
analysis. The DNA pulldown was performed using T47D nuclear extract and the A074SNP-17 COP, WF and 3bp deletion oligos that were used for EMSAs. We lost the DNAprotein complex that is unique to the WF allele in the process of the DNA pulldown (data
not shown). This is likely due to the protein being of low abundance and getting removed
during the stringent wash steps. We therefore concentrated on proteins that were found in
both the COP and WF samples but not in the 3bp deletion sample. Results are shown in
Table 20. This procedure resulted in the identification of many proteins binding to both
the WF and COP alleles of A074-SNP-17. Therefore, results were filtered for proteins
that are expressed in the nucleus, are expressed in T47D cells, have known transcriptional
regulation function, have known DNA binding domain and are known to be involved in
cancer. We chose to test three of these proteins in supershift EMSA experiments. These
are the progesterone receptor (PR), nuclear factor 1 C -type (NFIC) and interleukin
enhancer- binding factor (ILF2).
The COP allele of A074-SNP-17 pulled down the progesterone receptor A
isoform, while the WF allele pulled down the delta 3+ 6/2 isoform of the progesterone
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Table 20. Mass spectrometry results for A074-SNP-17 using T47D nuclear extracts.
ID
Abbreviation DNA binding domain Function
Isoform A of Progesterone
PR-A
C4- type zinc fingers
Transcriptional
receptor
regulation
Delta 3+6/2 progesterone
PR
C4- type zinc fingers
Transcriptional
receptor
regulation
Isoform 3 of Nuclear factor
NFIC
CTF/ NF-1
Transcriptional
1 C-type
regulation
Interleukin enhancer-binding ILF2
DZF
Transcriptional
factor 2
regulation
Cell division cycle and
CCAR1
SAP
Transcriptional
apoptosis regulator protein 1
regulation
RuvB-like 2
RUVBL2
Transcriptional
regulation
Isoform 2 of Casein kinase I CSNK1D
serine/threonine-protein
isoform delta
kinase
Superkiller viralicidic
SKIV2L2
mRNA splicing
activity 2-like 2
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receptor. The progesterone receptor is activated by progesterone and is involved in the
regulation of various genes. Progesterone has proliferative and carcinogenic effects on
breast tissue [146]. The progesterone receptor B differs from the A isoform through an
additional 164 a mino acids at the N-terminal. These 164 a mino acids contain an
additional transcription activation function. The two isoforms of the progesterone
receptor have distinct functions and the isoform A has been shown to be a transdominant
inhibitor of the B isoform and shows anti-estogenic effects [147]. The delta 3+ 6/2
isoform of the progesterone receptor lacks exon 3 a nd 52bps in exon 6. I t is unknown
how this affects the function of the protein [148]. T he progesterone receptor binds to
progesterone response elements (PRE), which are characterized by the sequence
5’GNAGANNNTGTNC’3 [149, 150]. We used an antibody that can recognize both A
and B isoforms of the progesterone receptor for the supershift EMSA experiment (Santa
Cruz, sc-538x). The results are shown in Figure 21A. There was a supershift detected for
the PRE positive control (marked by arrow in Figure 21A), suggesting that the supershift
worked correctly. However, there was no s upershift detected for the A074-SNP-17
alleles, suggesting that the progesterone receptor does not bind to A074-SNP-17.
We also performed a supershift EMSA for the nuclear factor 1 C (NFIC) protein.
NFIC is part of the nuclear factor 1 family of transcription factors. Other members
include NFIA, NFIB and NFIX. T hese transcription factors bind to the sequence 5'TTGGCNNNNNGCCAA-3 [151]. A positive control has been generated from this
sequence and is named NFIC consensus binding site in Figure 21B. No supershift was
detected for the A074-SNP-17 and positive control oligos. There is a large band for the

146

147

Figure 21. Supershift EMSAs of PR, NFIC and ILF2 for A074-SNP-17. EMSAs were
run on a 5% polyacrylamide gel. T47D nuclear extract was used for all EMSAs. A)
supershift EMSA for the progesterone receptor (PR). There is a supershift for the positive
PRE control oligo but not for the A074-SNP-17 alleles. Arrow indicates supershift B)
Supershift EMSA for nuclear factor I C (NFIC). There is no supershift detected for any of
the oligos used. C) Supershift EMSA for interleukin enhancer binding factor (ILF2).
There is no supershift detected for any of the oligos used.
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NFIC positive control oligo. All four members of the nuclear factor 1 family bind to the
same consensus sequence and it is possible that a supershift overlaps this large band. The
antibody (Abcam, ab86570) used has not been tested for gel supershifts and may not be
appropriate to use for this experiment.
The A074-SNP-17 alleles pulled down the interleukin enhancer binding factor 2
(ILF2) protein. ILF2 is the 45kda subunit of the nuclear factor of activated T-cells
(NFAT) and forms a complex with interleukin enhancer binding factor 3 (ILF3).
Together these proteins work as transcription factors for a variety of genes [152]. A
positive control that contains a ILF2 consensus binding site was used for the supershift
EMSA [153]. There were no s upershifts detected for any of the oligos, including the
positive control oligo (Figure 21C). This may be due to the antibody used having not
been tested in supershift EMSAs and may be inappropriate for this method (Abcam,
ab28772). It is possible that ILF2 does not bind to the A074-SNP-17 alleles, however, this
supershift EMSA is inconclusive. Note, there appears to be an extra band in the WF allele
when ILF2 antibody is added. However, the ILF2 antibody gives off a background
chemiluminescence (lane 1 of the supershift EMSA) that runs at the same size as the
extra band for the WF allele. This means the extra band is likely to be background
chemiluminescence from the ILF2 antibody. We did not have access to expression
vectors for the three genes tested and therefore could not perform any co-expression
studies with protein expression vectors and the A074-SNP-17 luciferase assay vectors.

D.

Luciferase assays for Mier3 promoter
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We previously performed luciferase assays for the three candidate Mcs1b SNPs in
a pGL3- Promoter vector, which contains a strong SV40 promoter. We wanted to test
how the Mcs1b candidate SNPs influence an endogenous promoter. We chose to use the
promoter of the Mesoderm induction early response protein 3 (Mier3), since it is the
candidate gene for the Mcs1b locus. Mier3 is expressed higher in the mammary glands of
12-week old WF compared to COP females both with and without DMBA [87]. There
are multiple annotated Mier3 mRNAs in public databases, so we wanted to determine the
transcription start site (TSS) for the Mier3 gene in WF mammary glands. There is no
sequence difference in the Mier3 promoter between the WF and COP rat strains,
therefore we focused on the WF rat strain only. We used 5’RACE to determine the TSS
for the Mier3 gene. The only known annotated Mier3 gene products differ in their exon 1.
Therefore, we considered exon 2 and beyond common to all Mier3 isoforms and designed
primers against common regions. We used pooled RNA from the mammary glands of six
WF females. Results are shown in Figure 22A. There was one predominant PCR product
(marked by arrow) after 5’RACE PCR. Several other faint bands can be seen on the gel,
indicating there may be multiple different splice forms of the Mier3 gene. However, after
cloning the PCR reaction, only one splice form could be found, which corresponds in size
to the predominant PCR product shown in Figure 22A. The alignment of the results from
the 5’RACE and the annotated Mier3 isoforms are shown in Figure 22B. The predicted
exons 1 of the isoforms are highlighted in gray. The results from the 5’ RACE overlap
the first annotated Mier3 transcript, except the 5’ untranslated region (UTR) is much
shorter. The coding regions highlighted in the figure are predicted, it is possible that the
coding regions starts downstream of the region highlighted here. There are several more

150

151

Figure 22. 5’RACE results for the Mier3 gene. A) Results from outer and inner PCR
specific to the Mier3 gene. PCR reaction results in one predominant PCR product marked
with an arrow. Several other PCR products formed, however, none of them were found in
the sequencing results. B) Results for the 5’RACE of Mier3. The two annotated rat
versions of the Mier3 gene are shown. These versions were found in the Nucleotide
NCBI database. The gray highlighted areas indicate predicted coding regions of the
Mier3 gene.
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“ATG” start codons that are in- frame with the one highlighted in the figure. It is likely
that this initial “ATG” is not where translation starts, but that a downstream, in-frame
“ATG” is used. The second annotated Mier3 transcript contains a much larger exon 1 and
5’ UTR. Only regions that overlap with the first annotated Mier3 transcript are shown in
Figure 22B. We used the results from the 5’RACE to determine which region to clone as
the Mier3 promoter. We picked a region up t o 1.5kb upstream of the TSS determined
from the 5’RACE results and 0.5kb downstream of the TSS. W e excised the SV40
promoter out of the pGL3 Promoter vector and replaced it with the 2kb r egion of the
Mier3 promoter. Interestingly, there are two separate regions containing a string of
thymidines in this region. We were not able to find a clone that contained the correct
sequence for both regions. We picked two independent clones. Each clone contained the
correct sequence for one of the regions and performed the luciferase activity with both
clones to determine if there is a difference. The results are shown in Figure 23A. There is
no significant difference in the luciferase activity of the two independent Mier3 promoter
clones. This suggests that either one of the clones can be used for the analysis. However,
there is a stark difference in the luciferase activity of the cloned Mier3 promoter and the
original SV40 promoter. The luciferase activity of the cloned Mier3 promoter is much
lower than the SV40 promoter activity. More importantly, there is no significant
difference in luciferase activities between the cloned Mier3 promoter and the pGL3Basic vector. This suggests that the region of the Mier3 gene that we cloned has no
promoter activity. The cloned region is located on chr2: 43,002,349-43,004,390. We only
cloned about 1.5kb ups tream of the Mier3 TSS. This is because there is a BglII site
located at the 5’ end of this region, making it difficult to clone more of this region using
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Figure 23. Luciferase assay results for the Mier3 promoter. A) Luciferase assay
results for the Mier3 promoter. Results are pooled from three independent experiments.
There is a significant difference between the SV40 and Mier3 promoter. There is no
significant difference between the pGL3- Basic vector and the Mier3 promoter. B)
Transcription factors that bind to the cloned Mier3 promoter using the program TF
SEARCH. Transcription factors shown in green are known activators. Transcription
factors shown in red are known repressors. Transcription factors shown in gold can act as
both activators and repressors. The type of gene regulation is unknown for transcription
factors in black. Marked on the figure are also the two thymidine stretches that could not
both be sequenced correctly in a clone and the transcription start site (TSS).
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this enzyme. Shown in Figure 23B are transcription factors predicted to bind to the
cloned region using the program TF SEARCH. There are several well known activators
predicted to bind this region, including AP-1 and E2F. However, there are also several
known repressors predicted to bind this region that could overpower the effects of any
activators binding to this region. However, it is more likely that this region is not
sufficient in activating transcription and that important transcriptional elements are found
either upstream or downstream of the cloned region. Because the cloned Mier3 promoter
region did not have an effect on luciferase activity, we did not continue with cloning this
region into the luciferase reporter vectors that contain the Mcs1b candidate SNP alleles.
The Mcs1b candidate SNPs lower the luciferase activity of the SV40 promoter and we
would therefore not be likely to detect any effects of the Mcs1b candidate SNPs on the
cloned Mier3 promoter region, since the luciferase activity of this region is already so
low.

E.

Luciferase assays for all three SNPs in the same pGL3-promoter vector
We initially cloned the three Mcs1b candidate SNPs into the pGL3- Promoter

vector individually (Figures 12). We wanted to know what happens if we clone all three
Mcs1b candidate SNPs into the same pGL3- Promoter vector. The idea is that we wanted
to test if the luciferase activity of any one of the SNPs will dominate the luciferase
activity when all three SNP alleles are present. We cloned A074-SNP-17 and A074-SNP18 into the first multiple cloning site of the pGL3- Promoter vector, upstream of the
SV40 promoter. We cloned A046-SNP-A into the second multiple cloning site
downstream of the luciferase gene. We selected this configuration because it mimics the
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physical location of these SNPs along rat chromosome 2. The configuration of
this vector can be seen in Figure 24. The results for the luciferase assays can be seen in
Figure 25. A s a reference the luciferase assay results from each Mcs1b candidate SNP
individually have been added to the figure. These are the same results as shown in Figure
12. The results in Figure 25A show that in T47D cells there is no di fference in the
luciferase activity between the WF and COP alleles when all three SNP alleles are cloned
into the same vector. The COP allele activity for all three SNPs combined mimics the
COP allele activity for A074-SNP-17 individually. The WF allele activity for all three
SNPs combined is much lower than for any of the three SNPs individually. However, in
all three SNPs individually the WF allele lowers the luciferase activity compared to the
pGL3-Promoter vector by itself. It is possible that all three SNPs have an additive effect
and the low luciferase activity we see for the WF allele when all three SNP alleles are
present is due to a limit a s to how low the SV40 activity can be reduced. This would
indicate that the SV40 promoter activity could not be reduced further than it already is by
the presence of all three SNPs in the same vector. The results are similar when repeating
the experiment in MDA-MB-231 cells (Figure 25B).
Interestingly, there is no difference in the COP and WF luciferase activity when
all three SNPs are present in the same vector, while there is a difference when all three
SNPs are tested individually. This system is very artificial and all information on t he
natural chromatin state within the cell is lost when using a plasmid- based system. It is
possible that there is chromatin looping in this region, which could put one or more of the
Mcs1b candidate SNPs in an insulator loop. It is also possible that one or more of these
SNPs is located within a region that is methylated in the cell. Therefore, experiments will
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Figure 24. p GL3- Promoter vector configuration for cloning all three Mcs1b
candidate SNPs into same vector. A074-SNP-18 and A074-SNP-17 were cloned into the
first multiple cloning site upstream of SV40 promoter. A046-SNP-A was cloned into
second multiple cloning site downstream of luciferase gene.
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Figure 25. Luciferase assay results for all three Mcs1b candidate SNPs in the same
pGL3- Promoter vector. (

)

Dark grey bars indicate adjusted relative luciferase

activity for the COP (resistant) allele. ( ) Light grey bars indicate adjusted relative
luciferase activity for the WF (susceptible) allele. Asterisks indicate luciferase activity
that is significantly different between the major and the minor alleles. All adjusted
relative luciferase activities are the mean of nine values from three independent
experiments. Errors bars indicate standard error from pooled experiments. As controls,
the luciferase activity for the pGL3-Basic and pGL3-Promoter were determined. The
pGL3-Promoter activity was used to adjust the relative luciferase activities to pool values
from independent experiments. As a reference the luciferase activity of the COP and WF
alleles for each of the Mcs1b SNPs individually is shown. These results are equivalent to
Figures 12 a nd 13. A) Luciferase activity in T47D cells for all three Mcs1b candidate
SNPs in the same pGL3- Promoter vector. There is no significant difference in the
activity between the WF and COP alleles for all three Mcs1b candidate SNPs. B)
Luciferase activity in MDA-MB-231 cells for all three Mcs1b candidate SNPs in the
same pGL3- Promoter vector. There is no s ignificant difference in the activity between
the WF and COP alleles for all three Mcs1b candidate SNPs.
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have to be done that do not use a plasmid-based system to determine the nature of these
SNPs in a less- artificial system.

F.

Chromosome conformation capture (3C) of the Mcs1b locus
Chromatin looping is a potential mechanism by which intronic or intergenic SNPs

can affect the regulations of genes. A study looking at the expression levels of MCS1B
genes in different tissues of the cardiovascular system revealed that there is a high
correlation in the expression levels of MIER3, MAP3K1 and GPBP1. The study also
revealed that the expression level of SETD9 is inversely correlated with the other MCS1B
genes in the tissues tested. This suggests that MIER3, MAP3K1 and GPBP1 are regulated
by a similar mechanism and that there is the potential for a chromatin loop containing
SETD9, which shields it from a common regulatory mechanism. Because of the position
of SETD9 it is possible that this chromatin loop is formed in-between MAP3K1 and
MIER3. The results of this study can be seen in Figure 26 [154]. The CCCTC- binding
factor (CTCF) is a protein that is essential for the formation of long-range chromatin
loops [155]. We therefore scanned the ENCODE project for CTCF sites within the
MCS1B region, to provide evidence for a chromatin loop within the vicinity of the
MIER3 and MAP3K1 genes. The results are shown in Figure 27. There are three CTCF
binding sites within the region of interest that were identified using the ENCODE project
data. It is possible that the MAP3K1 gene loops towards the MIER3 gene placing the
MIER3 and SETD9 gene into a chromatin loop. We used the human ENCODE data as a
guide to design a chromosome confirmation capture (3C) experiment to determine any
chromatin looping within the rat Mcs1b region. The hypothesis is that there is a
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Figure 26. Correlation of MCS1B transcript levels in different cardiovascular
tissues. Adapted from Folkersen et al. (2010) [154]. Expression levels of MCS1B genes
in different tissues of the cardiovascular system. The expression levels of MAP3K1,
MIER3 and GPBP1 are correlated in different tissue types. However, in some tissues
there appears to be an inverse correlation between the expression levels of SETD9 and
other MCS1B genes. It is possible that SETD9 is located in a chromatin loop in some of
these tissues and its expression is regulated through other mechanisms.
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Figure 27. Location of human ENCODE identified CTCF sites. ENCODE predicted
CTCF sites were identified using the UCSC Genome Browser. Location along human
chromosome 5 is shown. Also, marked in blue are locations of MCS1B transcripts.
ENCODE predicted CTCF sites were identified in a wide- array of human cell lines. The
CTCF site inbetween MAP3K1 and MIER3 was identified in T47D cells.
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chromatin loop forming between the Map3k1 gene and the Mier3 gene within the rat
mammary gland epithelial cells, which would bring the Mcs1b candidate SNPs in close
proximity to the Mier3 promoter. A diagram of the 3C hypothesis can be seen in Figure
28A. We designed the 3C experiment in such as way that a chromatin loop between the
Mier3 and Map3k1 gene can be tested. For this we selected a fixed primer downstream of
one of the CTCF sites (Figure 28B). Ten moving primers were designed that move way
from the fixed primer and span the distance between the Mier3 and Map3k1 gene. The
setup for the 3C experiment can be seen in Figure 28B.
We performed the 3C experiment using rat mammary epithelial cell enriched
preps (MEC prep). It is known that the Mcs1b locus acts within the mammary gland [87].
We believe that the mammary epithelial cells are the causative Mcs1b cell type. We
initially extracted the MEC preps from 18 different animals and divided them into six
groups of three rats each. However, after performing a PCR titration with primers in close
proximity to each other, we discovered that only three groups resulted in PCR product.
We used two DMBA treated groups, one contained COP females, the other WF females.
We also used one COP female group that did not receive DMBA. However, this group
consisted of only two animals. We started our analysis by performing the PCR reaction
using pooled DNA for each group. The results are shown in Figure 29A. There was no
difference in the pattern of the relative interaction frequencies between the different
groups. We therefore pooled the data from all three groups as shown in Figure 29B.
There are two increases in the relative interaction frequency above background.
The first one is seen with moving primer E. In a typical 3C experiment, there is an
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Figure 28. Hypothesis and experimental design for the 3C experiment. A) Hypothesis
for the 3C experiment. We used the human ENCODE data as a guide for the location of a
potential chromatin loop in the rat Mcs1b region. The loop would place rat SNPs in close
proximity to the Mier3 promoter. B) Experimental design for 3C in using rat mammary
epithelial cell enriched preps. Shown are the location of the Mcs1b candidate SNPs, and
shown in blue are the transcript locations for Mier3 and Map3k1. Black marks indicate
the location of BglII sites within this region and the location of the 3C primers used.
Marked in red is the fixed primer used. Note, the ID of the 3C primer is marked right
underneath its location. As a reference, the rat orthologous regions to the ENCODE
identified CTCF sites are shown.
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Figure 29. 3C results for the Mcs1b locus. A) 3C results for each group separately.
Results are pooled from three independent PCR reactions. COP no DMBA contains 2
females, while the other groups are made up of three females each. Relative interaction
frequency is the band intensity of the sample divided by the band intensity of the BAC
control for each primer pair. Error bars indicate standard error. B) Since there is no
difference in the pattern of relative interaction frequencies among the groups, the results
were pooled. Each value is the mean of nine separate data points. Error bars indicate
standard error. Separation between each value indicates relative distances. The location
of the fixed primer is indicated with an arrow and the location of moving primers is
marked under x-axis.
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increase in the interaction frequency when primers in close proximity to the fixed primer
are used. Usually, primer pairs within 10kb of each other have a higher relative
interaction frequency than primers further apart, because the smaller the distance is, the
more likely it is that these fragments come together without the need of looping
structures. Moving primer E is 13kb away from the fixed primer. It is possible that this
interaction indicates a chromatin loop but it is also possible that this is a remnant of the
higher interaction frequency due to close proximity of the primers. An additional
experiment typically done after 3C is to perform chromatin immunoprecipitation (ChIP)
for CTCF. This experiment would indicate if there is indeed a chromatin loop forming
between the fixed primer and primer E. However, the second increase in relative
interaction frequency at moving primer J indicates a chromatin looping structure. This
chromatin loop is shown in Figure 28A. This chromatin loop would bring the Mcs1b
candidate SNPs in close proximity to the Mier3 promoter and may indicate a possible
mechanism as to how these SNPs act on the Mcs1b candidate genes. Interestingly,
moving primer I is closest to the rat orthologous region to a CTCF binding site in the
human, however, no l ooping is detected using moving primer I (Figure 28B). It is
possible that an alternative CTCF site exists in the rat that is in close proximity to moving
primer J. While the 3C makes a compelling case for a chromatin loop forming between
the fixed primer and primer J, a follow-up ChIP experiment for CTCF is needed to verify
that CTCF binds in this region and facilitates the formation of a chromatin loop.
It is interesting that this chromatin looping would place Mier3 into the chromatin
loop. Chromatin loops can both increase or decrease the expression levels of transcripts
within them, but shield transcripts from the effects of elements outside of the loop. It is
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unknown how the Mcs1b candidate SNPs would interact with a gene located within a
chromatin loop. Overall, the 3C results indicate a chromatin loop between the Map3k1
and Mier3 gene, which would bring the Mcs1b candidate SNPs in proximity to the Mier3
promoter.

G.

Bisulfite sequencing of Mcs1b candidate SNPs
A074-SNP-17 is located within a predicted CpG island. CpG islands are regions

of high cytosine and guanine content. Cytosines in CpG pairs can be methylated. CpG
islands are often found in gene promoter and promoter methylation is often associated
with gene silencing [156]. We therefore wanted to test the methylation status of the
Mcs1b candidate SNPs. As previously done with the 3C experiment, we focused on MEC
preps, since we believe that the causative cell type is the mammary epithelial cell. We
tested three different rat groups. One group contained females treated with DMBA.
Results are shown in Figure 30. Overall, there is a h igh degree of methylation in these
regions. There are differences in the methylation status among different groups for some
of the CpG moieties tested. For A074-SNP-17 some CpG moieties are differentially
methylated (1,6 and 8), with the COP females that were not treated with DMBA having a
lower methylation status. One of the CpG moieties for A074-SNP-18 contains the SNP
nucleotide, therefore the WF allele cannot be methylated. However, the COP allele is
highly methylated. For A046-SNP-A there appears to be a lower degree of methylation in
WF females compared to both of the COP groups. Overall, there is a high degree of
methylation in this regions, however, some individual CPG moieties are differentially
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Figure 3 0. Results for bisulfite sequencing of Mcs1b candidate SNPs. Black circles
indicate individual CpG moieties within region tested. For each CpG moiety we
sequenced 10 individual clones. Values indicate the percentages of clones that were
methylated. Both the forward and reverse strands were sequenced. Arrows indicate the
locations of individual SNPs. Red rectangles indicate CpG moieties where there is a
difference in the methylation status among the groups tested. A) Methylation status of
A074-SNP-17. Overall, there is a high degree of methylation in this region. A lower
methylation status is observed in the COP groups for some of the CpG moieties. B)
Methylation status of A074-SNP-18. The WF allele of A074-SNP-18 cannot be
methylated, however, the COP allele is highly methylated. C) Methylation status for
A064-SNP-A. Overall, there is a high degree of methylation. There is a reduction in the
methylation status in the WF allele compared to the COP allele.
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methylated among the groups. Some of these CpG moieties are located in the vicinity of
SNP sites.

H.

CRISPR knockout of A074-SNP-17 in rat mammary gland cell lines
A074-SNP-17 is our most promising Mcs1b candidate SNP because of its

apparent role in gene regulation through differential binding of DNA binding proteins.
We wanted to know if gene editing of A074-SNP-17 can be achieved in rat mammary
gland cancer cells, with the ultimate goal being genetic manipulation of A074-SNP-17 in
WF and COP rats. We used the clustered regularly interspaced short palindromic repeats
(CRISPR) system to try to knockout A074-SNP-17 in rat mammary tumor cell lines. This
system uses single guide RNAs that guide the CAS9 nuclease to regions of interest
resulting in the formation of double- stranded breaks [157]. We transfected two different
cell lines with the A074-SNP-17 targeted CRISPR system. These were RBA and LA7 rat
mammary tumor cell lines. Both cell lines were derived from the Sprague- Dawley rat
strain and share the same genotype with WF rats at all three Mcs1b candidate SNPs. The
cell lines were derived from DMBA induced mammary tumors.
In order to determine the effectiveness of the A074-SNP-17 CRISPR system, we
used the SURVEYOR mismatch- specific DNA nuclease, which can identity mismatched
DNA regions due to INDELs and will cleave regions containing mismatches. The results
are shown in Figure 31 A and B. If there is a successful induction of an INDEL in the
A074-SNP-17 region, the A074-SNP-17 PCR product should be digested into two
fragments of about 107 and 226bp. There was no formation of the two digested fragments
visible for the two cell lines. A positive control, which contains plasmid DNA that have a
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Figure 31. Results for CRISPR knockout of A074-SNP-17 in rat mammary cancer
cell lines. A) and B) SURVEYOR nuclease results in RBA and LA7cells respectively.
Fragmentation resulted in the positive control only (marked with arrows). Agarose gel
was 2% high resolution stained with ethidium bromide. C) RBA cells transfected with
GFP show high transfection efficiency. D) and E) RBA cells mock transfected or
transfected with A074-SNP-17 CRISPR system. Few cells survive transfection with
A074-SNP-17 CRISPR system.
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single nucleotide mismatch should result in the formation of two fragments, which are
217and 416bp in size. Figure 31 A and B shows that the positive control resulted in the
formation of the appropriate fragments, indicating that the SURVEYOR enzyme was
functioning properly. It is possible that we didn’t detect any A074-SNP-17 PCR
fragments, because of low efficacy of the CRISPR system and not enough mismatches
are formed to be detected with this system. Low efficacy can be due to the system not
being specific enough or low transfection efficiency of the cells. Transfection efficiency
was not a problem. We were able to transfect both cell lines using a GFP vector as can be
seen in Figure 31C. Transfection of RBA cells with GFP resulted in high GFP
expression. However, we did notice that within the 72 hours post transfection, a lot of the
cells transfected with the A074-SNP-17 CRISPR vectors died when compared to cells
that were mock transfected with Lipofectamine 2000 (Figure 31 D and E). Therefore, it is
plausible that the extracted DNA used in SURVEYOR assays came from untransfected
cells and these cells did not undergo genome editing. It is also possible that cells that
were transfected with the A074-SNP-17 system died because of too much DNA damage
that was induced with the CRISPR system and could not be repaired on time. There is no
evidence that either one of these cells are deficient in DNA repair pathways, however, it
is possible that the CRISPR system resulted in a lot of off- target DNA damage that could
not be repaired before DNA extraction.

Discussion
Sequencing of the Mcs1b region between the WF and COP rat strain resulted in
the identification of three Mcs1b candidate SNPs. Since none of the SNPs are found
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within coding regions of genes, we hypothesized that the three SNPs are located within
gene regulatory regions and affect the expression levels of neighboring genes. This idea
is supported by the fact that Mcs1b candidate genes are expressed at different levels
within the mammary glands of the WF and COP rat strains [87]. We tested the ability of
the SNPs to regulate a luciferase gene in a reporter assay. All three candidate SNPs
showed a l uciferase activity that was different between the COP and WF alleles.
However, A074-SNP-17 is the only candidate SNP that had a pattern of gene regulation
that mimics the gene expression data of Mcs1b candidate genes for the two rat strains.
The Mcs1b locus has a human ortholog. Performing the same luciferase assay for all
seven rs889312 correlated SNPs indicated that rs1862626 has a p attern of gene
regulation that is the same as for A074-SNP-17. This indicates that rs1862626 may be the
functional ortholog to A074-SNP-17. The luciferase activity for A074-SNP-17 is similar
in T47D and MDA-MB-231 breast cancer cells. These two cell lines differ drastically in
their cellular environments. This may indicate that A074-SNP-17 has a u niversal
function. However, several other SNPs showed vastly different luciferase activities in the
two cellular environments, which indicates that these SNPs may bind transcription factors
that may be expressed differentially between the two cell lines.
A search for transcription factors binding to candidate SNPs revealed that the WF
allele of A074-SNP-17 binds a DNA binding protein complex that does not bind to the
COP allele. This DNA binding protein may be involved in the regulatory function of this
SNP region. Our EMSAs do not support rs1862626 being ortholog to A074-SNP-17,
because both major and minor alleles of rs1862626 result in the same DNA binding
protein shift pattern. However, rs1862626 could still be the functional ortholog, since the
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two alleles appeared to show a differential affinity for binding a DNA binding protein. A
hunt for DNA binding protein for A074-SNP-17 did not result in a positive identification
of a transcription factor binding to this SNP. NRF2 does bind to this SNP; however, the
binding appears to be non-specific. We focused on a small amount of transcription factors
from our mass spectrometry data; studying more of the transcription factors may be
fruitful.
A luciferase assay of all three Mcs1b candidate SNP in the same luciferase
reporter revealed that there is an additive effect of the suppressive activity of all three
SNPs. This made us wonder how all three SNPs affect the expression of the same set of
genes. We performed chromosome conformation capture and showed that there is a loop
forming between the Map3k1 and Mier3 gene, which would bring the three candidate
SNPs in close proximity to the Mier3 promoter. However, a follow-up experiment using
ChIP of CTCF is needed to confirm the 3C results. A luciferase assay of 2kb of the
region just upstream and downstream of the Mier3 transcription start site revealed that
there is no intrinsic promoter activity in this region. It is possible that DNA looping is
required for the three candidate SNPs to get in close proximity to the Mier3 promoter and
this is needed for promoter activation for the Mier3 gene.
A074-SNP-17 is located with a p redicted CpG island. We therefore checked the
methylation status of CpG moieties for the Mcs1b candidate SNPs. We tested the
methylation status using DNA extracted from MECs. We found that overall, there was a
high degree of methylation in these regions. There appears to be a difference in the
methylation status for some of the CpG moieties in the regions between the WF and COP
rats. For A074-SNP-17 there appears to be less methylation in the COP, while for A046-
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SNP-A there appears to be less methylation in the WF rat. A high degree of methylation
indicates silencing of specific regions. This could indicate that both SNPs are located
within important regions that may be involved in gene regulation and are tightly
regulated. One of the CpG moieties located in the A074-SNP-18 region contains the SNP
nucleotide. Therefore, the WF allele cannot be methylated, while the COP allele can.
There is a high degree of methylation of this CpG moiety in the COP rat. This might
indicate that this SNP does not have an effect in the COP rat because it is highly
methylated and therefore silenced.
Overall, we believe that A074-SNP-17 is a great candidate for the Mcs1b
phenotype. In order to provide further evidence that A074-SNP-17 is the causative SNP
for the Mcs1b region, we want to perform genome editing in the rat to knockout or
exchange alleles for A074-SNP-17. We tested the ability of an A074-SNP-17 CRISPR
construct to knockout the SNP region in rat mammary tumor cell lines. However, we
were not able to knockout this region efficiently, likely because of the death of
transfected cells. A different screening method or another method for genome editing
such as TALENs or zinc fingers may prove to be more fruitful than the CRISPR system.
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CHAPTER V
SIGNIFICANT OVERLAP BETWEEN HUMAN GENOME-WIDE
ASSOCIATION NOMINATED BREAST CANCER RISK ALLELES AND RAT
MAMMARY CANCER SUSCEPTIBILITY LOCI
Adapted from Sanders et al. (2014) [158]. See Appendix.
Introduction
Breast cancer is a co mplex disease characterized by environmental, genetic, and
epigenetic factors. Due to the complexity of developing this disease a woman’s
individual risk may vary greatly from population risk estimates. The familial relative risk
of developing breast cancer increases with the number of affected relatives, suggesting
that there is a strong genetic component associated with this disease [54, 159]. Highpenetrance breast cancer risk mutations such as those of BRCA1 and BRCA2 have been
identified [63, 64, 160]. Population frequencies of mutations with high-penetrance toward
risk are rare due to their severe effects on individuals; and thus, these mutations account
for only a small percentage of population risk. Risk alleles with moderate penetrance and
minor allele population frequencies of 0.005-0.01 (e.g. PALB2) are estimated to account
for approximately 3% of risk. Therefore, a majority of population-based breast cancer
risk is likely explained by low penetrance alleles with rare to common population
frequencies [60]. Genome-wide association (GWA) studies have been used to identify
several low penetrance breast cancer risk alleles [57]. Due to a need to control for
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numerous multiple comparisons made in GWA studies, a Bonferroni correction based pvalue cut-off of ≤ 1x10-7 is typically required for an association to be considered genomewide significant. It has been suggested that this approach is too stringent as it may result
in many false negative associations [161]. Furthermore, while GWA studies are unbiased
approaches to identify genomic regions associated with breast cancer risk, these
epidemiology- based approaches cannot easily determine risk genes or genetically
determined mechanisms of susceptibility. C urrently, only a small percentage of breast
cancer heritability is explained by published studies suggesting that considerable genetic
variation associated with breast cancer risk remains to be identified [60, 162].
Comparative genetics between rats and humans has also been used to identify
breast cancer risk alleles [111]. In general, the laboratory rat is a good experimental
organism to model breast cancer. Compared to induced mammary tumors in mice, rats
develop mammary carcinomas of ductal origin, which is similar to a majority of human
breast cancers. Also, rat mammary tumors are responsive to estrogen, just as a majority
of human breast tumors [97, 163]. Most importantly, the laboratory rat is a versatile
organism to study breast cancer susceptibility, as experiments can be controlled at genetic
and environmental levels.

Inbred rat strains exhibit differential susceptibility to

chemically induced carcinogenesis using 7,12-dimethylbenz[a]anthracene (DMBA) [92,
97, 98, 100]. Copenhagen (COP) and Wistar- Kyoto (WKY) rat strains are resistant to
DMBA, N-Nitroso-N-methylurea (NMU), and oncogene induced mammary carcinomas,
while the Wistar- Furth (WF) rat strain is susceptible.
Previous genetic studies using rats have identified eight Mammary carcinoma
susceptibility (Mcs) loci, named Mcs 1-8 [106-108, 123]. A ( WFxCOP)F1 x WF
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backcross design was used to identify Mcs 1-4. Copenhagen alleles at Mcs 1-3 are
associated with decreased mammary tumor multiplicity, while the Mcs 4 COP allele is
associated with increased tumor development [106]. Further analysis of the Mcs1 locus
using WF.COP congenic lines, spanning different regions of the quantitative trait locus
(QTL), identified three independent loci associated with mammary carcinoma
susceptibility, named Mcs 1a-c [123]. Another linkage analysis study using WF and
WKY rat strains revealed four additional QTLs associated with mammary carcinoma
susceptibility, named Mcs 5-8. Additionally, a modifier of Mcs8, Mcsm1, partially
counteracts the resistance phenotype conferred by Mcs8 [107, 108]. Further analysis of
the Mcs5 locus using WF.WKY congenic rat lines resulted in the identification of four
subloci named Mcs5a1, Mcs5a2, Mcs5b and Mcs5c [110, 111]. Additional linkage
analysis using the SPRD-Cu3 rat strain (DMBA-induced mammary carcinogenesis
susceptible) and the resistant WKY rat strain resulted in the identification of three more
rat QTLs associated with mammary cancer named Mcstm1, Mcstm2/Mcsta2 and Mcsta1
[115, 116]. Several rat genomic regions that associate with mammary cancer
susceptibility were identified using beta-estradiol instead of DMBA to induce
carcinogenesis. These QTLs were identified using the August Copenhagen Irish (ACI) rat
strain, which is susceptible to beta-estradiol carcinogenesis and the COP and Brown
Norway (BN) rat strains, which are resistant. These loci are named Estrogen- induced
mammary cancer loci or Emca 1-2 and Emca 4-8 [117, 118].
Comparative genomics between human breast and rat mammary cancer risk
alleles will continue to be warranted, especially if appreciable overlap in genetic
susceptibility exists between these species. In this study, genomic locations of human
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breast cancer risk GWA study-identified polymorphisms were compared to the rat
genome to determine if positive associations were more often located at orthologs to rat
mammary cancer risk loci than at randomly selected regions not known to be associated
with rat mammary cancer susceptibility. The hypothesis is that positive associations map
to orthologs of rat mammary cancer risk loci more often than to randomly selected rat
genomic region.

Methods
A.

Converting rat mammary cancer associated loci to human orthologous regions
Previously published information on r at mammary cancer associated loci was

used. H uman orthologous regions of rat regions that associate with mammary cancer
susceptibility listed in Table 21 were determined using the “In other genomes (convert)”
function available at the UCSC genome browser [119]. Rat Nov. 2004 (Baylor 3.4/rn4)
and human Feb. 2009 (GRCh37/hg19) genome assemblies were used. If a rat mammary
cancer locus split into multiple human orthologous regions, we noted all orthologous
regions until they reached less than 1% of the bases and spanned less than 1% of the
original rat mammary cancer locus using the UCSC genome browser.

B.

Identification of random rat regions
To determine if human GWA study identified polymorphisms map to rat

mammary cancer loci more frequently than to random regions of the rat genome, we
selected rat genome segments that have not shown an association with mammary cancer
risk. These rat genomic regions were named “random rat regions” and are listed in Table
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RNO2

D2M13Mit286 to D2Uia5

RNO8

D8Rat164 to D8Rat108

SNP-61634906 to SNP61666918
SNP-61667232 to gUwm23-29

Mcs4

Mcs5a1 (overlaps
Mcstm1, Emca8)

Mcs5a2 (overlaps
Mcstm1, Emca8)

RNO5

RNO5

RNO1

D1Rat27 to D1Mit12

RNO7

RNO2

D7rat39 to D7Uwm12

Region
(UCSC rat
assembly
2004)

Reference

61,667,05361,751,614

61,634,72761,666,739

28,414,10072,403,639

90,282,174156,954,117

4,936,70486,028,057

13,909,38320,666,092

42,364,15544,195,382

Samuelson et al. [111]

Samuelson et al. [111]

Shepel et al. [106]

Shepel et al. [106]

Sanders et al. [108]

Haag et al. [123]

DenDekker et al. [87]

DMBA induced mammary carcinogenesis
RNO2
5,601,528Haag et al. [123]
10,539,344

Rat chr

ENSRNOSNP2740854 to
g2Ul2-27

D2Mit29 to D2Uwm14

Boundary Markers

Mcs3

Mcs2 (overlaps
Mcs6, Emca4)

Mcs1c

Mcs1b

Mcs1a

Rat Mcs locus
(overlap)

Table 21. Location of rat mammary cancer susceptibility loci and human orthologous regions used.

Chr9: 37,590,988-37,654,512

Chr9: 37,562,516-37,589,491

Chr11: 107,453,990-132,383,506
Chr15: 62,105,069-76,028,735
Chr15: 76,091,658-78,185,872
Chr15: 78,380,119-78,998,961
Chr15:51,349,646-51,942,505

Ch12: 57,316,160-108,177,690
Chr8: 97,242,984-115,650,989
Chr19: 281,161-2,497,331
Chr19: 15,059,910-15,808,112
Chr15: 80,282,370-102,265,870
Chr15: 25,574,935-28,567,541
Chr11: 17,403,456-22,898,646
Chr11: 74,958,193-89,350,902
Chr19: 48,799,986-51,921,957
Chr19: 28,701,413-30,656,003

Chr5: 81,891,633-86,857,442
Chr5: 86,171,198-86,251,067

Chr5: 54,816,178-57,003,049

Chr5: 89,216,702-93,113,337

Human Orthologous Region
(UCSC human assembly 2009)
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89,575,060-100,335,500

12,386,493-26,416,791

34,039,303-114,032,192

RNO10

RNO14

RNO6

RNO5

D10Got124 to
gUwm58-136
D14Mit1 to D14Rat99

D6Mit9 to D6Rat12

Mcs7 (overlaps
Mcsta1)

Mcs8

D5rat124 to Pla2g2a
Mcstm1 (overlaps
Mcs5,Emca1, Emca8)

Mcstm2 (overlaps
Emca2)

D18Wox8 to D18Rat44 RNO18

22,382,725-55,384,873

Mcs6 (overlaps Mcs2) D7Rat171 to gUwm64-3 RNO7

Mcsm1 (overlaps
Emca7)

81,118,457-81,295,367

gUwm74-1 to gUwm54- RNO5
8

Mcs5c (overlaps
Mcstm1, Emca8)

32,458,819-86,863,412

19,206,257-157,657,360

65,498,190-67,464,050

gUwm50-20 to D5Got9 RNO5

Region (UCSC rat
assembly 2004)

Mcs5b (overlaps
Mcstm1, Emca8)

Rat chr

Boundary Markers

Rat Mcs locus
(overlap)

Table 21 continued.

Chr12: 71,270,266-105,502,699

Chr9: 118,231,525-118,416,951
Chr12: 72,033,141-72,033,263

Chr9: 103,492,712-105,220,552

Human Orthologous Region
(UCSC human assembly 2009)

[116]

Piessevaux et al.

[116]

Piessevaux et al.

Lan et al. [107]

Lan et al. [107]

Chr18: 10,202,644-13,129,349
Chr18: 41,356,963-54,158,113

Chr1: 20,301,931-59,012,763
Chr1: 59,119,520-67,602,141
Chr9: 27,325,071-123,488,955
Chr6: 87,792,854-100,245,025
Chr8: 87,055,841-97,247,307
Chr8: 58,994,818-62,700,945

Chr14: 25,151,530-80,417,386
Chr2: 334,41-18,603,019
Chr7: 12,561,599-19,619,365
Chr7: 107,770,320-111,916,436

Chr4: 65,556,457-81,559,483

Cotroneo et al. [165] Chr17: 40,183,547-67,946,104

Sanders et al. [108]

Veillet et al. [164]

[110]

Samuelson et al.

Reference
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Emca5

RNO7
RNO3

D3Rat227 to D3Rat210

RNO18

D18Rat27 to D18Rat43

Emca2 (overlaps
Mcstm2)

D7Rat44 to D7Rat15

RNO5

Emca4 (overlaps
Mcs2)

Region (UCSC rat
assembly 2004)

Reference

Human Orthologous Region
(UCSC human assembly 2009)

[118]

41,054,012-171,063,335 Schaffer et al.

[118]

Gould et al.

[117]

66,201,980-107,428,439 Schaffer et al.

18,562,643-66,652,947

[117]

103,677,474-155,121,024 Gould et al.

9,762,188-108,776,963

Chr20: 1,746,912-62,907,504
Chr2: 110,841,402-113,650,057
Chr2: 159,530,076-188,395,371
Chr11: 26,296,319-57,753,858
Chr15: 32,905,485-34,664,466
Chr15: 34,933,152-51,298,144

Chr8: 97,242,984-137,409,536
Chr12: 57,316,160-59,093,375

Chr5: 110,259,180-130,363,372
Chr5: 137,224,929-147,624,793
Chr5: 147,647,196-150,176,352
Chr18: 10,202,644-13,129,349
Chr18: 35,982,130-41,016,602
Chr18: 52,597,120-54,158,113
Chr18: 54,267,924-58,201,561
Chr2: 127,805,417-128,786,719

Chr1: 23,607,020-59,012,763
Chr1: 59,119,520-67,602,141
Chr9: 17,037,252-27,300,264

Piessevaux et al. Chr5: 130,482,861-173,663,969
[116]
Chr5: 177,530,539-180,675,650
Chr17: 690,639-15,624,409
Chr17: 16,916,926-20,222,700
Chr17: 25,525,650-78,247,249
Chr16: 78,402-6,094,950
β-estradiol induced mammary carcinogenesis
RNO10

D5Rat53 to D5Rat57

(overlaps D10Rat91 to D10Rat97

Rat chr

Emca1 (overlaps
Mcstm1, Emca8)

Mcsta1
Mcs7)

Table 21 continued.
Rat Mcs locus
Boundary Markers
(overlap)
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RNO6

D6Rat68 to D6Rat81

RNO5

RNO4

Rat chr

D4Rat14 to D4Rat202

D5Rat134 to D5Rat37
Emca8
(overlaps Mcs5,
Mcstm1,
Emca1)

Emca7
(overlaps
Mcsm1)

Emca6

Rat Mcs locus Boundary Markers
(overlap)

Table 21 continued.

52,434,178-148,460,381

2,802,670-111,967,837

41,729,583-159,115,617

Region (UCSC rat
assembly 2004)

Schaffer et al. [118]

Schaffer et al. [118]

Schaffer et al. [118]

Reference

Chr9: 6,756,013-27,300,264
Chr9: 27,925,947-123,488,955
Chr1: 33,159,021-59,012,763
Chr1: 59,119,520-67,602,141

Chr14: 25,151,530-78,362,253
Chr2: 33,441-35,642,893
Chr2: 38,644,737-51,698,454
Chr7: 12,561,599-19,619,365
Chr7: 105,197,211-111,916,436

Chr7: 23,252,368-33,103,107
Chr7: 115,026,301-150,558,396
Chr3: 88,756-12,883,445
Chr3: 13,004,609-15,163,132
Chr3: 64,018,604-75,322,612
Chr3: 125,977,400-128,219,297
Chr2: 68,713,643-89,165,869
Chr4: 89,504,626-95,273,083
Chr4: 120,978,632-122,320,931
Chr12: 156,786-2,821,588
Chr10: 43,277,230-46,218,580

Human Orthologous Region
(UCSC human assembly 2009)

22. We initially focused on f ourteen Mcs/Mcsm regions with an average size of
22,322,710 bp as these are generally smaller in size than other rat mammary cancer
associated loci identified. Fourteen random rat genome regions, each 22,322,710 bps in
size were used for comparison. Random rat regions were selected by picking a
chromosome using a random number generator function of Microsoft Excel. The range of
chromosomes entered into the random number generator function was 1 through 21 (rats
have 21 chromosomes, including a sex chromosome). The start position for each random
rat region was determined using a random number generator function of Excel. The rat
genome is 2.75 Gb in size [166]; or, 130,952,381bp per chromosome if divided equally
across chromosomes. Therefore, values for the rat genome start-position were chosen
from 1-130,952,381 using a random number generator. Following, 22,322,709 bps were
added to each random start position to obtain the desired full length. The 14 random rat
genome regions were then entered into the UCSC genome browser, and the human
orthologous regions were determined using the “in other genomes (convert)” function, as
described above [119]. Randomly-generated rat genome segments were used as controls
if the human orthologous segment did not contain sequence that was also orthologous to a
known rat mammary cancer associated locus. We also verified, using the UCSC genome
browser, that human orthologous regions to random rat regions were not located at
human centromeric regions, as genetic variation in these chromosomal regions is
underrepresented in GWA studies [167, 168]. Total sizes and percentages of rat genome
covered by rat mammary cancer loci and random genome regions used are in Table 23.

C.

Determining human GWA study nominated polymorphisms
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Table 22. Random rat genomic segments and human orthologous regions used.
Rat Mcs locus

Rat chr

Random rat region 1

RNO9

Region (UCSC rat
assembly 2004)
20,000,000-44,322,711

Random rat region 2

RNO15

60,000,001-84322711

Random rat region 3

RNO16

68,621,246-92,943,956

Random rat region 4

RNO9

91,398,460-115,721,170

Random rat region 5
Random rat region 6
Random rat region 7

RNO13
RNO11
RNO17

55,373,307-79,696,017
39,408,000-63,730,710
68,384,015-92,706,72

Random rat region 8

RNO3

12,585,543-36,908,253

Random rat region 9

RNO19

34,130,390-58,453,100

Random rat region
10

RNO12

18,203,110-42,525,820

Random rat region
11

RNO20

30,416,373-54,739,083

Random rat region
12
Random rat region
13
Random rat region
14

RNO13

955,085-25,277,795

RNO1

1,136,860- 25,459,569

RNO2

182,078,762206,401,472
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Human orthologous region
(UCSC human assembly 2009)
Chr2: 97,158,323-106,711,249
Chr6: 56,223,874-73,919,999
Chr2: 189,182,486-189,878,065
Chr13: 103,235,577-103,556,495
Chr2: 128,848,569-129,254,860
Chr13: 53,226,266-74,878,291
Chr13: 42,064,282-42,529,444
Chr13: 103,539,456-115,092,822
Chr8: 36,627,241-42,308,840
Chr8: 638,582-6,693,649
Chr8: 42,690,588-43,056,179
Chr13: 52,753,969-53,050,606
Chr5: 98,385,946-110,062,886
Chr18: 612,848-9,957,727
Chr2: 240,340,012-242,806,427
Chr1: 169,844,936-194,938,667
Chr3: 95,108,010-118,895,417
Chr10: 138,740-22,530,353
Chr1: 236,673,870-240,084,642
Chr2: 140,246,548-155,465,845
Chr9: 123,526,091-129,443,210
Chr16: 66,968,878-90,107,058
Chr10: 33,502,588-35,153,585
Chr1: 229,402,942-235,324,796
Chr4: 150,548,912-150,855,848
Chr12: 110,503,298-120,870,994
Chr12: 121,578,435-132,335,900
Chr7: 66,878,689-71,941,664
Chr7: 101,137,811-102,184,451
Chr7: 99,995,220-100,350,712
Chr7: 72,707,443-74,223,683
Chr7: 75,027,443-76,145,496
Chr6: 101,086,446- 116,620,662
Chr6: 117,266,139-123,147,126
Chr2: 109,065,537-109,613,060
Chr6: 116,688,407-116,905,609
Chr18: 58,351,906-63,553,937
Chr2: 124,758,685-125,682,595
Chr6: 128,011,342-150,185,813
Chr6: 123,315,387-124,317,854
Chr1: 107,259,608-154,441,176

Table 23. Total size and percentage of rat genome covered by rat mammary cancer loci and
random rat regions
Region

Mcs/Mcsm
only
All known rat
mammary
cancer loci
Random rat
regions

Loci

Total size (bases)

Total
overlapping
bases

Total unique
bases

14

345,323,605

33,002,148

312,321,457

Rat Genome
Portion (based
on total unique
bases)
11.4%

24

1,230,487,116

325,386,323

905,100,793

32.9%

14

312,517,940

-

312,517,940

11.4%
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Human breast cancer risk GWA studies considered were published through March
2013. In the first round of analysis we picked GWA studies with a clearly defined study
population of subjects of European descent. In the second round of analysis, the defined
population was broader and included studies that tested populations of non-European
descent. Studies that included non-European descent populations were subdivided into
respective populations used. The GWA studies evaluated are listed in Tables 24 and 25.
Results from GWA studies used consisted of multiple stages (2-4 stages) to evaluate
breast cancer risk association. In our analysis, all SNPs that entered the final stage of
their respective study were compared to the rat genome. A tested SNP was called either
“associated” if it reached genome wide significance in its respective study or “potentially
associated” if it failed to meet the respective study statistical criterion following the final
stage of analysis. Conventionally, a p-value level for an association to be considered
statistically significant in a GWA study is 1 x 10-7. T his stringency is to protect from
false-positives due to multiple comparisons on a genome-wide scale. It has been argued
that this low p-value requirement results in numerous false negative associations [161].
Therefore, we queried supplemental material of each published GWA study considered
and picked polymorphisms that failed the validation stage in the respective study. We
also included polymorphisms that did reach genome-wide significance. We considered
533 SNPs from studies that included populations of European descent, and 285 S NPs
from studies of non-European descent populations. Human genomic locations of
polymorphisms were found using dbSNP (GRCh37 assembly) [169]. These were
compared to locations of the human orthologous regions of rat mammary cancer loci and
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3
3
2
2

European
descent

European
descent

European
descent

European
descent

European
descent

European
descent /
African
descent

European
descent

European
descent

Easton et al.

Fletcher et al.
[171]

Garcia-Closas
et al. [172]

Gaudet et al.

Ghoussaini et
al. [173]

Haiman et al.
[174]

Hunter et al.
[175]

Li et al. [176]

[76]

[61]

2

2

2

2

2

European
descent

Antoniou et al.

[122]

4

European
descent

Ahmed et al.
[170]

Stages

Population

GWAS

617/4,583

1,145/1,142

African descent
(1,004/2,745),
European descent
(1,718/3,670)

56,989/58,098

899/804

4,193/35,194

3,981/ 2,365

408/400

1,011/7,604

1,776/2,072

European descent
(2,292/16,901)

69,564/68,150

1,264/1,222

6,514/41,455

4,804/3,936

3,990/3,916

5,986/2,974

3,990/3,928

390/364
1,193/ 1,190

Cases/ Controls
stage 2

Cases/ Controls
stage 1

4,237/5,044

21,860/22,578

3,878/3,928

Cases/ Controls
stage 3

Table 24. Breast cancer risk genome-wide association studies using populations of European descent.

33,134/
36,141

Cases/
Controls
stage 4

P<E-05

P<2E-05

-

P<E-04

P<E-05

P<5E-08

-

P<E-07

P<E-07

P<E-07

Study p-value cutoff for significance
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6,145/33,016
1,145/1,142

2
2
2
3

European
descent

European
descent

European
descent

European
descent

European
descent

European
descent

Murabito et al.

Sehrawat et al.
[179]

Stacey et al.
[180]

Stacey et al.
[181]

Thomas et al.

Turnbull et al.
[182]

[121]

[120]

European
descent

Michailidou et
al. [62]

2

1

2

2

European
descent

Mavaddat et al.
[178]

3,659/4,897

1,600/11,563

348/348

250/1,345

10,052/ 12,575

4,470/4,560

2,702/ 5,726

2

European
descent

Cases/ Controls
stage 1

Li et al. [177]

Stages

Population

GWAS

Table 24 continued.

12,576/12,223

4,547/4,434

5,028/32,090

4,554/17,577

1,153/1,215

45,290/ 41,880

?

?

Cases/ Controls
stage 2

4,078/5,223

Cases/ Controls
stage 3

Cases/
Controls
stage 4

P<E-04

P<5E-07

-

P<E-07/ P<6.8E-08

P<6.4E-08

P<5E-08

P<5E-08

P<5E-02/6.25E-03

P<E-06

Study p-value cutoff for significance
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249/299

3
2

Ashkenazi Jewish
descent

Gold et al.
[77]

Haiman et al. African descent/
[174]
European descent

2,918/2,324
1,505/1,522
23,637/25,579

3

4
3
2

Asian descent/
European descent

Asian descent

Asian descent

Asian descent

Long et al.
[185]

Long et al.
[186]

Zheng et al.
[187]

Zheng et al.
[124]

2,073/2,084

3

Kim et al. [78] Asian descent
2,273/2,052

African descent
(1,004/2,745), European
descent (1,718/3,670)

3,153/ 2,831

2

African- American
descent

Chen et al.
[184]

2,062/2,066

Stages Cases/ Controls stage 1
4

Population

Cai et al. [183] Asian descent

GWAS

1,554,1,576

3,972/3,852

4,425/1,915

2,052/2,169

European descent
(2,292/16,901)

950/979

3,607/ 11,330

4,146/1,823

3,472/900

5,203/5,138

Asian descent
(6,173/6,340), European
descent (2,797/2,662)

1,997/1,676

243/187

6,436/6,716

7,489/9,934

4,509/6,338

P<1.5E-03

P<5E-08

P<5E-08

-

P<5E-04

-

P<E-05

P<5E-08

-

Cases/ Controls Cases/ Controls stage 3 Cases/ Controls Study p-value cutstage 4
off for significance
stage 2

Table 25. Breast cancer risk genome-wide association studies of non-European descent populations.

random rat regions. If a polymorphism mapped to a region of interest, the name, location,
odds ratio,95% confidence interval, and p-value were noted.

D.

Statistics
The number of human polymorphisms that mapped to orthologous regions

containing rat mammary cancer loci (observed) was compared to the number of human
polymorphisms that mapped to random rat regions (expected) using a chi-square analysis
with one degree of freedom. Several rat mammary cancer loci overlap extensively and
subsequently several human polymorphisms mapped to multiple rat loci. Currently, it is
not known if these overlapping rat mammary cancer loci would fine-map to the same
locus or independent loci. For this study, human polymorphisms mapping to overlapping
rat mammary cancer susceptibility associated sequences were counted only once. For
analysis of associated (passed genome-wide significance level) versus potentially
associated (did not pass genome-wide significance level) associations, a logistic
regression was performed using SYSTAT 13™ statistical software. A threshold of
associated or potentially associated was used as the independent variable and outcome
was either the SNP mapped to a rat mammary cancer locus or it mapped to a random rat
region.

Results
A.

Significantly more breast cancer risk GWA study nominated SNPs are located at
orthologs of rat Mcs/Mcsm loci compared to random rat genomic regions
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We picked 28 G WA studies of breast cancer risk in which well defined
populations were analyzed (Table 21). Physical locations of polymorphisms that failed
the final validation step and polymorphisms that reached genome-wide significance were
determined using dbSNP [169]. We included SNPs that failed the final validation step of
the respective study, because it has been suggested that many true associations are ruled
out in a GWA study due to stringent statistical analysis methods [161]. We determined if
sequences containing these polymorphisms were located at either a human genome
region orthologous to a known rat mammary cancer locus or to a r andomly selected
region of the rat genome. Our goal was to determine if GWA study-nominated
potentially-associated (did not pass final validation) and associated (genome-wide
significant) risk polymorphisms, together map more often to human orthologous regions
of rat mammary cancer susceptibility loci than to randomly selected rat genome segments
of similar size. If yes, it would suggest that human GWA information combined with rat
genetic susceptibility information is broadly useful to determine true genetic associations.
Overall, rat Mcs/Mcsm loci are mapped to shorter genomic segments than other rat
mammary cancer risk loci; therefore, we first compared overlap between human GWAS
nominated breast cancer risk SNPs and rat Mcs/Mcsm loci to overlap of human associated
SNPs with randomly selected rat genomic regions not known to contain mammary cancer
susceptibility loci (Figure 32). Human GWA studies were grouped by population of
descent for comparison. There was a significant difference between the number of
GWAS nominated SNPs mapping to rat Mcs/Mcsm loci compared to random rat regions
in studies analyzing populations of European descent (66 SNPs to 51 SNPs respectively,
p-value <0.05). This result supports previous studies indicating rat genetic susceptibility
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Figure 32. Number of breast cancer risk GWA study nominated SNPs mapping to
rat Mcs/Mcsm regions. Adapted from Sanders et al. (2014) [158]. Number of GWA
study nominated SNPs mapping to orthologs of rat Mcs/Mcsm loci and rat random
regions. (

) Dark grey columns represent the number of GWA study nominated human

SNPs mapping to the human orthologous regions of the Mcs/Mcsm loci. (

) Light grey

columns represent the number of GWA study nominated human SNPs mapping to the
human orthologous regions of the random rat control regions. The difference between
risk associated SNPs mapping to rat Mcs/Mcsm and random rat regions was statistically
significant for European populations. Asterisk indicates P-value <0.05 using chi-square
analysis with number of SNPs mapping to Mcs/Mcsm set as the observed value and
number of SNPs mapping to random rat regions as the expected value.
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is useful to predict and study human breast cancer risk loci. There was no difference in
Asian or African-American descent populations. This is likely due to a limited number of
published population-based breast cancer risk genetic-association studies using these
populations.

B.

Breast cancer risk GWA study nominated polymorphisms map more often to
orthologs of all known rat mammary cancer loci than to randomly selected
regions
Next, we included additional rat mammary cancer susceptibility loci that have

been identified, but span large genomic segments. L oci added were Mcstm1, Mcstm2,
Mcsta1, Emca1-2 and Emca4-8 [115-118]. The same random rat genomic regions used
previously were used in this analysis to be consistent. Respectively, 179 and 51 G WA
study nominated polymorphisms were located in human orthologous regions to rat
mammary cancer loci and randomly selected rat regions (Figure 33A) when studies using
populations of European descent were considered. This difference was statistically
significant (P < 0.01). Note, some rat mammary cancer loci identified in independent
studies have long regions of overlap. C onsequently, several human GWA study
identified polymorphisms mapped to human sequence orthologous to overlapping rat
susceptibility loci. As it is not known if these rat loci contain unique sub-loci, human risk
associated polymorphisms mapping to overlapping rat regions were counted only once.
The size of the rat genome covered by all known rat mammary cancer susceptibility loci
compared to control loci was disproportionate (Table 23). However, the ratio of breast
cancer risk associated human SNPs at orthologs to rat mammary cancer susceptibility loci
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Figure 33. Number of breast cancer risk GWA study nominated SNPs mapping to
orthologs of rat mammary cancer loci or randomly selected rat genomic segments.
Adapted from Sanders et al. (2014) [158].

(

) Dark grey columns indicate GWA

study nominated SNPs that map to human orthologous regions of rat mammary cancer
loci. (

)

Light grey columns indicate GWA study nominated SNPs that mapped to

human orthologous regions of randomly selected rat genomic regions. A. Studies by
population descent. Asterisks indicate statistical significance (p < 0.01). The difference
between risk associated SNPs mapping to rat mammary cancer loci and random rat
regions in studies of European, Asian and African- American descent populations was
significant (P-values <0.01 using chi-square analysis with number of SNPs mapping to
rat mammary cancer loci set as the observed value and number of SNPs mapping to
random rat regions as the expected value). B. Associated and potentially associated
SNPs identified in populations of European descent that mapped to rat regions of interest
were compared using logistic regression. Threshold of association was not a significant
predictor of whether a SNP mapped to an ortholog of a rat mammary cancer locus or a
random rat region. “ns” indicates a comparison was not statistically significant.
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to SNPs at random segments was higher than the ratio of susceptibility loci bases to
random bases (3.5 vs. 2.9). This result was relatively proportionate to the previous result
when only rat Mcs/Mcsm loci were considered (1.29 for Mcs/Mcsm and 1.21 f or all
susceptibility loci), suggesting a potential bias was not introduced by the increase in total
genomic coverage.
Not surprisingly, only 179 of 533 or 33.6% of the total human GWA study
identified SNPs using populations of European descent were located at orthologs to rat
mammary cancer associated loci. It is notable that 57 of the 533 total SNPs evaluated
were reported in more than one GWA study; a majority of these were potential
associations that failed the final validation step of the respective study. These results
further suggest there are several breast cancer risk associated SNPs not reaching genomewide statistical significance in human population-based genetic studies.
Since more breast cancer risk polymorphisms nominated from GWA studies of
populations of European descent mapped to orthologs of rat mammary cancer loci than to
randomly selected regions of the rat genome, we determined if this was the case for
association studies using non-European descent populations. We queried the nine GWA
studies of populations of non-European ancestry that are listed in Table 25. These were
GWA studies using populations of African, African-American, Ashkenazi Jewish, and
Asian descent; however, only polymorphisms from studies using African-American,
Ashkenazi Jewish and Asian descent populations mapped to any of the human
orthologous segments to rat genomic regions picked for this study. First, results from all
studies of non-European descent populations were combined (Figure 33A). Eighty-nine
risk associated SNPs mapped to orthologs of rat mammary cancer loci and 26 SNPs were
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located at randomly selected rat regions. Next, studies using populations of Asian,
Ashkenazi Jewish and African-American descent were considered separately. This
resulted in 64 A sian descent population SNPs mapping to orthologs of rat mammary
cancer loci and 18 SNPs to random rat regions. Twenty-four SNPs identified in studies of
African-American descent populations were located at orthologs to rat mammary cancer
loci and eight SNPs in random rat regions. The difference between rat mammary cancer
loci and random regions was statistically significant (p < 0.01) for both populations
(Figure 33A). Interestingly, one SNP from a study of an Ashkenazi Jewish population
mapped to the human orthologous region of rat Mcsta1, but no G WA study nominated
SNP from that study mapped to a rat random region [77]. The lack of human SNPs
mapping to orthologs of rat mammary cancer loci from populations of African and
Ashkenazi Jewish decent may be due to a limited number of studies conducted on these
populations. On the other hand, it may indicate that susceptibility alleles different from
those currently identified in laboratory rats are segregating in these populations. Out of
285 SNPs considered from studies using populations of non-European descent, 89 SNPs
or 31% mapped to orthologs of rat mammary cancer loci. Fifteen risk associated SNPs
were represented in more than one human GWA study.
Next, GWA-study nominated variants from populations of European descent were
separated by associated (reached genome-wide significance) and potentially associated
(did not reach genome-wide significance after the final stage) variants (Figure 33B).
Nineteen associated SNPs were located at rat mammary cancer loci compared to seven
SNPs that mapped to random rat regions. Comparatively, 160 pot entially associated
SNPs mapped to rat mammary cancer susceptibility loci compared to 44 SNPs that
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mapped to random rat regions. A logistic regression was performed using threshold of
association (associated or potentially associated) as the independent variable and rat
genome location (ortholog of a r at mammary cancer risk locus or a randomly selected
locus) as the dependent variable. Threshold of association was not a significant effect (Pvalue = 0.54). This result, that both associated and potentially associated breast cancer
risk variants map more often to orthologs of rat mammary cancer risk loci than rat
regions not associated with susceptibility, strongly supports that comparative genomics
between humans and rats may be an effective integrative approach to determine which
potential associations nominated by human association studies are true positives.
Human populations have been studied more extensively for breast cancer genetic
risk than have rat populations; therefore, it is not surprising that human studies have
yielded a considerable number of genome-wide significantly associated SNPs in alleles
where it is not known if the rat genome contains a concordant allele. Interestingly, seven
strongly associated human SNPs were in sequences orthologous to the randomly selected
rat genome regions that are not known to associate with rat mammary cancer based on
studies evaluating specific rat strains; thus, it is possible that a portion of the rat genome
used in this study as rat random-genome control regions may actually associate with
unidentified rat mammary cancer susceptibility loci. T hus, more rat genomic regions
associated with mammary cancer risk may be identified with additional rat genetic
studies. To date, only six inbred rat strains have been used to identify rat genomic regions
associated with mammary cancer risk [106, 107, 115-118]. Therefore, it is highly likely
that more mammary cancer susceptibility loci may be identified by incorporating
additional rat strains. I t is also possible that more extensive analysis of previously
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studied rat strains may yield additional susceptibility loci by using a higher density of
genetic markers for example.
Twenty-one of the 24 known rat mammary cancer associated loci are orthologous
to human loci containing SNPs that are either associated or potentially associated to
breast cancer risk. F ourteen of the known rat mammary cancer associated loci are
orthologous to human risk alleles marked by GWA study nominated SNPs reaching
genome-wide significance. Human GWA study designs do not definitively determine
causative genes or mechanisms. The laboratory rat is a versatile experimental organism to
complement human studies of breast cancer. For example, inbred rat strains provide a
model with reduced genetic variation that can be genetically manipulated and
environmentally controlled. The overlap between human breast and rat mammary cancer
susceptibility associated loci suggests rats can be used extensively to study genetically
determined mechanisms and environment interactions that will translate directly to
human breast cancer risk and prevention.

C.

Human GWAS nominated breast cancer risk SNPs map similarly to rat mammary
cancer associated loci identified using 7,12-dimethylbenz[a]anthracene (DMBA)
or beta-estradiol
Several rat mammary cancer loci used in this study were identified using DMBA

to induce mammary tumors. These are Mcs1a-c, Mcs2-4, Mcs5a1, Mcs5a2, Mcs5b-c,
Mcs6-Mcs8, Mcsm1, Mcstm1-2 and Mcsta1. The remaining rat mammary cancer loci
considered were identified using beta- estradiol to induce mammary carcinogenesis.
Estradiol associated susceptibility loci are Emca1-2 and Emca4-8. While DMBA is
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representative of environmental polycyclic aromatic hydrocarbons, this synthesized
mammary carcinogen is not found in nature. Conversely, estradiol is an endogenous
environmental exposure associated with breast cancer risk. H uman GWA study
nominated SNPs mapping to orthologs of rat mammary cancer loci identified using
DMBA were compared to those identified using beta-estradiol. We considered SNPs
from all GWA studies, irrespective of the population used. We noted that many DMBA
and beta-estradiol identified rat mammary cancer loci overlap. In fact, seven of the 14
DMBA associated rat mammary cancer loci overlap at least one beta-estradiol associated
rat mammary cancer risk locus, and five of the seven beta-estradiol loci overlap rat
mammary cancer loci identified using DMBA. To account for this overlap, human SNPs
mapping to overlapping rat mammary cancer loci, one identified using DMBA and the
other using beta-estradiol, were included once in the “DMBA” group and once in the
“beta-estradiol” group. These results are shown in Figure 34. A relatively similar number
of GWA study nominated SNPs mapped to orthologs of rat mammary cancer loci that
were identified using DMBA (181 SNPs) and beta estradiol (146 SNPs). This suggests
that different mammary carcinoma induction methods can effectively identify rat
susceptibility loci relevant to human disease risk, and it also suggests that a plethora of
carcinogenesis mechanisms may be genetically determined.

Discussion
It has been suggested that the use of Bonferroni-based correction procedures to
protect against multiple comparisons in genome-wide association studies is too stringent
and results in an abundance of false negative associations with little recourse to sort these
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Figure 34. Number of breast cancer risk GWA study nominated SNPs mapping to
regions identified using DMBA or beta-estradiol. Adapted from Sanders et al. (2014)
[158]. Number of GWA study nominated SNPs mapping to rat mammary cancer loci
separated by method of mammary carcinogenesis induction. Slightly more SNPs mapped
to orthologs of rat loci that were identified using DMBA than beta-estradiol.
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from true-negative associations. T herefore, we considered associated and potentially
associated human SNPs from breast cancer risk GWA studies to determine if SNPs that
failed validation and SNPs that reached genome- wide significance map to respective
regions of the rat genome known to associate with rat mammary cancer risk more often
than to regions of the rat genome that are not known to associate with susceptibility.
Results presented here indicate that the rat genome is useful to prioritize and rank human
alleles potentially associated with risk. The rat genome is useful regardless of the human
population studied. S ignificantly more SNPs from GWA studies of populations of
European, Asian, and African-American descent map to human orthologous regions of
rat mammary cancer loci than to human orthologous regions of randomly selected rat
genomic regions not known to associate with mammary cancer susceptibility. This
supports the general idea that there are SNPs associated with breast cancer risk that are
missed due to conservative statistical methods used in GWA studies, and that the rat is
useful to parse out important genetic variation in susceptibility to mammary
carcinogenesis.
Interestingly, we were unable to map GWA study nominated SNPs to three of the
24 known rat mammary cancer loci. These were Mcs1a, Mcs5a1, and Mcs5c. However,
using a genome-targeted population-based genetic association study, a human SNP
associated with breast cancer risk has been identified at human MCS5A1 [111]. The risk
associated SNPs at MCS5A1 are adjacent to a breast cancer risk associated SNP at
MCS5A2, which was identified in two independent human population based studies [111,
178]. Taken together, there is a h igh correlation between genetics of breast cancer
susceptibility in humans and mammary cancer susceptibility in rats. Interestingly, there
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are several human genomic regions that are human GWA study nominated hotspots (e.g.
19q13, FGFR2) that are not known to have concordant rat orthologs. An explanation is
that human breast and rat mammary cancer susceptibility are controlled by overlapping
and non-overlapping genetic mechanisms. Another explanation is that there are rat
genomic regions associated with mammary cancer risk yet to be discovered by using
additional inbred strains, more extensive analysis of strains previously studied, and
different methods of carcinogenesis induction.
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CHAPTER VI
CONCLUDING REMARKS
Breast cancer is a complex disease, characterized by genetic, epigenetic and
environmental factors. The laboratory rat has been used extensively as a model to study
the genetic component of breast cancer. Several rat genomic regions have been identified
that associate with mammary cancer risk. This dissertation focuses on two of these
regions, Mcs6 and Mcs1b. The Mcs6 locus was initially mapped to a large region of about
33Mb. This makes this locus too large for functional studies. We focused on narrowing
this locus to a smaller interval using phenotyping of congenic animals. We were able to
conclude that the Mcs6 locus is located in an 8.5Mb region on rat chromosome 2:
46,915,037-55,364,398. This significantly reduced the size of this locus. Several GWAS
identified SNPs map to this location, making it an important locus to study. Overall, we
were able to generate the model needed to study this locus with this project. Studying this
locus is highly relevant, because there are no known breast cancer susceptibility genes in
this region and studying this locus may lead to the identification of a novel breast cancer
susceptibility gene.
The second rat genomic region, this dissertation focuses on, i s the Mcs1b locus.
We used next-generation sequencing to identify 72 variants between the two rat strains in
this region. Most of the variants are located at the extreme ends of the Mcs1b locus. We
used genotyping of existing congenic animals to rule out most of the variants. This
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resulted in the identification of three candidate Mcs1b SNPs and one INDEL within this
locus that have the potential of being responsible for the Mcs1b phenotypes. We focused
on the Mcs1b candidate SNPs because there are known orthologous human SNPs that
associate with breast cancer. Overall, we were able to use sequence capture using rat
DNA, which to our knowledge had not been done previously and we were able to use
sequencing, genetic analysis and bioinformatics to generate a l ist of candidate Mcs1b
variants.
Functional analysis of the candidate Mcs1b SNPs revealed that A074-SNP-17
shows a gene regulatory pattern that mimics a gene regulatory pattern that is seen
endogenously in the rat strains used for this analysis. Furthermore, a DNA binding
protein analysis revealed that some protein complexes appear only to bind to the SNP
allele of the mammary cancer susceptible rat strain, indicating that there is a difference in
the DNA binding proteins that bind to A074-SNP-17. Based on these data, A074-SNP-17
is considered the strongest candidate for conferring the Mcs1b phenotypes. Data from 3C
experiments reveal that there appears to be a chromatin loop forming in the Mcs1b
region, which would bring our candidate Mcs1b SNPs in close proximity to the Mcs1b
candidate gene Mier3. There does not appear to be a difference in chromatin loop
formation in the Mcs1b region between the mammary cancer resistant and susceptible rat
strains used in our analysis.
Overall, our model for the Mcs1b locus is that the Mcs1b candidate SNPs are
located in enhancer regions and affect the transcriptional regulation of nearby genes. The
luciferase activity for all three Mcs1b candidate SNPs is different between the susceptible
WF and resistant COP allele, suggesting that all three SNPs act as transcriptional
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regulators. A074-SNP-17 shows a luciferase activity pattern that is similar to the pattern
of differential gene expression of Mcs1b candidate SNPs. This indicates that A074-SNP17 may be involved in regulating the expression levels of Mcs1b candidate genes. Also,
analysis of DNA binding proteins revealed that a DNA binding protein binds to the WF
allele of A074-SNP-17 but not the COP allele. This makes A074-SNP-17 the most likely
candidate for conferring the Mcs1b phenotype. There is evidence that a chromatin loop
forms in the Mcs1b locus, which brings the candidate Mcs1b SNPs in close proximity to
one of the Mcs1b candidate genes. This would be a mechanism as to how A074-SNP-17
can affect the expression level of the Mcs1b candidate gene.
GWA studies have a great potential of identifying candidate SNPs associated with
breast cancer. However, they provide no i nformation on t he causative gene, variant or
what the underlying mechanism is. We were able to generate an animal model to study
one GWA identified SNP, rs889312, and the SNPs it tags. We were able to study the role
of these SNPs in gene regulation and provide a mechanism by which they could affect the
transcript levels of candidate genes. The only other GWA identified SNPs have been
studied for function reside within the FGFR2 gene. Therefore, studying these SNPs will
result in the identification of novel breast cancer susceptibility genes and will elucidate
the mechanisms underlying genetic susceptibility to breast cancer.
An analysis of the overlap between human breast and rat mammary cancer
susceptibility revealed that there is extensive genomic overlap. The rat genome may
provide utility to identify true-positive associations regardless of the human population
used for a GWA study. The laboratory rat will continue to be an important model
organism for researching genetically determined mechanisms of mammary cancer
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susceptibility that may translate directly to human susceptibility. An appreciable number
of GWA study nominated SNPs not meeting genome-wide significance levels have
genomic overlap with rat mammary cancer susceptibility loci. This supports the general
idea that Bonferroni-based multiple-comparison correction procedures are too stringent
and complementary approaches that integrate rat genomics would be highly efficacious to
prioritize breast cancer risk associated alleles.
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LIST OF ABBRVIATIONS
3C- chromosome conformation capture
95% CI- 95% confidence interval
ACI- August Copenhagen Irish
ARE- antioxidant response element
ATM- ataxia telangiectasia mutated
ATR- ataxia telangiectasia mutated rad3-related
BAC- bacterial artificial chromosome
Bcl-2- B-cell lymphoma 2
Bcl-X1- Bcl-2 associated X protein
BN- Brown Norway
BRCA1/2- breast cancer 1/2, early onset
BRIP1-BRCA1 interacting protein
BSA- bovine serum albumin
cAMP- cyclic adenosine monophosphate
CDC2- cell division cycle protein 2
CDH1- cadherin 1
ChIP- chromatin immunoprecipitation
CNV- copy number variation
COP- Copenhagen
CRISPR- clustered regularly interspaced short palindromic repeats

225

CTF/NF-1 domain- CCAAT box-binding transcription factor/ Nuclear factor -1 DNA
binding domain
DES- diethylstilbestrol
DMBA- 7,12-dimethylbenz[a]anthracene
DMEM/ F12- Dulbecco's Modified Eagle Medium
DNA- deoxyribonucleic acid
DTT- dithiothreitol
DZF- domain in DSRM or zinc finger C2H2 domain containing proteins
E2- 17β- estradiol
EMCA-estrogen induced mammary cancer loci
EMSA- electrophoretic mobility shift assay
ER- estrogen receptor
FBS- fetal bovine serum
FGFR2- fibroblast growth factor receptor 2
Frmpd1- FERM And PDZ Domain Containing 1
GFP- green fluorescent protein
GPBP1- GC- rich promoter binding protein 1
GWAS- genome- wide association study
HBSS- Hanks’ balanced salt solution
IL6ST-interleukin 6 signal transducer
Il8- interleukin 8
ILF2- interleukin enhancer binding factor 2
ILF3- interleukin enhancer binding factor 3
INDEL- insertion or deletion
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LD block- linkage disequilibrium block
LOD score- logarithm (base10) of odds score
MAP3K1- mitogen activated protein kinase kinase kinase 1
Mcs- mammary cancer susceptibility locus
Mcsm: mammary carcinoma susceptibility modifier
Mcsta: mammary cancer susceptibility tumor aggressiveness
Mcstm- mammaryv cancer susceptibility tumor multiplicity
MEC- mammary epithelial cell
MIER3- mesoderm induction early response protein 3
MMTV- mouse mammary tumor virus long terminal repeat promoter
MRI- magnetic resonance imaging
NAT2- N-acetyltransferase 2
NAV3- Neuron navigator 3
NFAT- nuclear factor of activated T-cells
NFIC- nuclear factor (eythroid derived)- like 2
NTN4- netrin4
PAH- polycyclic aromatic hydrocarbons
PALB2- partner and localizer of BRCA2
PBS- phosphate buffered saline
PCB- polychlorinated biphenyls
P:C:I- phenol: choloroform: isoamylalcohol (25:24:1)
PCR- polymerase chain reaction
PPP1R12A or MYPT1- Myosin Phosphatase- Targeting Subunit 1
PR- progesterone receptor
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PRE- progesterone response element
PTEN- Phosphatase and tensin homolog
QTL- quantitative trait locus
RACE- rapid amplification of cDNA ends
RNA- ribonucleic acid
RPMI- Roswell Park Memorial Institute medium
RR- relative risk
SAP domain- SAF-A/B, Acinus and PIAS domain
SERM- selective estrogen receptor modulators
SETD9- SET domain containing 9
sgRNA- single guide RNA
SNP- single nucleotide polymorphism
STK11-serine/ threonine kinase 11
TAP- tobacco acid phosphatase
TP53- tumor protein 53
TSPAN- tetraspanin
TSS- transcription start site
UTR- untranslated region
VEGF- vascular endothelial growth factor
WF- Wistar Furth
WKy- Wistar- Kyoto
ZDHHC17 or HIP-14-Huntingtin interacting protein

228

APPENDIX
PERMISSION TO USE PUBLISHED WORK
For research article: Sanders J, Samuelson D: Significant overlap between human
genome-wide association-study nominated breast cancer risk alleles and rat
mammary cancer susceptibility loci. Breast Cancer Research 2014, 16(1):R14.
Permission from Breast Cancer Research:
“Dear Dr Sanders,
Thank you for your email. As your publication was a research article and open access this
is absolutely fine. As long as the article is correctly cited in your dissertation then no
further permission is required.
If you have any further questions regarding this please do not hesitate to contact me.
Kind regards,
Laura Anstee”

229

CURRICULUM VITAE

Jennifer Sanders
E-mail: jennifersanders001@gmail.com
Address: 703 Fountain Avenue
Louisville, KY 40222
Phone: 502-777-3019
EDUCATION
University of Louisville, Louisville, KY
August 2009-June 2014
PhD, Biochemistry and Molecular Biology, GPA 3.9
Mentor: David Samuelson, PhD
Dissertation title: Genetic and Mechanistic Analysis of Rat Mammary Cancer Susceptibility

University of Louisville, Louisville, KY
August 2005- May 2009
Bachelor of Science in Chemistry with concentration in Biochemistry
Minor in Mathematics, GPA 3.9

POSITIONS
•
•

08/2010-12/2010
08/2009-

Teaching Assistant, University of Louisville
Graduate Research Assistant, University of Louisville

HONORS AND AWARDS
Honors
• Won first place for poster presentation at University of Louisville Department of
Biochemistry and Molecular Biology Retreat 2013
• Selected to give oral presentation at Cincinnati Children’s Hospital Postdoctoral
Symposium 2013
• Selected to give oral presentation at Cold Spring Harbor Meeting on Rat Genomics and
Models 2011
• Selected to give oral presentation at University of Louisville Department of Biochemistry
and Molecular Biology Retreat 2011
• CGeMM Travel Award Recipient 2011
• Research Committee Travel Award Recipient 2011
• Recipient of the National Scholars Award 2005-2009

230

•
•
•
•
•
•

3 time recipient of the Etscorn Scholar Award 2006-2009
B.S. awarded with magna cum laude
Graduated as an Honors Scholar
Member of Woodcock Honors Society
Member of Phi Kappa Phi Honors Society
Member of Alpha Epsilon Delta National Honorary Pre-Health Fraternity

Awards
• Integrated Programs in Biological Sciences Fellowship from 8/2009 to 7/2011
• T32-ES011564
Dr. Hein (PI)
7/2012- 6/2013
NIEHS
National Institute of Health Sciences-funded Training Program in Environmental Health
Sciences
Role: Pre-doctoral trainee
• 1st place poster presentation at Biochemistry and Molecular Biology Retreat 2013
• CGeMM Travel Award Recipient 2011
• Research Committee Travel Award Recipient 2011
ABSTRACTS AND PRESENTATIONS
Oral Presentations
• Samuelson DJ, Sanders J, Xu X, Vaughn D. Identification of rat mammary carcinoma
susceptibility-1b (Mcs1b) QTL candidate genes and elements. Abstract for presentation.
Rat Genomics and Models Cold Spring Harbor Laboratory Conference, December 7-10,
2011, Cold Spring Harbor, New York.
• Sanders J, Xu X, Kemper AF, Kalbfleisch T, Samuelson DJ. A074-SNP-17 is a Candidate
Rat Mammary Cancer Susceptibility SNP: Analysis of a M ammary Cancer QTL.
Abstract for presentation. Cincinnati Children’s Hospital Medical Center Postdoctoral
Research Symposium 2013, September 6, 2013, Cincinnati, Ohio
Posters
• Sanders J, Xu X, Kemper AF, Kalbfleisch T, Samuelson DJ. A074-SNP-17 is a
Candidate Rat Mammary Cancer Susceptibility SNP: Analysis of a Mammary Cancer
QTL. Abstract for poster presentation. James Brown Cancer Center Retreat 2013,
October 25, 2013, Louisville, Kentucky
• Sanders J, Xu X, Kemper AF, Kalbfleisch T, Samuelson DJ. A074-SNP-17 is a
Candidate Rat Mammary Cancer Susceptibility SNP: Analysis of a Mammary Cancer
QTL. Abstract for poster presentation. Research! Louisville 2013, September 24, 2013,
Louisville, Kentucky
• Sanders J, Xu X, Kemper AF, Kalbfleisch T, Samuelson DJ. A074-SNP-17 is a
Candidate Rat Mammary Cancer Susceptibility SNP: Analysis of a Mammary Cancer
QTL. Abstract for poster presentation. Biochemistry and Molecular Biology Retreat
2013, August 23, 2013, Louisville, Kentucky
• Samuelson DJ, Sanders J, Xu X. Rat Mammary carcinoma susceptibility-1b singlenucleotide-variant A074-SNV-17 is a candidate Mcs1b quantitative trait

231

•

•

•

•

•

•

•

nucleotide. Poster Presentation, Complex Trait Community 12th Annual Meeting,
Madison, Wisconsin, May 28-31, 2013
Sanders J, Xu X, Kemper AF, Kalbfleisch T, Samuelson DJ. Identification and
Mechanistic analysis of rat mammary carcinoma susceptibility-1b genetic elements.
Abstract for presentation. Biochemistry and Molecular Biology Department Student
Recruitment, February 15 2013, Louisville, Kentucky
Sanders J, Xu X, Kemper AF, Kalbfleisch T, Samuelson DJ. Identification and
Mechanistic analysis of rat mammary carcinoma susceptibility-1b genetic elements.
Abstract for presentation. Rat Genomics and Models Cold Spring Harbor Laboratory
Conference, December 7-10, 2011, Cold Spring Harbor, New York
Sanders J, Xu X, Kemper AF, Kalbfleisch T, Samuelson DJ. Identification and
Mechanistic analysis of rat mammary carcinoma susceptibility-1b genetic elements.
Abstract for poster presentation. James Graham Brown Cancer Retreat, Oct 28, 2011,
Louisville, Kentucky.
Sanders J, Xu X, Kemper AF, Kalbfleisch T, Samuelson DJ. Identification and
Mechanistic analysis of rat mammary carcinoma susceptibility-1b genetic elements.
Abstract for poster presentation. Research! Louisville, October 10-15, 2011, Louisville,
Kentucky.
Sanders J, Xu X, Kemper AF, Kalbfleisch T, Samuelson DJ. Mechanistic analysis of
rat mammary carcinoma susceptibility-1b genetic elements. Abstract for talk.
Biochemistry and Molecular Biology Retreat 2011, August 26, 2011, Louisville,
Kentucky.
Samuelson DJ, Xu X, denDekker AD, Sanders J, Kemper AF, Kalbfleisch T. Congenic
Mapping and Functional Characterization of a Rat Mammary Carcinoma Susceptibility
QTL, Mcs1b, Identifies MAP3K1 and MIER3 as Candidate Breast Cancer
Susceptibility Genes. Poster Presentation, Quantitative Genetics & Genomics Gordon
Research Conference, February 20-25, 2011, Galveston, Texas
Sanders J. 2009. Analyzing Inpatient Data for Hepatitis Patients. Abstract for poster
presentation, International Society for Pharmacoeconomics and Outcomes Research
Conference 2009.

PUBLICATIONS
Research articles
• Sanders J, Samuelson D: Significant overlap between human genome-wide
association-study nominated breast cancer risk alleles and rat mammary cancer
susceptibility loci. Breast Cancer Research 2014, 16(1):R14
•

Sanders J, Haag JD, Samuelson DJ (2011) Physical Confirmation and Mapping of
Overlapping Rat Mammary Carcinoma Susceptibility QTLs, Mcs2 and Mcs6. PLoS
ONE 6(5): e19891. doi:10.1371/journal.pone.0019891

•

Devapatla B, Sanders J, Samuelson DJ (2012) Genetically determined inflammatoryresponse related cytokine and chemokine transcript profiles between mammary
carcinoma resistant and susceptible rat strains. Cytokine 59: 223-227

Books
• Co-author of: Cerrito, P.B. (2009). A Casebook on Pediatric Disease (Bentham Science
Publishers).

232

